Document:

Clinical
Trial Agreement

PHASE
II STUDY

 

between

 

NSABP
Foundation, Inc.

and

 

Antigen
Express, Inc.

 

    	 

    	 

    

TABLE
OF CONTENTS

 

	RECITALS		3
	 	 	 
	ARTICLE I	DEFINITIONS	3
	 	 	 
	ARTICLE II	SCOPE OF SERVICES	5
	 	 	 
	ARTICLE III	STUDY CONDUCT	6
	 	 	 
	ARTICLE IV	FINANCIAL SUPPORT	7
	 	 	 
	ARTICLE V	SUPPLY, OWNERSHIP, AND DISTRIBUTION OF STUDY DRUG	8
	 	 	 
	ARTICLE VI	BIOLOGIC RESPOSITORY AND TISSUE COLLECTION	9
	 	 	 
	ARTICLE VII	WARRANTIES AND DISCLAIMERS	10
	 	 	 
	ARTICLE VIII	AUDITS, MONITORING, SITE QUALIFICATION, AND ACCESS TO RESEARCH RECORDS	10
	 	 	 
	ARTICLE IX	RECORDS AND REPORTS	10
	 	 	 
	ARTICLE X	FINANCIAL DISCLOSURE AND CONFLICT OF INTEREST	11
	 	 	
	ARTICLE XI	CONFIDENTIAL INFORMATION	12
	 	 	 
	ARTICLE XII	PUBLICATIONS / PRESENTATIONS AND GENERAL PUBLICITY	14
	 	 	 
	ARTICLE XIII	DATA OWNERSHIP AND INVENTIONS	15
	 	 	 
	ARTICLE XIV	NOTICE	17
	 	 	 
	ARTICLE XV	INDEMNIFICATION; INSURANCE; LIMITATIONS OF LIABILITY	18
	 	 	 
	ARTICLE XVI	HUMAN SUBJECTS	20
	 	 	 
	ARTICLE XVII	TERM AND TERMINATION	20
	 	 	 
	ARTICLE XVIII	AMENDMENTS	21
	 	 	 
	ARTICLE XIX	SEVERABILITY	21
	 	 	 
	ARTICLE XX	INTEGRATION	22
	 	 	
	ARTICLE XXI	ASSIGNMENT	22
	 	 	 
	ARTICLE XXII	INDEPENDENT CONTRACTOR	22
	 	 	 
	ARTICLE XXIII	NO TRANSFER OF PROPRIETARY RIGHTS NOT SPECIFIED	22
	 	 	 
	ARTICLE XXIV	CONFORMANCE WITH LAW AND ACCEPTED PRACTICE	22
	 	 	 
	ARTICLE XXV	WAIVER	22
	 	 	 
	ARTICLE XXVI	FORCE MAJEURE	23
	 	 	 
	ARTICLE XXVII	DEBARMENT	23
	 	 	 
	ARTICLE XXVIII	GOVERNING LAW	23
	 	 	 
	ARTICLE XXX	ENTIRE AGREEMENT	23
	 	 	 
	ARTICLE XXXI	COUNTERPARTS	23
	 	 	 
	BINDING EXECUTION		24

 

 

    	 	1	 

     

    

 

APPENDICES

 

 

	Appendix A	NSABP Protocol entitled, "A Phase II Clinical Trial of Pembrolizumab
    in Combination with the AE37 Peptide Vaccine in Patients with Metastatic Triple Negative Breast Cancer, (FB-14)," including
    the sample Informed Consent Form
	 	 
	Appendix B	Budget, Payment Schedule, and Task List
	 	 
	Appendix C	NSABP Ownership of Data/Materials Policy
	 	 
	Appendix D	Selected Terms of Agreement for Disclosure to Sites

 

    	 	2	 

     

    

 

CLINICAL
TRIAL AGREEMENT

This
Clinical Trial Agreement (“Agreement”)
is entered into and effective as of the 20th day of November, 2018 (“Effective Date”), by and between NSABP Foundation,
Inc., a 501(c)(3) non-profit Pennsylvania membership corporation with its principal office and place of business at Nova Tower
2, Two Allegheny Center, Suite 1200, Pittsburgh, Pennsylvania 15212-5234 (“NSABP”), and Antigen Express, Inc., a Delaware
corporation with its principal office and place of business at 33 Redwing Road, Wellesley, MA 02481 (“Antigen Express”).
NSABP and Antigen Express shall hereinafter be referred to individually as “Party,” and together as “Parties.”

RECITALS

 

WHEREAS,
NSABP conducts research and educational activities designed to improve the outcome for cancer patients via improved therapeutic
and prevention modalities. The activities contemplated by this Agreement are of interest and benefit to NSABP and Antigen Express,
and such activities will further NSABP's medical research objectives in a manner consistent with its non-profit, scientific and
charitable status;

WHEREAS,
Antigen Express is a platform and product-based company developing proprietary immunotherapeutic vaccine formulations for large,
unmet medical needs, with a focus on antigen-specific stimulation of immunological response;

WHEREAS,
NSABP and Antigen Express wish to have NSABP conduct the clinical research contemplated in this Agreement on behalf of Antigen
Express, using Antigen Express' immunotherapeutic vaccine, AE37 in combination with pembrolizumab (KeytrudaÒ), for the treatment
of metastatic triple negative breast cancer.

NOW,
THEREFORE, the Parties enter into this Agreement with the intent to be legally bound under the terms and conditions herein set
forth.

ARTICLE
I

DEFINITIONS

The
following terms, whether used in the singular or plural, have the respective meaning as set forth hereinbelow, as follows:

		1.1	“AE”
                                         or “Adverse Event” shall have the meaning given in the Protocol.

		1.2	"Antigen
                                         Express Study Drug" shall mean the Antigen Express AE37 peptide immunotherapeutic
                                         vaccine.

		1.3	“Applicable
                                         Law” shall have the meaning given in Section 3.2 of this Agreement.

		1.4	“Claims”
                                         shall have the meaning given in Section 15.1 of this Agreement.

    	 	3	 

     

    
 

		1.5	“Confidential
                                         Information” shall have the meaning given in Section 11.1 of this Agreement.

		1.6	“CRFs”
                                         shall mean the case report forms for the Study and shall include electronic CRFs (“eCRFs”)
                                         and the data contained therein.

		1.7	“Data”
                                         shall mean all data generated by the conduct of the Study. For purposes of clarity, Data
                                         does not include patient medical records (other than CRFs, Informed Consent Forms, and
                                         SAE filings and narratives in respect of Subjects) or other Participating Site source
                                         documentation, which shall remain the property of the Participating Site. 

		1.8	“Disclosing
                                         Party” shall have the meaning given in Section 11.2 of this Agreement.

		1.9	“EC/IRB”
                                         shall mean the Ethics Committee/Institutional Review Board established pursuant to 21 CFR Part 56
                                         for the purpose of reviewing clinical investigations and their equivalents in countries
                                         other than the United States.

		1.10	“FDA”
                                         shall mean the United States Food and Drug Administration.

		1.11	“Good
                                         Clinical Practices" or "ICH GCP” shall mean good clinical practices as
                                         adopted by the International Conference on Harmonisation (“ICH”) of Technical
                                         Requirements for Registration of Pharmaceuticals for Human Use Good Clinical Practices.
                                         For clarification for U.S. sites, ICH GCP shall mean as defined in the most recent version
                                         of any FDA rules, regulations and guidelines on good clinical practice. 

		1.12	“IB”
                                         shall mean the clinical investigator brochure for the Antigen Express Study Drug and/or
                                         the Merck Study Drug, to be provided by Antigen Express and Merck, as applicable, hereunder,
                                         as it may be updated and amended from time to time by Antigen Express or Merck, as the
                                         case may be.

		1.13	“IND”
                                         shall mean a claimed Investigational New Drug Application under 21 CFR § 312.

		1.14	“Indemnitees”
                                         shall have the meaning given in Section 15.1 of this Agreement.

		1.15	“Informed
                                         Consent Form” shall mean the informed consent form that is to be signed by all
                                         Subjects enrolled in the Study, together with any amendments thereto.

		1.16	“Investigator”
                                         shall mean a licensed health professional who is a qualified clinical investigator willing
                                         and able, and engaged by NSABP or Participating Sites, in accordance with this Agreement,
                                         to conduct a clinical investigation under the Protocol pursuant to 21 CFR § 312.

		1.17	“Materials”
                                         shall have the meaning set forth in Article VI.

		1.18	“Merck”
                                         means Merck Sharp & Dohme B.V.

		1.19	“Merck
                                         Agreement” means the Clinical Trial Collaboration and Supply Agreement by and among
                                         Merck and Antigen Express made as of June 28, 2017 as the same may be amended from time
                                         to time in accordance with the terms thereof.

		1.20	"Merck
                                         Study Drug" shall mean Pembrolizumab, a humanized anti-human PD-1 monoclonal antibody.

    	 	4	 

     

    
		1.21	“NDA”
                                         shall mean a New Drug Application under the Federal Food, Drug and Cosmetic Act, as amended.

		1.22	“Other
                                         Inventions” shall have the meaning given in Section 13.4 of this Agreement.

		1.23	“Participating
                                         Sites” shall mean Research Collaborators and their respective Research  Site(s)
                                         that are participating in the Study

		1.24	“Protocol”
                                         or “FB-14” shall mean the NSABP protocol entitled “A Phase II Clinical
                                         Trial of Pembrolizumab in Combination with the AE37 Peptide Vaccine in Patients with
                                         Metastatic Triple Negative Breast Cancer,” and will be interpreted to include all
                                         modifications and amendments made in accordance with this Agreement, as well as the original
                                         Protocol and sample patient Informed Consent Form attached hereto as Appendix A
                                         and incorporated into this Agreement by this reference, and other Protocol related documents
                                         necessary for the effective communications of the Protocol. 

		1.25	“Receiving
                                         Party” shall have the meaning given in Section 11.2 of this Agreement.

		1.26	“Research
                                         Collaborator” shall mean an entity where a Subject is seen, consented, treated
                                         and/or data is collected and completed for the Study, which entity is the official designated
                                         lead institution of a research collaborator through a collaborative arrangement
                                         with NSABP and is participating in the Study.

		1.27	“Research
                                         Site(s)” shall mean a site that is cooperating with a Research Collaborator and,
                                         through that cooperation, is participating in the Study. 

		1.28	“SAEs”
                                         shall have the meaning given in the Protocol.

		1.29	“Sponsor”
                                         shall mean Antigen Express.

		1.30	“Study”
                                         shall mean all work to be carried out pursuant to the Protocol and this Agreement.

		1.31	“Study
                                         Drugs” shall mean the Antigen Express Study Drug and the Merck Study Drug.

		1.32	“Study
                                         Drug Inventions” shall have the meaning given in Section 13.1. 

		1.33	“Study
                                         Personnel” shall mean the personnel conducting the Study at Participating Sites,
                                         including Investigators.

		1.34	“Subject(s)”
                                         shall mean those individuals who provide their informed consent and participate in the
                                         Study.

All
other capitalized terms used herein shall have the meaning expressly ascribed to them herein.

ARTICLE
II

SCOPE
OF SERVICES

2.1              
NSABP will conduct the Study in accordance with (a) the Protocol; (b) this Agreement; and (c) all Applicable Law.

2.2              
This Agreement is not intended to be an exclusive contract and shall not limit the freedom of the Parties or any individuals participating
in this work to engage in other research or other activities. NSABP and Antigen Express both retain the right to collaborate with
other entities to conduct the types of clinical trials contemplated by this Agreement.

    	 	5	 

     

    

2.3              
 Antigen Express is the holder of the IND for the Study.

		2.4	Norman
                                         Wolmark, M.D., shall be the NSABP Principal Investigator.

2.5              
NSABP will enter into signed, written contracts with its Research Collaborators who wish to participate in the Study to (a) require
that all Study Personnel are qualified to conduct the Study; (b) require that the Study is conducted under the direction
of the applicable Investigators at a Participating Site and under the direction of the NSABP Principal Investigator and with the
prior approval and on-going review of all appropriate and necessary review authorities; (c) obligate Research Collaborators,
who shall obligate their respective Research Sites, to terms and conditions with respect to the Study that are required pursuant
to this Agreement; and (d)  comply with Applicable Law. For clarification purposes, references herein to contractual
obligations of Participating Sites shall include the requirement that each Research Collaborator impose such obligations
upon its Research Sites.

2.6              
Antigen Express shall use commercially reasonable efforts to timely perform its obligations hereunder (a) in a good and scientific
manner; (b) in accordance with all standard laboratory and clinical practices; and (c) in compliance with all Applicable
Law.

2.7              
The Parties acknowledge and agree that Pembrolizumab is to be provided free of charge by Merck for purposes of the Study. NSABP
acknowledges and agrees that Antigen Express has entered into the Merck Agreement for the supply of Pembrolizumab. Antigen Express
will direct Merck to deliver the Merck Study Drug to NSABP’s designated drug distributor. The Parties agree that, if for
any reason, the Merck Study Drug is not available for the Study, the Study will not be conducted and either Party may terminate
this Agreement in accordance with Article XVIII.

ARTICLE
III

STUDY
CONDUCT

		3.1	Antigen
                                         Express’s willingness to provide the Study funding and supply the Antigen Express
                                         Study Drug pursuant to this Agreement is predicated upon (a) its review of, and
                                         the mutual agreement of the Parties with respect to, the Protocol; (b) Subject enrollment
                                         and Study progress in accordance with Appendix B, and (c) the terms and conditions
                                         of this Agreement. 

		3.2	The
                                         Study will be performed in accordance with the terms and conditions contained herein,
                                         the terms and conditions of the Protocol, and all applicable laws, rules, regulations,
                                         and guidelines including but not limited to those regulations promulgated by the FDA
                                         including 21 CFR 312, as applicable, federal and state privacy and patient confidentiality
                                         laws, and ICH Good Clinical Practices (collectively, “Applicable Law”). 

 

		3.3	Antigen
                                         Express acknowledges that NSABP does not consider itself a HIPAA-covered entity; however,
                                         NSABP shall collect, use, store, access, and disclose personal health information
                                         (as that term is defined in HIPAA) (“PHI”) collected from Subjects only as
                                         permitted by the IRB approved Informed Consent Form or HIPAA authorization form
                                         obtained from a Subject. Antigen Express agrees that, to the extent Antigen Express and
                                         any Antigen Express designee has access to PHI, Antigen Express and such Antigen Express
                                         designee shall collect, use, store, access, and disclose PHI collected from Subjects
                                         only as permitted by the IRB approved Informed Consent Form or HIPAA authorization
                                         form obtained from a Subject. Any IRB approved Informed Consent Form or any HIPAA authorization
                                         form shall expressly permit Antigen Express to share Data with Merck. In order for Antigen
                                         Express to share or provide any Data that includes PHI with Merck, Antigen Express shall
                                         first obligate Merck to store, use, process, and handle any such Data with PHI only as
                                         permitted by the IRB approved Informed Consent Form or HIPAA authorization form.

    	 	6	 

     

    

 

		3.4	NSABP
                                         or Antigen Express may at any time suggest amendments to the Protocol as may appear desirable;
                                         such amendments shall be discussed between Antigen Express and NSABP and (except as set
                                         forth below) such amendments may be made binding only upon mutual, signed written amendment
                                         to the Protocol. If such amendments are requested by Antigen Express and have been agreed
                                         to by NSABP, and such amendments increase or decrease the costs of the Study, NSABP will
                                         submit to Antigen Express a written estimate of the difference in costs arising from
                                         the amendments requested by Antigen Express and Antigen Express, at its discretion, shall
                                         decide whether NSABP shall implement such amendments. If such amendments are requested
                                         by NSABP, NSABP will submit to Antigen Express a written estimate of the difference in
                                         costs arising from the amendments requested by NSABP and Antigen Express, at its sole
                                         discretion, shall decide whether it will pay any increased costs. Notwithstanding anything
                                         to the contrary, if NSABP reasonably believes that generally accepted standards of clinical
                                         research and/or medical practice, or other appropriate concerns, justify an amendment
                                         to the Protocol such amendment shall become effective thirty (30) days after Antigen
                                         Express’s receipt of notice thereof from NSABP. Amendments to the Protocol shall
                                         result in a description of the impact the amendment will have on the schedule of financial
                                         support, if any. NSABP shall require that the Protocol and Informed Consent Form, and
                                         amendments thereto, be submitted to the appropriate EC/IRBs. NSABP will make all required
                                         submissions to the IND in connection with any amendment to the Protocol made pursuant
                                         to this Section 3.4.

		3.5	Antigen
                                         Express shall sponsor an IND application with the FDA and will cross-reference appropriate
                                         INDs held by Merck and Antigen Express. The Parties acknowledge and agree that this is
                                         a combo-IND as the Antigen Express Study Drug is an immunotherapeutic vaccine, which
                                         falls under the Center for Biologics Evaluation and Research ("CBER"), while
                                         the Merck Study Drug is a drug that falls under the Center for Drug Evaluation and Research
                                         ("CDER"). NSABP shall perform the regulatory required filings on behalf of
                                         Antigen Express. NSABP shall copy Antigen Express on all regulatory filings and communications
                                         in respect of the IND. Antigen Express shall provide to, and shall require Merck to provide
                                         to, NSABP all necessary documentation and information required in support of such IND
                                         filings and reporting. Antigen Express shall approve any IND filings and reporting prior
                                         to NSABP submitting such documents, with the exception of SAEs due to the required timing
                                         of filings. NSABP will provide Antigen Express any SAEs filings promptly after submission
                                         to the FDA. NSABP shall provide Antigen Express with a copy of the IND application and
                                         the letter issued by the FDA, which references the IND application number, and other
                                         communications regarding the IND. Without limitation, Article XI shall apply to any Confidential
                                         Information Antigen Express supplies directly to NSABP in support of the IND. 

ARTICLE
IV

FINANCIAL
SUPPORT

		4.1	In
                                         consideration for NSABP’s activities pursuant to this Agreement, including those
                                         obligations specifically undertaken by NSABP as shown in the Task List attached hereto
                                         as Appendix B (“Budget, Payment Schedule, and Task List”), Antigen Express
                                         agrees to pay to NSABP a total sum as set forth in Appendix B in accordance with
                                         the terms and conditions set forth in Appendix B.

    	 	7	 

     

    
		4.1.1	The
                                         total amount payable, as set forth in Appendix B. assumes completed enrollment in the
                                         Study and 12-month accrual of not less than 29 evaluable Subjects, or such greater number
                                         ultimately determined appropriate to reach the Study endpoints using an intent to treat
                                         analysis at a level of statistical significance.

		4.1.2	Antigen
                                         Express shall not be obligated to make any payments to NSABP in excess of the amount
                                         set forth in Appendix B unless Antigen Express and NSABP agree to such excess amount
                                         in writing.

		4.2	If
                                         Antigen Express requests the attendance of NSABP staff and/or Study Personnel at any
                                         meeting necessary to provide information regarding the Study or one or both of the Study
                                         Drugs, Antigen Express shall reimburse NSABP for reasonable and necessary travel and
                                         lodging expenses incurred by such personnel to attend such meeting(s) and that have been
                                         specifically approved in advance in writing by Antigen Express. Antigen Express shall
                                         make such reimbursements within thirty (30) days of receiving acceptable detailed
                                         documentation of such expenses.

		4.3	The
                                         Parties agree that the compensation being paid to NSABP under this Agreement constitutes
                                         the fair market value for the activities to be conducted hereunder. No amounts paid under
                                         this Agreement are intended to be for, nor shall they be construed as an offer or payment
                                         made in exchange for any explicit or implicit agreement to purchase, prescribe, recommend,
                                         or provide a favorable formulary status for any Antigen Express product or service.

		4.4	It
                                         is expected that for all items required under the Protocol for which Antigen Express
                                         has agreed to provide compensation, Antigen Express will be the sole source of monetary
                                         compensation. Accordingly, NSABP shall inform its Research Collaborators that they
                                         shall not charge any Subject nor submit claims to, or otherwise seek reimbursement from,
                                         third party payers or any federal healthcare program for the Study Drugs or any
                                         examinations, tests or procedures paid by Antigen Express under the Protocol, nor shall
                                         they include the cost of the Study Drugs in any cost report to third party payers.

ARTICLE
V

SUPPLY,
OWNERSHIP AND DISTRIBUTION OF STUDY DRUG

		5.1	Study
                                         Drug Supply. Without charge to NSABP, Antigen Express shall, and shall require Merck
                                         to, use commercially reasonable efforts to ensure timely, safe, and accurate shipment
                                         of the Antigen Express Study Drug and the Merck Study Drug, respectively, for use solely
                                         in the Study and in accordance with the Protocol, in quantities sufficient to meet the
                                         requirements of the Study. For clarification purposes, references in this Article V to
                                         contractual obligations of Antigen Express shall include the requirement that Antigen
                                         Express imposes such obligations upon Merck.

		5.1.1	Antigen
                                         Express (including, as applicable, through Antigen Express' drug distributor vendor),
                                         at its expense, shall take commercially reasonable steps to assure appropriate supply,
                                         handling and storage up to the point of delivery to NSABP’s contracted drug distributor
                                         of the Study Drugs, in accordance with the terms of this Agreement, the Protocol, and
                                         any Applicable Law relating thereto. 

    	 	8	 

     

    

		5.1.2	Antigen
                                         Express represents and warrants to NSABP that the Study Drugs are manufactured under
                                         Good Manufacturing Practices.

		5.1.3	Antigen
                                         Express will provide Certificates of Analysis to NSABP for each lot of finished Study
                                         Drugs provided. Upon request of NSABP copies of documentation of shipment of the Study Drugs
                                         to NSABP’s drug distributor will be provided to NSABP by Antigen Express. 

		5.1.4	NSABP
                                         shall obligate all Participating Sites to maintain accurate records of all Study Drugs
                                         received, dispensed, and destroyed in accordance with the Protocol and to store all Study
                                         Drugs in accordance with labeled conditions in a secure and locked location to prevent
                                         theft or misuse.

		5.1.5	Title
                                         to and ownership of all Antigen Express Study Drug and Merck Study Drug provided hereunder
                                         shall remain with Antigen Express and Merck, respectively. 

		5.1.6	In
                                         the event that Antigen Express or any regulatory agency orders a recall or withdrawal
                                         of the Study Drugs (a “Recall”), Antigen Express agrees to reimburse NSABP
                                         all reasonable fees that NSABP is obligated to pay NSABP’s drug distributor to
                                         the extent related to such Recall. The Parties agree to cooperate fully with each other
                                         in effecting any Recall.

		5.2	Study
                                         Drug Distribution. 

		5.2.1	Antigen
                                         Express will ship, or have shipped, the Study Drugs to NSABP’s drug distributor
                                         in appropriately marked containers in accordance with 21 CFR § 312.6.
                                         NSABP will contract with its drug distributor for the redistribution of the Study Drugs
                                         to Participating Sites in accordance with Applicable Law. NSABP will obligate its drug
                                         distributor to (a) store and distribute the Study Drugs according to the labeled
                                         conditions, (b) distribute the Study Drugs only to Participating Sites in countries
                                         where the Study is approved in accordance with Applicable Law, and (c) to maintain
                                         complete and accurate records of the Study Drugs shipment, receipt, disposition, return
                                         and destruction, as applicable. 

		5.3	Disposition
                                         of Unused Supplies. Following termination or completion of the Study, any unused
                                         Study Drugs shall be handled as described in the Protocol and NSABP's written
                                         instructions. 

		5.4	Continued
                                         Supply. If medically appropriate, at the time the Protocol closes early to accrual,
                                         Study Drugs shall continue to be supplied in accordance with this Article V to Subjects
                                         receiving the Study Drugs, until completion of treatment as prescribed in the Protocol.

ARTICLE
VI

BIOLOGIC
REPOSITORY AND BIOSPECIMEN COLLECTION

Under
the terms and conditions set forth in this Article VI, Antigen Express and/or NSABP may agree to design specific research
projects in the Study, which require the collection of all serum, blood, tissue or other biospecimen samples obtained in connection
with the Study ("the Materials"). Such research projects shall be expressly set forth in specific prospective clinical
research designs in the Protocol, included in the Informed Consent Form for the Study, and addressed in this Agreement. In addition,
if agreed to by the Parties, and to the extent expressly set forth in the Protocol, and in
conformance with Applicable Law, NSABP will make its Biologic Repository available for storage of such Materials. Nothing
in this Agreement obligates either Party to do anything with respect to any such research projects.

    	 	9	 

     

    

 

ARTICLE
VII

WARRANTIES
AND DISCLAIMERS

EXCEPT
AS EXPRESSLY SET FORTH IN THIS AGREEMENT, NEITHER OF THE PARTIES MAKES ANY, AND EACH HEREBY DISCLAIMS AND NEGATES ANY AND ALL
REPRESENTATIONS AND WARRANTIES (EXPRESS, IMPLIED, STATUTORY, OR OTHERWISE), WHETHER WRITTEN OR ORAL, EXPRESSED OR IMPLIED, WITH
RESPECT TO THE SUBJECT MATTER OF THIS AGREEMENT, INCLUDING ANY AND ALL IMPLIED WARRANTIES OF QUALITY, PERFORMANCE, MERCHANTABILITY,
FITNESS FOR A PARTICULAR PURPOSE OR USE, THE PATENTABILITY, VALIDITY, SCOPE, OR ENFORCEABILITY OF THE RIGHTS GRANTED HEREIN, AND/OR
THE NON-INFRINGEMENT OF THIRD PARTY INTELLECTUAL PROPERTY RIGHTS.

ARTICLE
VIII

AUDITS

AND ACCESS TO RESEARCH RECORDS

		8.1	At
                                         mutually agreeable times NSABP will give Antigen Express, Merck, and their designees
                                         access to all records and documentation maintained by NSABP (however stored) relating
                                         to the Study for audit purposes. NSABP will also make those records available for the
                                         purposes of any audit by a regulatory authority.

		8.2	Antigen
                                         Express may arrange in advance with the NSABP Principal Investigator and NSABP to conduct
                                         co-audits of Participating Sites during normal business hours. Antigen Express and NSABP
                                         agree to use commercially reasonable efforts to limit such audits to one day or less
                                         in length. Notwithstanding the above, NSABP or Antigen Express may conduct for cause
                                         audits where the immediate need to assure Subject safety, data integrity, or regulatory
                                         compliance exists or as required to address FDA or other government requests with as
                                         little as forty-eight (48) hours' notice. Notwithstanding anything to the contrary, the
                                         Parties agree and acknowledge that any visit to a Participating Site may be subject to
                                         that Participating Site’s policies and procedures, such as those for patient confidentiality
                                         and privacy, security, safety, and the like. The Parties agree to comply with any such
                                         policies and procedures of any such Participating Site while at such Participating Site’s
                                         facilities of which a Party is informed.

 

		8.3	NSABP
                                         will obligate Research Collaborators to make their records or documents available for
                                         the purposes of any audit by a regulatory authority.

 

		8.4	The
                                         Parties agree to treat any information obtained in any audit or during any visit as Confidential
                                         Information subject to Article 11 hereunder.

 

ARTICLE
IX

RECORDS
AND REPORTS

		9.1	NSABP,
                                         or its designated representative shall perform the following recordkeeping and reporting
                                         obligations in a timely and accurate fashion in accordance with NSABP's standard procedures
                                         and Applicable Law, as follows:

    	 	10	 

     

    
		(a)	preparation
                                         and maintenance of complete and accurate written records, accounts, notes, reports, and
                                         data of the Study; and

		(b)	preparation
                                         and submission to Antigen Express of CRFs for each Subject.

		9.2	Each
                                         Party will provide to the other Party copies of all Study communications exchanged by
                                         the Party and the FDA, the Office for Human Research Protection (“OHRP”),
                                         or other regulatory agency, including any that characterize any analyses or conclusions
                                         of Study Data or which otherwise cite an opinion about the Study rendered by NSABP.

		9.3	Adverse
                                         Reactions and SAEs.

		9.3.1	Antigen
                                         Express shall, and shall require Merck to, promptly provide NSABP with relevant IB updates,
                                         significant safety information, including without limitation those serious and unexpected
                                         suspected adverse reactions (as defined by FDA regulations) for the Antigen Express Study
                                         Drug and the Merck Study Drug, respectively, (from any source) and other relevant
                                         information upon which the Parties may mutually agree.

		9.3.2	As
                                         related to the Antigen Express Study Drug, NSABP agrees to report all serious and unexpected
                                         suspected adverse reactions that emerge during the Study to the FDA according to 21 CFR
                                         § 312.32, to other regulatory agencies and the appropriate EC/IRB as required
                                         by Applicable Law within the requisite applicable timeframes and will concurrently forward
                                         all such reports to Antigen Express.

		9.3.3	As
                                         related to the Merck Study Drug, the IND will be filed with a request for a waiver that
                                         exempts Merck from any requirement to notify the FDA of any suspected unexpected serious
                                         adverse reactions related to the administration of the Merck Study Drug in any clinical
                                         study other than as part of the Study. In the event such waiver is not granted, Antigen
                                         Express will sponsor the Study under its extant IND for the Antigen Express Drug (with
                                         a right of reference to the IND for the Merck Study Drug).

		9.4	NSABP
                                         agrees to maintain adequate and accurate records as required under 21 CFR § 312.62
                                         relating to the disposition of the Investigational New Drug and the treatment of Subjects
                                         in the Study, if applicable. Prior to discarding such records, NSABP will notify Antigen
                                         Express of pending destruction, at which time Antigen Express may elect, at its own expense,
                                         to maintain the records until the requirements of marketing applications in other territories
                                         have been met. NSABP shall provide Antigen Express with interim Study status reports
                                         (e.g., toxicity reports, monthly accrual reports, site status information)
                                         in accordance with Appendix B.

		9.5	NSABP
                                         shall register the Study with www.ClinicalTrials.gov.

ARTICLE
X

FINANCIAL
DISCLOSURE AND CONFLICT OF INTEREST

NSABP
shall collect financial disclosure statements from each Investigator sufficient to allow Antigen Express to submit complete and
accurate certification or disclosure statements required under 21 CFR Part 54. In the event Antigen Express decides
to file the results and Antigen Express Study Data with the FDA and/or another health authority in support of a marketing authorization,
NSABP will reasonably assist Antigen Express in meeting its certification and disclosure obligations including, without limitation,
by providing Antigen Express with the financial disclosure statements and assisting Antigen Express in collecting any missing
information from Investigators.

    	 	11	 

     

    

 

ARTICLE
XI

CONFIDENTIAL
INFORMATION

		11.1	“Confidential
                                         Information” shall mean all information and materials related to the Study (whether
                                         owned by a Disclosing Party or by a third party to whom such Disclosing Party owes an
                                         obligation of confidence) disclosed by a Disclosing Party to a Receiving Party, including
                                         (without limitation) the Study Protocol, case report forms, the IB, proprietary technology,
                                         procedures, formulations, protocols, patient information or identifiers, know-how, clinical
                                         data, specifications, documents and related Study materials, techniques, processes, biospecimens,
                                         products samples, apparatus, research plans, business plans, or identity of potential
                                         collaborators.

		11.2	The
                                         Parties may disclose to each other (including their respective agents and representatives
                                         and to Participating Sites and their respective agents and representatives) Confidential Information
                                         to aid in effecting or completing performance of the Study under this Agreement. Confidential Information,
                                         whether written, electronic, or verbal, disclosed by either Party hereunder (the “Disclosing
                                         Party”) to the other (the “Receiving Party”) shall be treated
                                         as confidential by the Receiving Party for a period of five (5) years following
                                         completion or closure of the Study to accrual. All such disclosures of Confidential Information
                                         shall be in writing or other tangible form and shall be prominently marked with the legend
                                         “CONFIDENTIAL” or “CONFIDENTIAL INFORMATION” or the like.
                                         If disclosed orally or in other than documentary or electronic form, Confidential Information
                                         shall be reduced to a tangible form within thirty (30) days thereafter and a copy
                                         of such tangible form, bearing the foregoing confidentiality legend, shall be provided
                                         to the designated representative of the Receiving Party. Notwithstanding the foregoing,
                                         failure by a Party to mark any item "Confidential" or reduce an item to writing
                                         does not constitute a designation of non-confidentiality when the confidential nature
                                         is readily apparent to a reasonable observer from context and subject matter. The Receiving
                                         Party further agrees not to disclose to others or use for any purpose, other than as
                                         reasonably necessary for performance of the Study or exercise of rights under this Agreement,
                                         Confidential Information disclosed pursuant to this Agreement. These obligations of non-disclosure
                                         and non-use shall not apply to information:

		(a)	that
                                         is or becomes publicly available through no fault of the Receiving Party;

		(b)	that
                                         is already independently known to the Receiving Party hereunder prior to receipt from
                                         the Disclosing Party hereunder, as shown by its prior written records or is independently
                                         developed by the Receiving Party without use of any Confidential Information received
                                         from the Disclosing Party; or

		(c)	that
                                         subsequent to its disclosure hereunder, is disclosed to the Receiving Party on a non-confidential
                                         basis by a third party with the legal right to do so.

		11.3	In
                                         the event Antigen Express, or its designees, or Merck, or its designees shall come into
                                         contact with a Subject’s Study records, Antigen Express, or its designees, shall,
                                         and Antigen Express will require Merck, or its designees to, hold in confidence the identity
                                         of the Subject, and shall comply with Applicable Law regarding the confidentiality of
                                         such records as if these records were patient medical records.

    	 	12	 

     

    
		11.4	Confidential
                                         Information shall not be disclosed by the Receiving Party without prior written approval
                                         of the Disclosing Party to any third party, which approval shall not be unreasonably
                                         withheld or delayed, except as set forth in this Article XI or, if required by the FDA
                                         or any other applicable governmental or regulatory agency having the authority to make
                                         such a demand or to any court of law pursuant to a subpoena, or a judicial order, or
                                         as permitted by Applicable Law. NSABP and Antigen Express agree to contact the other
                                         Party prior to the release of any Confidential Information pursuant to this Section 11.3
                                         and allow the other Party to exhaust any legal action it may take to prevent or limit
                                         the disclosure and, at Disclosing Party's request, shall cooperate with the Disclosing
                                         Party to seek a protective order or other appropriate remedy. In the event the Receiving
                                         Party hereunder finds it necessary to disclose Confidential Information of the Disclosing
                                         Party to a proper governmental authority, if permitted by Applicable Law, it shall first
                                         notify the Disclosing Party hereunder and the Parties shall endeavor to agree upon a
                                         mutually satisfactory way to disclose such Confidential Information as is necessary for
                                         this limited purpose and required by Applicable Law. Nothing herein shall prevent
                                         a Party from complying with a legal obligation to disclose Confidential Information of
                                         the other Party so long as the Receiving Party:

		(a)	to
                                         the extent practicable, provides the Disclosing Party prompt notice of the Receiving Party’s
                                         perceived obligation of disclosure and intent to disclose (or to resist disclosure);

		(b)	cooperates
                                         with the Disclosing Party's lawful attempts to prevent or limit the disclosure or obtain
                                         protection for such Confidential Information; and;

		(c)	only
                                         disclosing that portion of Confidential Information that is legally required to disclose.

		11.5	Receiving
                                         Party must within thirty (30) days, upon written request of a Disclosing Party (a) return
                                         all Confidential Information in its possession or control to the Disclosing Party; or
                                         (b) destroy or delete all Confidential Information in its possession or control.
                                         Notwithstanding the foregoing, the Receiving Party may retain one (1) physical copy
                                         of such Confidential Information for archival and legal purposes and electronic back-up
                                         and/or archival storage copies made in accordance with the Receiving Party’s standard
                                         document retention procedures solely for purposes of disaster recovery and compliance
                                         with such policies. When Receiving Party has complied with its obligations described
                                         above, upon request by Disclosing Party, it shall confirm to Disclosing Party, in writing
                                         that it has returned, destroyed or deleted all Confidential Information.

		11.6	Permitted
                                         Disclosures. 

		11.6.1	Receiving
                                         Party may provide Disclosing Party’s Confidential Information to its directors,
                                         employees, consultants, contractors and agents. NSABP may provide, or permit Participating
                                         Sites to provide, Confidential Information to (a) Research Collaborators
                                         and their Research Sites, (b) EC/IRBs and Study Personnel, and (c) applicable accreditation
                                         organizations (including their respective agents and representatives). In each case,
                                         Confidential Information may (i) be provided on a need-to-know basis, and (ii) provided
                                         that the Receiving Parties thereof are subject to written obligations, or bound by institutional
                                         policies, of confidentiality and non-use with regard to such Confidential Information
                                         that are the same or substantially the same as those contained hereunder.

    	 	13	 

     

    
		11.6.2	Notwithstanding
                                         the foregoing, Participating Sites may disclose Confidential Information: (a) to
                                         the applicable EC/IRB(s) or other necessary oversight or governmental or regulatory authority
                                         as required by Applicable Law, and (b) to obtain informed consent from patients
                                         who may wish to enroll in a Study, provided, however, that such Confidential Information
                                         shall only be disclosed to the extent necessary and will not be provided in response
                                         to unsolicited inquiries by telephone or to individuals who are not eligible Study candidates.

		11.6.3	A
                                         Participating Site may disclose Confidential Information to the extent such disclosure
                                         is necessary for the medical treatment of a Subject in an emergency and is unable to
                                         provide prior notice of the disclosure, so long as NSABP provides notice to Antigen Express
                                         of such disclosure promptly after NSABP becomes aware of such disclosure, and such
                                         disclosure only includes such Confidential Information as is medically necessary for
                                         such medical treatment. 

		11.7	The
                                         terms and conditions of this Agreement shall be deemed the Confidential Information
                                         of NSABP, subject to this Article XI. Notwithstanding the foregoing, Antigen Express
                                         acknowledges that pass-through provisions for NSABP contracts with its Research Collaborators
                                         may allow disclosure of the terms and conditions of such contracts pursuant to institutional
                                         policies or Applicable Law. 

ARTICLE
XII

PUBLICATIONS
/ PRESENTATIONS AND GENERAL PUBLICITY

		12.1	Notwithstanding
                                         the obligations of confidentiality and non-use set forth below, NSABP will be free to
                                         publish and present the results of the Study subject to the following conditions: Antigen
                                         Express will be furnished with a copy of any proposed publication, presentation, or abstract
                                         of previously unpublished Data relating to the Study conducted under this Agreement for
                                         review and comment, thirty (30) days prior to such submission for publication or presentation
                                         (collectively, "Review Period"). Such Review Period does not begin until receipt
                                         of the proposed publication, presentation, or abstract by Antigen Express. Antigen Express
                                         shall have the Review Period to respond with any requested revisions, including without
                                         limitation the deletion of Antigen Express Confidential Information (which shall be deemed
                                         to include Merck's Confidential Information), other than the results of the Study, and
                                         revisions to protect any existing or future patents. NSABP shall act in good faith upon
                                         such requested revisions, except NSABP shall delete any Antigen Express Confidential
                                         Information (which shall be deemed to include Merck Confidential Information), other
                                         than the results of the Study, from such proposed publication. At the expiration of such
                                         Review Period, NSABP may proceed with the submission for publication, presentation, or
                                         abstract; provided, however, that in the event Antigen Express has notified
                                         NSABP in writing during the Review Period that Antigen Express reasonably believes that
                                         prior to such publication, presentation, or abstract it must take action to protect its
                                         intellectual property interests, such as the filing of a patent application claiming
                                         an invention or a trademark registration application, NSABP shall either (1) delay such
                                         publication, presentation, or abstract for an additional seventy-five (75) days or until
                                         the foregoing action(s) have been taken, whichever shall first occur; or (2) if NSABP
                                         is unwilling to delay the publication, presentation, or abstract, NSABP will remove from
                                         the publication, presentation, or abstract the information which Antigen Express has
                                         specified it reasonably believes would jeopardize its intellectual property interests.
                                         Under certain circumstances, a shorter review period may be granted in writing by Antigen
                                         Express.

    	 	14	 

     

    
		12.2	Notwithstanding
                                         anything to the contrary in this Agreement, in the event that neither NSABP nor Antigen
                                         Express publishes a manuscript on the primary endpoint of the Study within eighteen (18)
                                         months after the occurrence of the Study primary endpoint events or after the early termination
                                         of the Study, whichever occurs first, Participating Sites, or multiple Participating
                                         Sites, will have the right to publish or present with respect to the applicable Participating
                                         Sites’ own Study-related data provided that any such Participating Sites first
                                         comply with the strictures applicable to NSABP in section 12.1 above.

		12.3	Neither
                                         Party shall mention or otherwise use (nor authorize others to use) the name, trademark,
                                         trade name, logo or names of the employees of the other Party in any publication, press
                                         release or promotional material without the prior written approval of the other Party;
                                         provided, however, that Antigen Express shall have the right to identify NSABP
                                         as the group responsible for conducting the Study. Antigen Express agrees that its use
                                         of the name, symbols, and/or marks of NSABP, or names of NSABP’s employees, shall
                                         be limited to identification of NSABP and its Research Collaborators and subcontractor's
                                         staff as collaborators with NSABP. Antigen Express will not use, nor authorize others
                                         to use, the name, symbols, or marks of NSABP in any advertising or publicity material
                                         or make any form of representation or statement, which would constitute an express or
                                         implied endorsement by NSABP of the Antigen Express Study Drug without prior written
                                         approval from NSABP. Likewise, NSABP shall not use the name of Antigen Express or the
                                         marks of Antigen Express in such a manner without the written permission of Antigen Express.
                                         Antigen Express agrees to allow the following information to appear on NSABP’s
                                         and/or Participating Site’s Clinical Trials Directory website: the identification
                                         of Antigen Express, as the Sponsor of the Study, Study title, Study status, trial type,
                                         Study phase, Study category and subcategory, Study objectives and designs, conditions
                                         treated, treatment(s) or intervention(s), key eligibility criteria and exclusion criteria;
                                         provided, however, that such information includes no additional information
                                         beyond the information Antigen Express posts on its own website or on www.clinicaltrials.gov.

ARTICLE
XIII

DATA
OWNERSHIP AND INVENTIONS

		13.1	NSABP
                                         shall not acquire, as a result of the Study, and nothing transfers by operation of this
                                         Agreement, any proprietary rights in the Study Drugs or any patent right, copyright or
                                         other proprietary right that Antigen Express or Merck owns as of the Effective Date.
                                         Any inventions or discoveries (whether patentable or not) relating to the Antigen Express
                                         Study Drug ("AE Study Drug Invention(s)") or the Merck Study Drug ("Merck
                                         Study Drug Invention(s)") and conceived or made during the performance of the Study
                                         (collectively, hereinafter “Study Drug Invention(s)”), by NSABP, Participating
                                         Sites or Study Personnel, alone or jointly with others, shall be solely owned by Antigen
                                         Express or Merck, respectively. 

		13.2	NSABP
                                         shall, and will contractually obligate Participating Sites and Study Personnel to (through
                                         NSABP), promptly notify Antigen Express of any Study Drug Inventions. “Contractually
                                         obligate,” as used in Article XIII, means that NSABP will include contractual provisions
                                         with its Research Collaborators requiring them to obligate Participating Sites and Study
                                         Personnel to perform the specified action(s). NSABP hereby assigns and will assign, and
                                         will contractually obligate Participating Sites and Study Personnel to, assign and agree
                                         to assign, any and all of their rights, title and interest in Study Drug Inventions to
                                         Antigen Express or Merck, as applicable. Upon Antigen Express’ request, NSABP shall
                                         take, and shall contractually obligate Participating Sites and Study Personnel to take,
                                         at Antigen Express’ or Merck's expense, such actions as Antigen Express or Merck
                                         reasonably deems necessary or appropriate to obtain patent or other proprietary protection
                                         in Antigen Express’ or Merck's name, as applicable, with respect to the applicable
                                         Study Drug Inventions, and shall execute and deliver, and shall contractually obligate
                                         Participating Sites and Study Personnel to execute and deliver, all reasonably requested
                                         applications, assignments, and other documents and take such other measures as Antigen
                                         Express or Merck reasonably requests, in order to record Antigen Express’ or Merck's
                                         rights, as applicable, in the applicable Study Drug Inventions. 

    	 	15	 

     

    
		13.3	All
                                         Data generated or obtained in connection with the Study, and all proprietary rights to
                                         the foregoing, shall be owned by Antigen Express and/or Merck. All Materials generated
                                         or obtained in connection with the Study, and all proprietary rights to the foregoing,
                                         shall be owned by NSABP and be subject to the NSABP Ownership of Data/Materials
                                         Policy attached as Appendix C except to the extent such policy conflicts with the
                                         terms of this Agreement. NSABP agrees to treat such Data as Confidential Information
                                         of Antigen Express pursuant to Article XI prior to public release of the Data in
                                         accordance with the terms of this Agreement. Antigen Express agrees to treat the Materials
                                         as Confidential Information of NSABP pursuant to Article XI. Antigen Express hereby grants
                                         to Subject to Article XI, NSABP (and NSABP may grant to Participating Sites) a perpetual,
                                         irrevocable, world-wide, royalty-free, non-exclusive right and license to use the Data
                                         for non-commercial research, scientific, and educational purposes. Subject to Article
                                         XI, NSABP hereby grants to Antigen Express a royalty-free, non-exclusive right and license
                                         to use the Materials to perform the Study. Notwithstanding Article XI, Antigen Express
                                         shall have the right to use the Data for regulatory purposes in its sole discretion.
                                         NSABP agrees not to use the Data for an NDA, supplemental NDA, or any other regulatory
                                         submission relating to a regulatory approval for the Study Drugs by others.

		13.4	With
                                         respect to any inventions or discoveries (whether patentable or not) (i) conceived or
                                         made in the performance of the Study, or (ii) from the use of Data or Materials (or data
                                         or materials derived therefrom), by NSABP, Participating Sites or Study Personnel, alone
                                         or jointly with others, that are not conceived in the course of NSABP’s performance
                                         of the Study that do not constitute Study Drug Inventions (“Other Inventions”)
                                         shall have the determination of the ownership of such Other Inventions by inventorship
                                         (as determined by U.S. patent law)., even if they arise from research using Data and/or
                                         Materials, or data and/or materials derived therefrom, obtained in connection with the
                                         Study. The Parties agree that for purposes of this Article XIII, performance of
                                         sub-studies conducted by NSABP and/or Antigen Express with such Data and/or Materials
                                         shall not be deemed performance of the Study, unless any such sub-study is expressly
                                         and specifically defined in the Protocol as a sub-study within the Study.

		13.5	NSABP
                                         shall promptly notify Antigen Express of any Other Inventions, and will contractually
                                         obligate its Participating Sites and Study Personnel to, promptly notify NSABP of any
                                         Other Inventions. 

		13.6	Antigen
                                         Express agrees to, and has obtained from Merck the agreement to, grant to NSABP, NSABP
                                         Principal Investigator, Participating Sites, Investigators and/or Study Personnel
                                         who conceived or actually reduced to practice the Study Drug Invention(s) or Joint Study
                                         Drug Invention(s) the right to use such Study Drug Invention or Joint Study Drug Invention
                                         for internal non-commercial academic/educational clinical, and research purposes of NSABP
                                         and/or the Participating Site.

		13.7	NSABP
                                         hereby grants, and will obligate its Participating Sites and Study Personnel (for this
                                         Section 13.7, each an "Institution") to grant, to Antigen Express: 

		13.7.1	a
                                         royalty-free, perpetual license to use Other Inventions solely for Antigen Express’
                                         internal research purposes, provided that the license granted under this Section does
                                         not include the right to use Other Inventions to make, have made, sell, offer for sale,
                                         import or export any products or services, and

    	 	16	 

     

    
		13.7.2	an
                                         option to negotiate to obtain an exclusive royalty-bearing, worldwide license, including
                                         the right to sublicense, to Institution’s interest in Other Inventions. Antigen
                                         Express’ option under this section may be exercised at any time during a period
                                         of 180 days (the “Option Period”) after the written submission to Antigen
                                         Express of each such Other Invention by notice in writing from Antigen Express to Institution.
                                         Upon Antigen Express’ exercise of its option with regard to any particular Other
                                         Invention, Institution and Antigen Express will negotiate in good faith in an attempt
                                         to reach a license agreement satisfactory to all interested parties (the “Negotiation
                                         Period”). Unless extended by the written mutual consent of the interested parties,
                                         the Option Period and the Negotiation Period shall not exceed twelve (12) months in the
                                         aggregate. If Antigen Express fails to exercise an option during an Option Period or
                                         the interested parties fail to conclude an exclusive license to any Other Invention within
                                         the applicable Negotiation Period, Institution shall have no further obligation to Antigen
                                         Express hereunder with regard to Institution’s interest in such Other Inventions.

 

ARTICLE
XIV

NOTICE

Any
notice required or permitted hereunder related to this Agreement shall be in writing and shall be deemed given as of the date
it is: (a) delivered by hand; (b) by overnight courier; (c) delivered by facsimile (with transmission confirmed); or (d)
received by the Party to receive such notice by registered or certified mail, postage prepaid, return receipt requested, and addressed
as set forth below, or to such other address as is subsequently specified in writing.

 

	If to NSABP:	With a copy to:
	Joan Beyer Goldberg, MPH	Norman Wolmark, M.D.
	Chief Executive Officer	Chairman
	NSABP Foundation, Inc.	NSABP Foundation, Inc
	Nova Tower 2	Nova Tower 2
	Two Allegheny Center, Suite 1200	Two Allegheny Center, Suite 1200
	Pittsburgh, PA 15212-5234	Pittsburgh, PA 15212-5234
	 	 
	If to Antigen Express:	With a copy to:
	Antigen Express, Inc.	
	33 Redwing Road	Generex Biotechnology Corporation
	Wellesley, MA 02481	4145 North Service Road, Suite 200
	 	Burlington, Ontario, Canada L7L 6A3
	 	Attention:	Mark Fletcher
	 	 	Executive Vice-President & General Counsel
	 	 	 
	 	 	 
	 	 	 
	 	 
	 	 

 

Any
change(s) to the list in this Article XIV will be communicated in writing to the other Party, pursuant to the terms of this
Article XIV.

    	 	17	 

     

    

ARTICLE
XV

INDEMNIFICATION;
INSURANCE; LIMITATIONS OF LIABILITY

		15.1	Antigen
                                         Express Indemnification.Antigen Express shall defend, indemnify, and hold harmless
                                         the NSABP Principal Investigator, NSABP, Participating Sites, and their respective officers,
                                         employees, IRBs, contractors, and agents (collectively the “NSABP Indemnitees”),
                                         from any and all liabilities, expenses including attorneys' fees, claims, actions, or
                                         suits, including (without limitation) those for personal injury or death (the “Claims”):

		(a)	related
                                         to the use of the Antigen Express Study Drug used in accordance with the Study and written
                                         instructions/information provided by Antigen Express to NSABP or through NSABP to any
                                         third party including participants in connection with the Study;

		(b)	related
                                         to the use of the Antigen Express Study Drug in accordance with the Protocol and/or written
                                         instructions/information supplied or distributed to third parties (including the general
                                         public) by Antigen Express in connection with the Antigen Express Study Drug; 

		(c)	related
                                         to any claimed design defect, manufacturing defect, contamination or adulteration, or
                                         failure to warn relating to the Antigen Express Study Drug.

REGARDLESS
OF WHETHER THE SAME ARE CAUSED, IN WHOLE OR IN PART, BY THE CONCURRENT NEGILGENCE OF THE INDEMNITEES; PROVIDED, HOWEVER:

		(i)	that
                                         NSABP Indemnitees conduct the Study in accordance with Protocol requirements and written
                                         instructions delivered by Antigen Express concerning administration of the Antigen Express
                                         Study Drug and the Merck Study Drug and applicable ICH GCP guidelines;

		(ii)	that
                                         such loss does not arise out of, in the case of NSABP, the breach of this Agreement by
                                         the NSABP or, in the case of the Participating Site Indemnitees, the negligence or willful
                                         malfeasance of any Indemnitees;

		(iii)	that
                                         Antigen Express is promptly notified in writing of any written complaint or claim, or
                                         any serious injury relating to any loss subject to this indemnification; and,

		(iv)	that
                                         Antigen Express shall have the right to select defense counsel and to direct the defense
                                         or settlement of any such claim or suit. Notwithstanding the foregoing, this Section 15.1(iv)
                                         shall apply to state universities or institutions only to the extent allowed under applicable
                                         state law.

		15.2	Merck
                                         Indemnification.Antigen Express represents and warrants that under the terms
                                         of the Merck Agreement, Merck has agreed to defend, indemnify and hold harmless Antigen
                                         Express, its affiliates, and its and their employees, directors, subcontractors and agents
                                         from and against any liability to the extent such liability was directly caused by:

		(a)	negligence
                                         or willful misconduct on the part of Merck (or any of its affiliates, or its and their
                                         employees, directors, subcontractors or agents;

		(b)	a
                                         breach on the part of Merck of any of its representations and warranties or any other
                                         covenants or obligations of Merck under the Merck Agreement; or

(c)       a
breach of Applicable Law by Merck.

    	 	18	 

     

    
		15.3	Antigen
                                         Express shall provide diligent defense against or settlement of any Claims, whether such
                                         Claims are rightfully or wrongfully brought or filed.

		15.4	Any
                                         Claim, to the extent found by a court of competent jurisdiction to have resulted from
                                         the negligence or willful malfeasance of an Indemnitee, is excluded from the Antigen
                                         Express indemnity obligations under this Agreement to such extent. Deviations, defined
                                         as single event variations from the terms of Protocol which would not have a significant
                                         deleterious effect on the research or on the participant that may arise out of necessity,
                                         do not constitute negligence or willful malfeasance or a violation of the requirements
                                         of Section 15.1(i) and/or Section 15.1(ii) above.

		15.5	The
                                         NSABP Indemnitee(s) shall reasonably cooperate with Antigen Express and its legal representatives
                                         in the investigation and defense of any Claim covered under this Agreement. In the event
                                         a Claim is or may be asserted, NSABP shall have the right to select and to obtain representation
                                         by separate legal counsel. Legal counsel selected by NSABP may participate in any settlement
                                         negotiations or legal proceedings subject to Article XV, but Indemnitor(s) shall
                                         retain the right to direct the settlement or defense of any Claim, subject to the NSABP
                                         Indemnitee’s consent and to the extent allowed under state law for Participating
                                         Sites that are state universities and institutions, which consent shall not be unreasonably
                                         withheld or delayed. If NSABP, or Participating Sites that are state universities and
                                         institutions, exercises such right, all costs and expenses incurred by NSABP, or such
                                         Participating Sites, for such separate counsel shall be borne by NSABP, or such Participating
                                         Site.

		15.6	Selected
                                         Terms of Agreement for Disclosure to Sites. Attached as Appendix C to this Agreement
                                         is a listing of Selected Terms of Agreement for Disclosure to Sites. NSABP may provide
                                         a copy of Appendix D to Research Collaborators and/or subcontractors as reasonably deemed
                                         necessary or helpful by NSABP in connection with negotiating the terms of agreements
                                         with Research Collaborators and/or subcontractors for performance of the Study.

		15.7	Antigen
                                         Express warrants that it maintains a policy or program of insurance or self-insurance
                                         at levels sufficient to support the indemnification obligation assumed herein. Upon request,
                                         Antigen Express will provide evidence of its insurance.

		15.8	Each
                                         of the Participating Sites is responsible for maintaining, at its own expense and throughout
                                         the term of this Agreement, insurance as it deems appropriate to protect its liabilities
                                         and contractual obligations. However, failure of any Participating Site to have insurance
                                         coverage, ability to obtain insurance coverage or any inadequacy of insurance coverage
                                         shall not relieve or decrease liabilities, if any, of the Parties or that Participating
                                         Site under this Agreement. It is understood that NSABP, including its agents, Participating
                                         Sites, and subcontractors, is not responsible for the acts or omissions of Antigen Express.
                                         A program of self-insurance will suffice for compliance with this provision.

		15.9	NSABP
                                         SHALL NOT BE LIABLE BEFORE OR AFTER TERMINATION OF THIS AGREEMENT UNDER ANY CONTRACT,
                                         STRICT LIABILITY, NEGLIGENCE, STATUTORY, OR OTHER LEGAL OR EQUITABLE THEORY:

		15.9.1	FOR
                                         ANY DIRECT, SPECIAL INCIDENTAL, CONSEQUENTIAL, OR OTHER DAMAGES RELATED TO ANY PRODUCT,
                                         MATERIAL, EQUIPMENT, DATA, SERVICE, OR OTHER ITEM, IF ANY, PROVIDED HEREUNDER, OR ANY
                                         PRODUCT, MATERIAL, EQUIPMENT, SERVICE, OR ITEM, IF ANY, SUPPLIED TO THIRD PARTIES BY
                                         ANTIGEN EXPRESS AS A RESULT OF THE RESEARCH CONDUCTED UNDER STUDY; OR

    	 	19	 

     

    
		15.9.2	FOR
                                         COST OF PROCUREMENT OF SUBSTITUTE SERVICES OR ANY SPECIAL, INCIDENTAL, OR CONSEQUENTIAL
                                         DAMAGES RELATED TO ANY OBLIGATIONS UNDER THIS AGREEMENT.

ARTICLE
XVI

HUMAN
SUBJECTS

		16.1	Informed
                                         consent of the Subjects shall be obtained in accordance with 45 CFR Part 46.
                                         Related EC/IRB review and approval of Protocol, including the Informed Consent Form,
                                         shall be obtained in accordance with 21 CFR Part 56. The patient consent and/or
                                         HIPAA authorization form(s) as approved by the EC/IRB shall disclose that documentation
                                         may be provided to representatives of Antigen Express, the FDA, or other regulatory agencies
                                         and that patient identifying information will be removed prior to submission thereto.
                                         Subject to Applicable Law, during audits of the Study at NSABP, Participating Sites,
                                         or their designated agents and representatives, Antigen Express shall have the right
                                         to review informed consent forms to assure that they conform to Applicable Law.

		16.2	If
                                         a Subject suffers an adverse reaction, illness, or injury which was directly caused by
                                         the Antigen Express Study Drug, Antigen Express will reimburse for the reasonable
                                         and necessary costs of diagnosis and treatment of any Subject’s injury, including
                                         hospitalization, but only to the extent such expenses are not attributable to (a) the
                                         negligence, recklessness, or willful misconduct of a participating Investigator, a Participating
                                         Site or its officers, agents, consultants, contractors, or employees; (b) a material
                                         failure to follow Protocol not required for medical treatment of a Subject; or (c) the
                                         natural progression of an underlying or pre-existing condition or events, unless exacerbated
                                         by participating in the Study. 

ARTICLE
XVII

TERM
AND TERMINATION

17.1          
This Agreement shall be effective upon the Effective Date and shall continue until the completion of the obligations of this Agreement.

		17.2	This
                                         Agreement may be terminated by either Party, immediately upon prior written notice to
                                         the other Party, if any of the following conditions occur.

		17.2.1	Immediately
                                         upon written notice to the other Party:

		17.2.1.1	if
                                         the authorization and approval to perform the Study in the United States is withdrawn
                                         by the FDA; 

		17.2.1.2	if
                                         human and/or toxicology test results, in the reasonable opinion of either Antigen Express
                                         or NSABP, are of such magnitude and/or frequency of incidence as to support termination
                                         of the Study;

		17.2.1.3	if
                                         the emergence of any adverse reaction or side-effect of any drug administered in the
                                         Study or a modification to the Protocol raises safety issues of such magnitude and/or
                                         incidence in the reasonable opinion of either Antigen Express or NSABP to support termination
                                         of the Study;

    	 	20	 

     

    
		17.2.1.4	If
                                         the manufacture of the Antigen Express Study Drug or Merck Study Drug ceases and/or the
                                         supply of the Antigen Express Study Drug or Merck Study Drug has been exhausted.

		17.2.2	Either
                                         Party shall have the right to terminate this Agreement in the event the other Party remains
                                         in material breach of any Section of this Agreement after thirty (30) days to cure any
                                         such material breach after its receipt of notice of same in writing from the other Party.

		17.3	NSABP
                                         shall have the right to terminate this Agreement in the event Antigen Express fails to
                                         pay an undisputed amount due to NSABP hereunder within forty-five (45) days after
                                         being notified by NSABP that it is in arrears of payments due hereunder; or 

		17.4	Obligations
                                         Upon Termination. If this Agreement is terminated for any reason, the Study shall
                                         be discontinued in accordance with the provisions of the Protocol, this Agreement, and
                                         in a manner designed to preserve Subject safety and data integrity. Both Parties shall
                                         take all reasonable steps to cooperate with the other to wind-down the Study in an efficient,
                                         safe, and cost-effective manner. The need for any continued Subject safety monitoring
                                         and the appropriate manner to cease conducting Study procedures will be reasonably determined
                                         by NSABP in accordance with Applicable Law. In addition, payments will be made to NSABP
                                         by Antigen Express for reasonable costs incurred for all NSABP services performed up
                                         to the time of termination in accordance with this Agreement, and for any reasonable,
                                         non-cancelable expenses related to the Study. Such amounts shall take into account any
                                         payments previously made to NSABP hereunder. 

		17.5	Survival.
                                         No expiration or termination of this Agreement will release the Parties from their rights
                                         or obligations accrued prior to expiration or the effective date of termination. The
                                         rights and duties under (a) Sections 2.6, 4.1, 4.2, 4.3, 4.4, 5.1; (b) Articles VIII,
                                         IX, XI, XII, XIII, XV, XVI, XXIV, XXV, and XXVII; and (c) Appendix B will survive
                                         the expiration or termination of this Agreement. 

ARTICLE
XVIII

AMENDMENTS

This
Agreement may be extended, renewed, or otherwise amended at any time only by the mutual prior written consent of Parties hereto.

ARTICLE
XIX

SEVERABILITY

If
any provision(s) of this Agreement is or becomes invalid, is ruled illegal by any court of competent jurisdiction, or is held
unenforceable, the unenforceability thereof shall not affect the remainder of this Agreement which shall remain in full force
and effect and enforceable in accordance with its terms. Further, it is the intention of the Parties that in lieu of each such
provision, which is invalid, illegal, or unenforceable, there shall be a new provision as similar as possible in economic and
business objective intended by the Parties for such invalid, illegal, or unenforceable provision, but which substituted provision
shall be valid, legal, and enforceable.

    	 	21	 

     

    

 

ARTICLE
XX

INTEGRATION

Appendices
identified within this Agreement are incorporated in this Agreement by reference.

ARTICLE
XXI

ASSIGNMENT

		21.1	Neither
                                         Party hereto may assign, cede, or otherwise transfer any of its rights or obligations
                                         under this Agreement without the prior written consent of the other Party; which consent
                                         may not be unreasonably withheld; provided, however, that without such consent
                                         either Party may freely assign this Agreement in connection with the transfer or sale
                                         of all, or substantially all, of its assets or business, or its merger or consolidation
                                         with another company. Notwithstanding the above, either Party may assign this Agreement
                                         in whole or in part to any wholly-owned subsidiary or its affiliate without consent
                                         of the other Party.

		21.2	This
                                         Agreement shall inure to the benefit of, and be binding upon, each Party signatory hereto,
                                         its successors, and permitted assigns. No assignment shall relieve either Party of the
                                         performance of any accrued obligation, which such Party may then have under this Agreement.
                                         Any permitted assignee will assume the rights and obligations of its assignor under this
                                         Agreement.

ARTICLE
XXII

INDEPENDENT
CONTRACTOR

The
relationship of the Parties to this Agreement is that of independent contractors. Neither Party is authorized or empowered to
act as an agent for the other for any purpose save and except as expressly provided for in this Agreement, and shall not on behalf
of the other enter into any contract, warranty, or representation as to any matter. Neither Party shall be bound by the acts or
conduct of the other, except as provided by the terms of this Agreement.

ARTICLE
XXIII

NO
TRANSFER OF PROPRIETARY RIGHTS NOT SPECIFIED

It
is agreed that neither Antigen Express nor NSABP transfers to the other by operation of this Agreement any patent right, copyright,
or other proprietary right of either Party, except to the extent expressly set forth herein.

ARTICLE
XXIV

CONFORMANCE
WITH LAW AND ACCEPTED PRACTICE

In
performing their respective obligations hereunder, the Parties shall comply, as applicable, with generally accepted standards
of clinical practice, with the Protocol, and with all Applicable Law governing the performance of clinical investigations as applicable
to the Study.

ARTICLE
XXV

WAIVER

No
waiver of any term, provision, or condition of this Agreement whether by conduct or otherwise in any one or more instances shall
be deemed to be or construed as a further or continuing waiver of any such term, provision or condition, or of any other term,
provision or condition of this Agreement.

    	 	22	 

     

    

 

ARTICLE
XXVI

FORCE
MAJEURE

Neither
Party shall be liable for any failure to perform as required by this Agreement, to the extent such failure to perform is due to
circumstances reasonably beyond either Party's control, such as labor disturbances or labor disputes of any kind, accidents, failure
of utilities, mechanical breakdowns, material shortages, hurricanes, tornadoes, blizzards, electrical outages, disease, or other
such occurrences.

ARTICLE
XXVII

DEBARMENT

NSABP
certifies that as of the Effective Date, neither NSABP nor any person engaged or employed thereby directly in the performance
of or providing services for the Study is (i) currently debarred under Section 306(a) or (b) of the Federal Food, Drug and
Cosmetic Act; or (ii) disqualified. NSABP shall obligate its Research Collaborators to certify that (i) none of its Investigators
or Participating Sites, nor any of their respective Study Personnel, are currently debarred; or disqualified; and (ii) will
notify NSABP immediately of any such occurrence. If at any time after execution of this Agreement, NSABP becomes aware of any
such debarment or disqualification, NSABP hereby certifies that NSABP will promptly notify Antigen Express.

ARTICLE
XXVIII

GOVERNING
LAW

 

This
Agreement and the rights and obligations of the Parties hereunder shall be governed by and construed under the laws of the Commonwealth
of Pennsylvania without reference to principles of conflicts of laws. The Parties hereby agree that any and all disputes or controversies
arising out of or related to this Agreement shall be subject to venue and jurisdiction in the state and federal courts situated
in Pittsburgh, Allegheny County, Pennsylvania. Notwithstanding the foregoing, this Article XXIX shall not apply to Participating
Sites that are state universities or institutions, and contracts with such Research Collaborators will be silent on choice of
law.

 

ARTICLE
XXX

ENTIRE
AGREEMENT

This
Agreement and the Appendices hereto, represent the entire understanding and agreement of the Parties with respect to the subject
matter herein, and supersedes all prior discussions, agreements, and understanding entered into orally or otherwise between the
Parties in connection with the subject matter herein. Each Party confirms that it is not relying on any representations or warranties
of any other Party except as specifically set forth in this Agreement. To the extent of any conflict or inconsistency between
the terms of this Agreement, Appendices or the Protocol, the terms of this Agreement will control, except that the terms of the
Protocol will nonetheless control with respect to scientific and medical issues in connection with any such conflict or inconsistency.
This Agreement may only be modified by a writing duly executed by both Parties.

ARTICLE
XXXI

COUNTERPARTS

This
Agreement and any amendments may be executed in any number of counterparts, each of which shall be an original and all of which
together shall constitute one and the same document, binding on all Parties notwithstanding that each of the Parties may have
signed different counterparts. Facsimiles or scanned copies of signatures or electronic images of signatures shall be considered
original signatures unless prohibited by Applicable Law.

 

[The
remainder of this page intentionally left blank.]

 

    	 	23	 

     

    

 

BINDING
EXECUTION

 

IN
WITNESS WHEREOF, the Parties hereto have executed this Agreement in duplicate by the proper persons thereunto duly authorized.

 

NSABP
FOUNDATION, INC.ANTIGEN EXPRESS, INC.

 

	 

        By:
	 	 

        By:

	 	 	 
	 

        Joan
        Beyer Goldberg, MPH
	 	 

         

	Printed
    Name	 	Printed
    Name
	 

        Chief
        Executive Officer
	 	 

         

	Title	 	Title
	 

         
	 	 
	Date	 	Date

 

    	 	24	 

     

    

 

Appendix
A

 

PROTOCOL

 

 

A
Phase II Clinical Trial of Pembrolizumab in Combination with the AE37 Peptide Vaccine in Patients with Metastatic Triple Negative
Breast Cancer (FB-14)

 

[Appendix
A is set out on the following pages]

 

    	 	A-1	 

     

    

 

Appendix
B

 

BUDGET,
PAYMENT SCHEDULE, AND TASK LIST

 

 

		1.	Antigen
                                         Express agrees to pay NSABP an amount not to exceed $2,118,461 as set forth in this Appendix
                                         B to perform the work under the terms of this Agreement. Such payments assumes (a) an
                                         actual enrollment of twenty-nine (29) evaluable patients, (b) five (5) sites, (c) twelve
                                         (12) months accrual, (d) six (6) months average treatment, and (d) at least one (1) patient
                                         receives treatment for 24 months.

 

		2.	Antigen
                                         Express will make payments to NSABP in the increments and at the times indicated on the
                                         Payment Schedule in this Appendix B. Payments to NSABP shall be made in four phases as
                                         follows – Start-Up Activities, Accrual and Treatment Period, Follow-Up Period and
                                         Primary Endpoint. Antigen Express shall pay NSABP invoices not later than thirty (30)
                                         days after receipt of an invoice.

 

		3.	Start-Up
                                         Activities – $340,000 – Within thirty days after receipt of a fully
                                         executed Agreement, Antigen Express will make an initial payment (“Initial Payment”)
                                         to NSABP in the amount of $340,000. The Initial Payment shall become nonrefundable upon
                                         execution of this Agreement to the extent it has been expended for costs actually reasonably
                                         incurred or committed pursuant to this Agreement. The Initial Payment supports: pre-study
                                         activities, site start-up costs, drug distributor, central lab, and database start-up
                                         costs, and other initiation and administration functions, and protocol education and
                                         awareness building.

 

		4.	Accrual
                                         and Treatment Period – $1,458,461 – Antigen Express will pay NSABP
                                         $1,458,461 during the Accrual and Treatment Period commencing with the enrollment of
                                         the first (1) Subject randomized to FB-14 and in increments as indicated on the Payment
                                         Schedule contained in this Appendix B. These payments support the costs of regulatory,
                                         administrative, and other services as anticipated in the performance of FB-14. In addition,
                                         payments include support for activities performed and costs incurred at Participating
                                         Sites, such as: patient screening, eligibility assessment and recruitment activities,
                                         patient instruction, incidental supplies and materials, tissue acquisition and storage,
                                         other unfunded costs related to the study, and the cost of patient care procedures that
                                         are considered non-routine care. 

 

		5.	Follow-Up
                                         Period - $240,000 – Antigen Express shall pay an amount up to $240,000
                                         in three (3) annual payments of $80,000 each. Invoices for annual payments will be submitted
                                         at the beginning of the calendar years for which the payments are related.

 

		6.	Primary
                                         Endpoint - $80,000 – Antigen Express will make a final payment of $80,000
                                         upon completion of the primary endpoint analysis and submission of the primary endpoint
                                         manuscript to Antigen Express.

 

		7.	Antigen
                                         Express shall not be obligated to make any payments to NSABP in excess of the amounts
                                         provided herein, unless such excess amounts have been agreed upon in advance and in writing
                                         by NSABP and Antigen Express.

 

		8.	In
                                         the event Antigen Express disputes any portion of an invoice, Antigen Express shall pay
                                         NSABP the undisputed amount of the invoice within thirty (30) days after Antigen Express'
                                         receipt of the invoice and notify NSABP in writing within fifteen (15) days after Antigen
                                         Express' receipt of the invoice of the amount of the invoice that is disputed and the
                                         reason for the dispute, after which each of Antigen Express and NSABP shall endeavor
                                         to resolve the disputed portion of the invoice.

    	 	B-1	 

     

    

 

 

		9.	If,
                                         for any reason, FB-14 is terminated, or FB-14 is closed to accrual prior to completion,
                                         or FB-14 is not completed with final analysis, in accordance with Article XVIII herein,
                                         Antigen Express agrees to pay NSABP for services rendered and commitments for services
                                         rendered through the termination date. Payment of the outstanding amount due determined
                                         by the final accounting analysis and will be made by Antigen Express after Antigen Express
                                         has received a final report and accounting for the FB-14 and all queries are resolved.
                                         

 

		10.	NSABP
                                         shall invoice Antigen Express referring to this Agreement and any appropriate invoice
                                         number provided by Antigen Express. Invoices shall be payable by Antigen Express forty-five
                                         (45) days from Antigen Express’s receipt of invoice.

 

 

Generex
Biotechnology Corporation

4145
North Service Road, Suite 200

Burlington,
Ontario, Canada L7L 6A3

Attention:
Mark Fletcher, Executive Vice-President & General Counsel

mfletcher@generex.com

416-364-2551,
ext 235

 

		11.	Checks
                                         shall be made payable to “NSABP Foundation, Inc.”, (Tax Identification Number
                                         25-1781357) and sent to: 

 

Accounts
Receivables

NSABP
Foundation, Inc.

Nova
Tower 2

Two
Allegheny Center, Suite 1200

Pittsburgh,
PA 15212

 

    	 	B-2	 

     

    

 

 

 

 

 

 

    	 	B-3	 

     

    

 

Appendix
B

FB-14

Task
List

 

	Compound:	Pembrolizumab
    and AE37 Peptide Vaccine  (collectively, "Study Drugs")
	Protocol:	FB-14
	SOP
    Accountability:	NSABP
	IND
    Holder:	Antigen
    Express
	Version
    Date: 	02/06/2018

 

	Key:
    

    E = Execute; R = Review; S = Support

    A = Approve; AC = Accept	 

        Antigen
        express
	 

        NSABP
	 

        merck

	1.      
    Protocol Preparation	 	 	 
	Approve
    / Accept final Study proposal	AC	E	AC
	Write
    draft Protocol (consultants, literature review, background research)	 	E	 
	Review
    draft Protocol	R	 	R
	Write
    final Protocol	A	E	AC
	Write
    Protocol amendments	A	E	AC
	Provide
    copies of Protocol 	 	E	 
	2.      
    Informed Consent Document Preparation	 	 	 
	Prepare
    informed consent template 	 	E	 
	Assist
    sites with informed consent modification(s)	 	E	 
	Prepare
    and review translations	 	E	 
	3.      
    eCRF Development & eCRF Completion Guide	 	 	 
	Design
    eCRF	 	E	 
	Write
    eCRF Completion Guidelines	 	E	 
	eCRF
    Distribution	 	E	 
	4.      
    Design Systems Required for Data Management	 	 	 
	IT
    Set-Up, System Administration and Maintenance	 	E	 
	5.      
    Design & Implement Patient Registration	 	 	 
	Develop
    registration mechanism	 	E	 
	6.      
    Database Design & Implementation	 	 	 
	Design
    clinical database	 	E	 
	Programming
    and mapping of SAS datasets	 	E	 
	7.      
    Distribution of Study Documents	 	 	 
	Distribute
    Protocol to Sites	 	E	 
	Distribute
    amendments to Sites	 	E	 
	Distribution
    of IB to NSABP	E	 	E
	Distribution
    of IB to Sites	 	E	 
	8.      
    Site Qualifications	 	 	 
	Develop
    list of Sites for qualification	R,
    A	E	 
	Site
    qualification	 	E	 
	Site
    selection	R,
    A	E	 
	9.      
    Investigator Site Contracts & Budgets	 	 	 
	Negotiate
    and finalize Site-specific CDAs	 	E	 
	Negotiate
    and finalize Site-specific Study Agreements	 	E	 
	10.  
    Site Regulatory Documents	 	 	 
	Collect
    the following regulatory documents for Sites:	 	 	 
	Ø 
    FDA Form 1572	 	E	 
	Ø 
    CVs for Investigators and Subinvestigators	 	E	 
	Ø 
    Medical licenses for Investigators and Subinvestigators	 	E	 
	Ø 
    Financial Disclosure for Investigators and Subinvestigators	 	E	 
	Ø 
    Protocol Signature Page signed by Investigator	 	E	 
	Ø 
    IB Acknowledgement Page signed by Investigator	 	E	 
	Ø 
    IRB-approved Institution Informed Consent Form	 	E	 
	Ø 
    IRB approval documents	 	E	 
	Ø 
    OHRP IRB registration	 	E	 
	11.  
    Agency Regulatory Documents	 	 	 
	IND-related
    filings with the FDA	S/A	E	S
	clinicaltrials.gov
    registration	 	E	 
	12.  
    Study Initiation Visits (SIV)	 	 	 
	Plan,
    organize, manage webcast SIV	 	E	 
	Record
    and post SIV content	 	E	 
	Present
    Science / Protocol / Safety Profile	 	E	 
	Present
    regulatory topics	 	E	 
	Present
    AE / SAE reporting	 	E	 
	Present
    monitoring information	 	E	 
	Present
    eCRFs	 	E	 
	Present
    Biologic Repository lab procedures / information	E	E	E
	Present
    Study Drugs Ordering Process to Sites	 	E	 
	13.  
    Site Monitoring	 	 	 
	Develop
    and Implement monitoring plan	 	E	 
	Conduct
    monitoring (Source document verification, drug accountability, regulatory document review, eCRF review, supply inventory,
    etc.)	 	E	 
	Identify
    and report non-compliance	 	E	 
	Provide
    written monitoring reports	 	E	 
	Conduct
    Site close-out procedure (final source document verification, drug accountability, regulatory document review, eCRF review,
    study supply disposition, etc.)	 	E	 
	14.  
    Quality Control & Quality Assurance Audits	 	 	 
	Develop
    Protocol-specific Audit Plan	 	E	 
	Perform
    QC review of Study Data and TMF	 	E	 
	Perform
    QA audits according to Audit Plan	 	E	 
	Perform
    audits of vendors	 	E	 
	15.  
    Operational Issues	 	 	 
	Provide
    on-going Site support	 	E	 
	16.  
    Serious Adverse Event Management	 	 	 
	Receive
    SAE report from Sites and review	 	E	 
	Write
    Protocol-specific SAE Reporting Work Instruction	 	E	 
	Maintain
    a tracking log of all SAE reports from Sites	 	E	 
	Write
    SAE Narrative	 	E	 
	SAE
    follow-up and resolution	 	E	 
	SAE
    reporting to FDA	R/A	E	 
	SAE
    reporting to Antigen Express/Merck (as applicable)	 	E	 
	Distribution
    of IND Safety Reports (expedited reports) to Investigators	 	E	 
	SAE
    reconciliation	 	E	 
	Global
    SUSARS reporting	S	E	S
	17.  
    Sample Management	 	 	 
	Tumor
    Samples	 	E	 
	Blood
    Samples	 	E	 
	18.  
    Project Management	 	 	 
	Process
    and provide payments to Sites	 	E	 
	Organize
    and participate in periodic conference calls with Antigen Express/Merck (agenda, logistics, etc.)	S	E	S
	Prepare
    meeting and conference call minutes following meeting/call completion and distribute to project team	 	E	 
	Manage
    project management issues	 	E	 
	19.  
    Management of Study Kits	 	 	 
	Supply
    Study Kits	 	E	 
	Process
    Study Kit orders and reorders	 	E	 
	Distribute
    Study Kits to Sites	 	E	 
	Coordinate
    post-Study disposition of Study Kits	 	E	 
	Manage
    general Study Kit issues	 	E	 
	20.  
    Management of Study Drugs	 	 	 
	Manufacture
    of the Study Drugs	E	 	E
	Labeling
    (investigational use)	E
    (both study drugs)	 	E
	Distribute
    to the designated NSABP drug distributor	E	 	 
	Receipt
    of the Study Drugs from the manufacturer  	 	E	 
	Process
    Site Study orders and reorders	 	E	 
	Coordinate
    post-Study disposition of Study Drugs	 	E	 
	Provide
    post-Study accountability of Study Drugs	 	E	 
	Manage
    general Study Drugs issues	 	E	 
	21.  
    Data Management	 	 	 
	Write
    data validation plan	 	E	 
	Write
    data management plan	 	E	 
	Write
    statistical analysis plan	R	E	 
	Provide
    Electronic Data Capture System	 	E	 
	Validate
    EDC System	 	E	 
	Resolve
    queries	 	E	 
	Perform
    QC review of eCRFs	 	E	 
	Code
    terms	 	E	 
	Approve
    coding	 	E	 
	22.  
    Tables, Listings & Figurines	 	 	 
	Define
    safety listings and tables	 	E	 
	Define
    efficacy listings and tables	 	E	 
	Produce
    safety listings and tables	 	E	 
	Produce
    efficacy listings and tables	 	E	 
	Validate
    safety listings and tables	 	E	 
	Validate
    efficacy listings and tables	 	E	 
	23.  
    Study Reports	 	 	 
	Provide
    final statistical report	R/AC	E	 
	Prepare
    primary publication	R	E	 
	Prepare
    subsequent publications / abstracts	R	E	 

 

    	 	B-4	 

     

    

 

Appendix
C

 

NSABP’s
Ownership of Data and Materials Ownership Policy

 

[Appendix
C is set out on the following pages]

 

    	 	C-1	 

     

    

 

 

Appendix
D

 

SELECTED
TERMS OF AGREEMENT FOR DISCLOSURE TO SITES

 

Indemnification

 

This
is to confirm that Antigen Express and NSABP have agreed to the following for the FB-14 trial:

 

		1.	Antigen
                                         Express (Indemnitor) shall defend, indemnify, and hold harmless the NSABP Principal Investigator,
                                         NSABP, Participating Sites, and their respective officers, employees, IRBs, contractors,
                                         and agents (collectively the “NSABP Indemnitees”), from any and all liabilities,
                                         expenses including attorneys' fees, claims, actions, or suits, including (without limitation)
                                         those for personal injury or death (the “Claims”):

 

		(a)	related
                                         to the use of the Antigen Express Study Drug used in accordance with the Study and written
                                         instructions/information provided by Antigen Express to NSABP or through NSABP to any
                                         third party including participants in connection with the Study;

 

		(b)	related
                                         to the use of the Antigen Express Study Drug in accordance with the Protocol and/or written
                                         instructions/information supplied or distributed to third parties (including the general
                                         public) by Antigen Express in connection with the Antigen Express Study Drug;

 

		(c)	related
                                         to any claimed design defect, manufacturing defect, contamination or adulteration, or
                                         failure to warn relating to the Antigen Express Study Drug.

REGARDLESS
OF WHETHER THE SAME ARE CAUSED, IN WHOLE OR IN PART, BY THE CONCURRENT NEGILGENCE OF THE INDEMNITEES; PROVIDED, HOWEVER:

		(i)	that
                                         NSABP Indemnitees conduct the Study in accordance with Protocol requirements and written
                                         instructions delivered by Antigen Express concerning administration of the Antigen Express
                                         Study Drug and applicable ICH GCP guidelines;

		(ii)	that
                                         such loss does not arise out of, in the case of NSABP, the breach of the Clinical Trial
                                         Agreement by NSABP or, in the case of the Participating Site Indemnitees, the negligence
                                         or willful malfeasance of any Indemnitees;

		(iii)	that
                                         Antigen Express is promptly notified in writing of any written complaint or claim, or
                                         any serious injury relating to any loss subject to this indemnification; and,

		(iv)	that
                                         Antigen Express shall have the right to select defense counsel and to direct the defense
                                         or settlement of any such claim or suit. Notwithstanding the foregoing, this Section 15.1(iv)
                                         shall apply to state universities or institutions only to the extent allowed under applicable
                                         state law.

 

    	 	D-1	 

     

    

		2.	Antigen
                                         Express represents and warrants that under the terms of the agreement between Merck and
                                         Antigen Express, Merck ("Indemnitor") has agreed to defend, indemnify and hold
                                         harmless Antigen Express, its affiliates, and its and their employees, directors, subcontractors
                                         and agents from and against any liability to the extent such liability was directly caused
                                         by:

		(a)	negligence
                                         or willful misconduct on the part of Merck (or any of its affiliates, or its and their
                                         employees, directors, subcontractors or agents;

		(b)	a
                                         breach on the part of Merck of any of its representations and warranties or any other
                                         covenants or obligations of Merck under this Agreement; or

		(c)	a
                                         breach of Applicable Law by Merck.

		3.	Indemnitor(s)
                                         shall provide diligent defense against or settlement of any Claims, whether such Claims
                                         are rightfully or wrongfully brought or filed.

		3.	Any
                                         Claim, to the extent found by a court of competent jurisdiction to have resulted from
                                         the negligence or willful malfeasance of an Indemnitee, is excluded from the Indemnitor(s)'
                                         indemnity obligations under this Agreement to such extent. Deviations, defined as single
                                         event variations from the terms of Protocol which would not have a significant deleterious
                                         effect on the research or on the participant that may arise out of necessity, do not
                                         constitute negligence or willful malfeasance or a violation of the requirements of Section
                                         15.1(i) and/or Section 15.1(ii) above.

		4.	The
                                         NSABP Indemnitee(s) shall reasonably cooperate with Indemnitor(s) and its legal representatives
                                         in the investigation and defense of any Claim covered under this Agreement. In the event
                                         a Claim is or may be asserted, NSABP shall have the right to select and to obtain representation
                                         by separate legal counsel. Legal counsel selected by NSABP may participate in any settlement
                                         negotiations or legal proceedings subject to Article XV, but Antigen Express shall
                                         retain the right to direct the settlement or defense of any Claim, subject to the NSABP
                                         Indemnitee’s consent and to the extent allowed under state law for Participating
                                         Sites that are state universities and institutions, which consent shall not be unreasonably
                                         withheld or delayed. If NSABP, or Participating Sites that are state universities and
                                         institutions, exercises such right, all costs and expenses incurred by NSABP, or such
                                         Participating Sites, for such separate counsel shall be borne by NSABP, or such Participating
                                         Site.

Antigen
Express, Inc.:

__________________________________

		Name	

		__________________________________	

		Title	

		__________________________________	

		Signature	

    	 	D-2Exhibit 4.1

  

    WESCO DISTRIBUTION, INC.

     

    as Issuer,

     

    the Parent Guarantor named herein

     

    and

     

    U.S. BANK NATIONAL ASSOCIATION

     

    as Trustee

     

    
      

     

    INDENTURE

     

    Dated as of June 12, 2020

     

    

    
      

     

    7.125% Senior Notes due 2025

     

    7.250% Senior Notes due 2028

     

    
      

      
        

      

    

    
    TABLE OF CONTENTS

    

    	 	
            Page

          
	 
	
            ARTICLE ONE

          
	  	 
	
            DEFINITIONS AND INCORPORATION BY REFERENCE

          
	 
	
            SECTION 1.01.

          	
            Definitions.

          	
            1

          
	
            SECTION 1.02.

          	
            No Incorporation by Reference of Trust Indenture Act.

          	
            28

          
	
            SECTION 1.03.

          	
            Rules of Construction.

          	
            28

          
	 	 	 
	
            ARTICLE TWO

          
	 	 	 
	
            THE SECURITIES

          
	 
	
            SECTION 2.01.

          	
            Amount of Notes.

          	
            29

          
	
            SECTION 2.02.

          	
            Form and Dating; Legends.

          	
            29

          
	
            SECTION 2.03.

          	
            Execution and Authentication.

          	
            30

          
	
            SECTION 2.04.

          	
            Registrar and Paying Agent.

          	
            31

          
	
            SECTION 2.05.

          	
            Paying Agent To Hold Money in Trust.

          	
            32

          
	
            SECTION 2.06.

          	
            Noteholder Lists.

          	
            32

          
	
            SECTION 2.07.

          	
            Transfer and Exchange.

          	
            32

          
	
            SECTION 2.08.

          	
            Replacement Notes.

          	
            33

          
	
            SECTION 2.09.

          	
            Outstanding Notes.

          	
            33

          
	
            SECTION 2.10.

          	
            Treasury Notes.

          	
            34

          
	
            SECTION 2.11.

          	
            Temporary Notes.

          	
            34

          
	
            SECTION 2.12.

          	
            Cancellation.

          	
            35

          
	
            SECTION 2.13.

          	
            Defaulted Interest.

          	
            35

          
	
            SECTION 2.14.

          	
            CUSIP and ISIN Numbers.

          	
            35

          
	
            SECTION 2.15.

          	
            Deposit of Moneys.

          	
            36

          
	
            SECTION 2.16.

          	
            Book-Entry Provisions for Global Notes.

          	
            36

          
	
            SECTION 2.17.

          	
            Transfer and Exchange of Notes.

          	
            37

          
	
            SECTION 2.18.

          	
            Computation of Interest.

          	
            45

          
	 	 	 
	
            ARTICLE THREE

          
	 	 	 
	
            REDEMPTION

          
	 
	
            SECTION 3.01.

          	
            Election To Redeem; Notices to Trustee.

          	
            45

          
	
            SECTION 3.02.

          	
            Selection by Trustee of Notes To Be Redeemed.

          	
            45

          
	
            SECTION 3.03.

          	
            Notice of Redemption.

          	
            45

          
	
            SECTION 3.04.

          	
            Effect of Notice of Redemption.

          	
            47

          
	
            SECTION 3.05.

          	
            Deposit of Redemption Price.

          	
            47

          
	
            SECTION 3.06.

          	
            Notes Redeemed in Part.

          	
            48

          

    

    

    
      

      -i-

      
        

      

    

    
    	 	 	
            Page

          
	 	 	 
	
            SECTION 3.07.

          	
            Special Mandatory Redemption.

          	
            48

          
	 	 	 
	
            ARTICLE FOUR

          
	 	 	 
	
            COVENANTS

          
	 
	
            SECTION 4.01.

          	
            Payment of Notes.

          	
            49

          
	
            SECTION 4.02.

          	
            Maintenance of Office or Agency.

          	
            49

          
	
            SECTION 4.03.

          	
            Legal Existence.

          	50
	
            SECTION 4.04.

          	
            Waiver of Stay, Extension or Usury Laws.

          	
            50

          
	
            SECTION 4.05.

          	
            Compliance Certificate.

          	
            50

          
	
            SECTION 4.06.

          	
            Taxes.

          	
            51

          
	
            SECTION 4.07.

          	
            Repurchase at the Option of Holders upon Change of Control.

          	
            51

          
	
            SECTION 4.08.

          	
            Limitation on Asset Disposition.

          	
            54

          
	
            SECTION 4.09.

          	
            Limitation on Restricted Payments.

          	
            56

          
	
            SECTION 4.10.

          	
            Limitation on Liens.

          	
            60

          
	
            SECTION 4.11.

          	
            Activities Limiting Use of Proceeds Prior to the Merger.

          	
            64

          
	
            SECTION 4.12.

          	
            Limitation on Sale and Leaseback Transactions.

          	
            64

          
	
            SECTION 4.13.

          	
            Reports to Holders.

          	
            65

          
	
            SECTION 4.14.

          	
            Additional Guarantees.

          	
            66

          
	
            SECTION 4.15.

          	
            Termination of Certain Covenants When Notes are Rated Investment Grade.

          	
            67

          
	 	 	 
	
            ARTICLE FIVE

          
	 	 	 
	
            SUCCESSOR OBLIGOR

          
	 	 	 
	
            SECTION 5.01.

          	
            Merger, Consolidation or Sale of Assets.

          	
            67

          
	
            SECTION 5.02.

          	
            Successor Person Substituted.

          	
            69

          
	 	 	 
	
            ARTICLE SIX

          
	 
	
            DEFAULTS AND REMEDIES

          
	 
	
            SECTION 6.01.

          	
            Events of Default.

          	
            69

          
	
            SECTION 6.02.

          	
            Acceleration of Maturity; Rescission.

          	
            71

          
	
            SECTION 6.03.

          	
            Other Remedies.

          	
            72

          
	
            SECTION 6.04.

          	
            Waiver of Existing Defaults and Events of Default.

          	
            73

          
	
            SECTION 6.05.

          	
            Control by Majority.

          	
            73

          
	
            SECTION 6.06.

          	
            Limitation on Suits.

          	
            73

          
	
            SECTION 6.07.

          	
            No Personal Liability of Directors, Officers, Employees and Stockholders.

          	
            74

          
	
            SECTION 6.08.

          	
            Rights of Holders To Receive Payment.

          	
            74

          

    

    

    
      

      -ii-

      
        

      

    

    	 	 	
            Page

          
	 	 	 
	
            SECTION 6.09.

          	
            Collection Suit by Trustee.

          	
            74

          
	
            SECTION 6.10.

          	
            Trustee May File Proofs of Claim.

          	
            75

          
	
            SECTION 6.11.

          	
            Priorities.

          	
            75

          
	
            SECTION 6.12.

          	
            Undertaking for Costs.

          	
            76

          
	 	 	 
	
            ARTICLE SEVEN

          
	 	 	 
	
            TRUSTEE

          
	 
	
            SECTION 7.01.

          	
            Duties of Trustee.

          	
            76

          
	
            SECTION 7.02.

          	
            Rights of Trustee.

          	
            78

          
	
            SECTION 7.03.

          	
            Individual Rights of Trustee.

          	
            79

          
	
            SECTION 7.04.

          	
            Trustee’s Disclaimer.

          	
            80

          
	
            SECTION 7.05.

          	
            Notice of Defaults.

          	
            80

          
	
            SECTION 7.06.

          	
            [reserved].

          	
            80

          
	
            SECTION 7.07.

          	
            Compensation and Indemnity.

          	
            80

          
	
            SECTION 7.08.

          	
            Replacement of Trustee.

          	
            82

          
	
            SECTION 7.09.

          	
            Successor Trustee by Consolidation, Merger, etc.

          	
            83

          
	
            SECTION 7.10.

          	
            Eligibility; Disqualification.

          	
            83

          
	
            SECTION 7.11.

          	
            Paying Agents.

          	
            83

          
	 	 	 
	
            ARTICLE EIGHT

          
	 	 	 
	
            AMENDMENT, SUPPLEMENT AND WAIVER

          
	 
	
            SECTION 8.01.

          	
            Without Consent of Noteholders.

          	
            84

          
	
            SECTION 8.02.

          	
            With Consent of Noteholders.

          	
            85

          
	
            SECTION 8.03.

          	
            Revocation and Effect of Consents.

          	
            86

          
	
            SECTION 8.04.

          	
            Notation on or Exchange of Notes.

          	
            87

          
	
            SECTION 8.05.

          	
            Trustee To Sign Amendments, etc.

          	
            87

          
	 	 	 
	
            ARTICLE NINE

          
	 	 	 
	
            SATISFACTION AND DISCHARGE OF INDENTURE; DEFEASANCE

          
	 
	
            SECTION 9.01.

          	
            Satisfaction and Discharge of Indenture.

          	
            87

          
	
            SECTION 9.02.

          	
            Legal Defeasance.

          	89
	
            SECTION 9.03.

          	
            Covenant Defeasance.

          	90
	
            SECTION 9.04.

          	
            Conditions to Defeasance or Covenant Defeasance.

          	
            90

          
	
            SECTION 9.05.

          	
            Deposited Money and U.S. Government Obligations To Be Held in Trust.

          	
            91

          
	
            SECTION 9.06.

          	
            Reinstatement.

          	
            92

          
	
            SECTION 9.07.

          	
            Moneys Held by Paying Agent.

          	
            92

          
	
            SECTION 9.08.

          	
            Moneys Held by Trustee.

          	93

    

    

    
      

      -iii-

      
        

      

    

    	

          	
            Page

          
	 	 
	
            ARTICLE TEN

          
	 	 	 
	
            GUARANTEE OF SECURITIES

          
	 
	
            SECTION 10.01.

          	
            Guarantee.

          	93
	
            SECTION 10.02.

          	
            Execution and Delivery of Guarantee.

          	
            94

          
	
            SECTION 10.03.

          	
            Release of Guarantors.

          	
            95

          
	
            SECTION 10.04.

          	
            Waiver of Subrogation.

          	
            96

          
	
            SECTION 10.05.

          	
            Notice to Trustee.

          	
            96

          
	
            SECTION 10.06.

          	
            Limitation on Guarantor’s Liability.

          	
            97

          
	 	 	 
	
            ARTICLE ELEVEN

          
	 	 	 
	
            MISCELLANEOUS

          
	 
	
            SECTION 11.01.

          	
            Notices.

          	
            97

          
	
            SECTION 11.02.

          	
            [reserved].

          	
            99

          
	
            SECTION 11.03.

          	
            Certificate and Opinion as to Conditions Precedent.

          	
            99

          
	
            SECTION 11.04.

          	
            Statements Required in Certificate and Opinion.

          	
            100

          
	
            SECTION 11.05.

          	
            Rules by Trustee and Agents.

          	
            100

          
	
            SECTION 11.06.

          	
            Business Days; Legal Holidays.

          	
            100

          
	
            SECTION 11.07.

          	
            Governing Law.

          	
            100

          
	
            SECTION 11.08.

          	
            No Adverse Interpretation of Other Agreements.

          	
            101

          
	
            SECTION 11.09.

          	
            Successors.

          	
            101

          
	
            SECTION 11.10.

          	
            Multiple Counterparts.

          	
            101

          
	
            SECTION 11.11.

          	
            Table of Contents, Headings, etc.

          	
            101

          
	
            SECTION 11.12.

          	
            Separability.

          	
            101

          
	
            SECTION 11.13.

          	
            Waiver of Jury Trial.

          	
            101

          
	
            SECTION 11.14.

          	
            Force Majeure.

          	
            102

          
	
            SECTION 11.15.

          	
            U.S.A. Patriot Act.

          	
            102

          
	 	 	 
	
            SIGNATURES 

            

          	 	S-1

    

    

    	
            EXHIBITS

          
	 
	
            Exhibit A-1.

          	
            Form of Senior Note Due 2025

          	
            A-1-1

          
	
            Exhibit A-2.

          	
            Form of Senior Note Due 2028

          	
            A-2-1

          
	
            Exhibit B.

          	
            Form of Private Placement Legend

          	
            B-1

          
	
            Exhibit C.

          	
            Form of Legend for Global Note

          	
            C-1

          
	
            Exhibit D.

          	
            Form of Regulation S Legend

          	
            D-1

          
	
            Exhibit E.

          	
            Form of Certificate of Transfer

          	
            E-1

          
	
            Exhibit F.

          	
            Form of Certificate of Exchange

          	
            F-1

          
	
            Exhibit G.

          	
            Form of Guarantee

          	
            G-1

          
	
            Exhibit H.

          	
            Form of Supplemental Indenture to be Delivered by Subsequent Guarantors

          	H-1

    

    

    
      

      -iv-

      
        

      

    

    INDENTURE, dated as of June 12, 2020, among WESCO Distribution, Inc., a Delaware corporation and its successors (the “Issuer”), the Parent Guarantor (as defined below) and U.S. Bank National Association, as trustee (the “Trustee”).

     

    Each party agrees as follows for the benefit of the other parties and for the equal and ratable benefit of the Holders (as defined below) of the 7.125%
      Senior Notes due 2025 (the “5-Year Notes”) and the 7.250% Senior Notes due 2028 (the “8-Year Notes”
      and, together with the 5-Year Notes, the “Notes”).

     

    ARTICLE ONE

    

    

    DEFINITIONS AND INCORPORATION BY REFERENCE

     

    	SECTION 1.01.	
            Definitions.

          

     

    “5-Year Notes” has the meaning set forth in the recitals
      hereto.

     

    “5-Year Notes Applicable Treasury Rate” for any 5-Year
      Notes Make-Whole Redemption Date means the yield to maturity at the time of computation of United States Treasury securities with a constant maturity (as compiled and published in the most recent Federal Reserve Statistical Release H.15(519) that has
      become publicly available two Business Days prior to the date the Issuer gives notice of such 5-Year Notes Make-Whole Redemption Date (or, if such Statistical Release is no longer published, any publicly available source of similar market data)) most
      nearly equal to the period from such 5-Year Notes Make-Whole Redemption Date to June 15, 2022; provided, however, that if the period from the 5-Year Notes Make-Whole Redemption Date to June 15, 2022 is not equal to the constant maturity of a United States Treasury security for which a weekly average yield is given,
      the 5-Year Notes Applicable Treasury Rate shall be obtained by linear interpolation (calculated to the nearest one-twelfth of a year) from the weekly average yields of United States Treasury securities for which such yields are given except that if
      the period from the 5-Year Notes Make-Whole Redemption Date to June 15, 2022 is less than one year, the weekly average yield on actually traded United States Treasury securities adjusted to a constant maturity of one year shall be used.

     

    “5-Year Notes Make-Whole Premium” means, with respect to
      a 5-Year Note at any 5-Year Notes Make-Whole Redemption Date, an amount equal to the greater of (i) 1.0% of the principal amount of such 5-Year Note and (ii) the excess, if any, of (x) the present value of the sum of the principal amount and premium
      that would be payable on such 5-Year Note on June 15, 2022 and all remaining interest payments to and including June 15, 2022 (but excluding any interest accrued to the 5-Year Notes Make-Whole Redemption Date), discounted on a semiannual basis
      (assuming a 360-day year consisting of twelve 30-day months) from June 15, 2022 to the 5-Year Notes Make-Whole Redemption Date at a per annum interest rate equal to the 5-Year Notes Applicable Treasury Rate on such 5-Year Notes Make-Whole Redemption
      Date plus 0.50%, over (y) the outstanding principal amount of such 5-Year Note.

     

    
      

      
        

      -2-

      

    

    
    “5-Year Notes Make-Whole Redemption Date” with respect to
      a 5-Year Notes Make-Whole Redemption, means the date such 5-Year Notes Make-Whole Redemption is effectuated (and not, for the avoidance of doubt, the date of the related notice of redemption).

     

    “8-Year Notes” has the meaning set forth in the recitals
      hereto.

     

    “8-Year Notes Applicable Treasury Rate” for any 8-Year
      Notes Make-Whole Redemption Date means the yield to maturity at the time of computation of United States Treasury securities with a constant maturity (as compiled and published in the most recent Federal Reserve Statistical Release H.15(519) that has
      become publicly available two Business Days prior to the date the Issuer gives notice of such 8-Year Notes Make-Whole Redemption Date (or, if such Statistical Release is no longer published, any publicly available source of similar market data)) most
      nearly equal to the period from the 8-Year Notes Make-Whole Redemption Date to June 15, 2023; provided, however, that if the period from the 8-Year Notes Make-Whole Redemption Date to June 15, 2023 is not equal to the constant maturity of a United States Treasury security for which a weekly average yield is given,
      the 8-Year Notes Applicable Treasury Rate shall be obtained by linear interpolation (calculated to the nearest one-twelfth of a year) from the weekly average yields of United States Treasury securities for which such yields are given except that if
      the period from the 8-Year Notes Make-Whole Redemption Date to June 15, 2023 is less than one year, the weekly average yield on actually traded United States Treasury securities adjusted to a constant maturity of one year shall be used.

     

    “8-Year Notes Make-Whole Premium” means, with respect to
      an 8-Year Note at any 8-Year Notes Make-Whole Redemption Date, an amount equal to the greater of (i) 1.0% of the principal amount of such 8-Year Note and (ii) the excess, if any, of (x) the present value of the sum of the principal amount and premium
      that would be payable on such Note on June 15, 2023 and all remaining interest payments to and including June 15, 2023 (but excluding any interest accrued to such the 8-Year Notes Make-Whole Redemption Date), discounted on a semiannual basis
      (assuming a 360-day year consisting of twelve 30-day months) from June 15, 2023 to such the 8-Year Notes Make-Whole Redemption Date at a per annum interest rate equal to the 8-Year Notes Applicable Treasury Rate on such the 8-Year Notes Make-Whole
      Redemption Date plus 0.50%, over (y) the outstanding principal amount of such 8-Year Note.

     

    “8-Year Notes Make-Whole Redemption Date” with respect to
      an 8-Year Notes Make-Whole Redemption, means the date such 8-Year Notes Make-Whole Redemption is effectuated (and not, for the avoidance of doubt, the date of the related notice of redemption).

     

    
      

      
        

      -3-

      

    

    “2021 Indenture” means that indenture dated November 26,
      2013, among WESCO Distribution, Inc., as issuer, WESCO International, Inc., as parent guarantor, and U.S. Bank National Association, as trustee.

     

    “2024 Indenture” means that indenture dated June 15,
      2016, among WESCO Distribution, Inc., as issuer, WESCO International, Inc., as parent guarantor, and U.S. Bank National Association, as trustee.

     

    “ABL Credit Facility” means that certain Third Amended
      and Restated Credit Agreement dated as of September 26, 2019 (as the same may be further amended, modified or supplemented from time to time) among the Issuer, JPMorgan Chase Bank, N.A., as administrative agent, JPMorgan Chase Bank, N.A. Toronto
      Branch, as Canadian administrative agent and the other parties from time to time party thereto, together with all related notes, letters of credit, collateral documents, guarantees and any other related agreements and instruments executed and
      delivered in connection therewith, in each case as amended, modified, refinanced, refunded or replaced in whole or in part (including by sales of debt securities) from time to time including by or pursuant to any agreement(s) or instrument(s)
      (including an indenture) extending the maturity of or refinancing (including increasing the amount of available borrowings thereunder or adding any Subsidiaries of the Parent Guarantor as borrowers or guarantors thereunder) all or any portion of the
      Indebtedness under such agreement(s) or instrument(s) any successor or replacement bank credit agreement(s) and whether by the same or any other agent, lender, group of lenders, purchasers, debt holders, creditor or group of creditors.

     

    “Additional 5-Year Notes” means additional 5-Year Notes
      (other than the Initial 5-Year Notes) issued under this Indenture in accordance with Section 2.01 hereof, as part of the same series as the Initial 5-Year Notes.

     

    “Additional 8-Year Notes” means additional 8-Year Notes
      (other than the Initial 8-Year Notes) issued under this Indenture in accordance with Section 2.01 hereof, as part of the same series as the Initial 8-Year Notes.

     

    “Additional Assets” means:

     

    (1)          any property or assets (other than
        Indebtedness and Capital Stock)  to be used by the Parent Guarantor or any of its Subsidiaries;

     

    
      

      
        

      -4-

      

    

    (2)          the Capital Stock of a Person that
        becomes a Subsidiary of the Parent Guarantor as a result of the acquisition of such Capital Stock by the Parent Guarantor or any of its Subsidiaries; or

     

    (3)          Capital Stock constituting a
        non-controlling interest in any Person that at such time is a Subsidiary of the Parent Guarantor.

     

    “Additional Notes” means Additional 5-Year Notes and
      Additional 8-Year Notes.

     

    “Additional Obligor” has the meaning set forth in Section
      4.14(2).

     

    “Affiliate” of any specified Person means any other Person directly or
      indirectly controlling or controlled by or under direct or indirect common control with such specified Person.  For purposes of this definition, “control” (including, with
      correlative meanings, the terms “controlling,” “controlled by” and “under common control with”), as used with respect to any Person, means the possession, directly or indirectly, of the power to direct or cause the direction of the management or policies of such
      Person, whether through the ownership of voting securities, by agreement or otherwise.

     

    “Agent” means any Registrar, Paying Agent, Depositary Custodian, or agent
      for service or notices and demands.

     

    “Agent Members” has the meaning set forth in Section 2.16(a).

     

    “amend” means to amend, supplement, restate, amend and restate or otherwise
      modify; and “amendment” shall have a correlative meaning.

     

     “asset” means any asset or property, whether real, personal or mixed,
      tangible or intangible.

     

    “Asset Disposition” means any sale, lease, transfer or other disposition (or
      series of related sales, leases, transfers or dispositions) by the Parent Guarantor or any of its Subsidiaries, including any disposition by means of a merger, consolidation or similar transaction (each referred to for the purposes of this definition
      as a “disposition”), of:

     

    (1)          any shares of Capital Stock of any of
        the Parent Guarantor’s Subsidiaries (other than directors’ qualifying shares or shares required by applicable law to be held by a Person other than the Parent Guarantor or a Subsidiary);

     

    (2)          all or substantially all the assets
        of any division or line of business of the Parent Guarantor or any of its Subsidiaries; or

     

    
      

      
        

      -5-

      

    

    (3)          any other assets or property of the
        Parent Guarantor or any of its Subsidiaries outside of the ordinary course of business of the Parent Guarantor or such Subsidiary.

     

    Notwithstanding the foregoing, none of the following shall be deemed to be an Asset Disposition:

     

    (1)          a disposition by a Subsidiary of the
        Parent Guarantor to the Parent Guarantor or by the Parent Guarantor or any of its Subsidiaries to any Subsidiary of the Parent Guarantor;

     

    (2)          for purposes of Section 4.08 only, a
        disposition of all or substantially all the assets of the Parent Guarantor or the Issuer in compliance with Section 5.01 or a disposition that constitutes a Change of Control pursuant to this Indenture;

     

    (3)          a sale, contribution, conveyance or
        other transfer of accounts receivable and related assets of the type specified in the definition of Qualified Receivables Transaction by or to a Receivables Entity in a Qualified Receivables Transaction;

     

    (4)          the license or sublicense of
        intellectual property or other intangibles;

     

    (5)          the lease, assignment or sublease of
        any real or personal property in the ordinary course of business;

     

    (6)          any surrender or waiver of contract
        rights or settlement, release, recovery on or surrender of contract, tort or other claims in the ordinary course of business;

     

    (7)          the granting of Security Interests
        not prohibited by Section 4.10;

     

    (8)          the disposition by the Parent
        Guarantor or any of its Subsidiaries in the ordinary course of business of (i) cash and cash equivalents, (ii) inventory and other assets acquired and held for resale in the ordinary course of business, (iii) damaged, worn out or obsolete assets or
        assets that, in the Parent Guarantor’s reasonable judgment, are no longer used or useful in the business of the Parent Guarantor or its Subsidiaries, or (iv) rights granted to others pursuant to leases or licenses, to the extent not materially
        interfering with the operations of the Parent Guarantor or its Subsidiaries;

     

    (9)          a Restricted Payment that is
        permitted by this Indenture;

     

    (10)        any exchange of assets for assets
        (including a combination of assets) (which assets may include Equity Interests or any securities convertible into, or exercisable or exchangeable for, Equity Interests, but which assets may not include any Indebtedness) of comparable or greater
        market value or usefulness to the business of the Parent Guarantor and its Subsidiaries, taken as a whole, which in the event of an exchange of assets with a fair market value in excess of (a) $50.0 million shall be evidenced by an Officer’s
        Certificate and (b) $100.0 million shall be set forth in a resolution approved by at least a majority of the members of the Board of Directors of the Parent Guarantor; provided that the Parent Guarantor shall apply any cash or cash equivalents received in any such exchange of assets as described in Section 4.08(a);

     

    
      

      
        

      -6-

      

    

    (11)        dispositions of receivables in
        connection with the compromise, settlement or collection thereof in the ordinary course of business or in bankruptcy or similar proceedings and exclusive of factoring or similar arrangements;

     

    (12)        the issuance by any Subsidiary of the
        Parent Guarantor of Preferred Stock or any convertible securities;

     

    (13)        any sale of Capital Stock or
        Indebtedness or other securities of a Foreign Subsidiary;

     

    (14)        any sale of assets received by the
        Parent Guarantor or any of its Subsidiaries upon foreclosure on a Security Interest;

     

    (15)        the unwinding of any Hedging
        Obligations (including sales under forward contracts);

     

    (16)        any dispositions to the extent
        required by, or made pursuant to customary buy/sell arrangements between the joint venture parties set forth in joint venture arrangements and similar binding agreements;

     

    (17)        the lease or sublease of office
        space;

     

    (18)        the abandonment, farm-out, lease,
        assignment, sub-lease, license or sub-license of any real or personal property in the ordinary course of business;

     

    (19)        dispositions of property pursuant to
        casualty events;

     

    (20)        dispositions of property pursuant to
        a Sale and Leaseback Transaction permitted by this Indenture;

     

    (21)        foreclosures on assets to the extent
        they would not otherwise result in a Default or Event of Default; or

     

    (22)        a single transaction or series of
        related transactions that involve the disposition of assets with a fair market value of less than the greater of (x) $50.0 million and (y) 1.0% of Consolidated Total Assets.

     

    
      

      
        

      -7-

      

    

    “Attributable Indebtedness,” when used with respect to any Sale and
      Leaseback Transaction, means, as at the time of determination, the present value (discounted at a rate borne by the Notes, compounded on a semiannual basis) of the total obligations of the lessee for rental payments during the remaining term of the
      lease included in any such Sale and Leaseback Transaction.

     

    “Bankruptcy Law” means Title 11 of the United States Code, as amended, or
      any similar federal, state, local or foreign law for the relief of debtors.

     

    “Board of Directors” means, with respect to any Person, the board of
      directors or comparable governing body of such Person or, other than in connection with a Change of Control, any duly authorized committee thereof.

     

    “Business Day” has the meaning set forth in Section 11.06.

     

    “Capital Stock” means:

     

    (1)          in the case of a corporation,
        corporate stock;

     

    (2)          in the case of an association or
        business entity, any and all shares, interests, participations, rights or other equivalents (however designated) of corporate stock; and

     

    (3)          in the case of a partnership or
        limited liability company, partnership or membership interests (whether general or limited).

     

    “Capitalized Lease” means a lease required to be capitalized for financial
      reporting purposes in accordance with GAAP.

     

    “Capitalized Lease Obligations” of any Person means the obligations of such
      Person to pay rent or other amounts under a Capitalized Lease, and the amount of such obligation shall be the capitalized amount thereof determined in accordance with GAAP.

     

    “Cash Consideration” has the meaning set forth in Section 4.08(a)(2).

     

    “CFC Subsidiary” means any Subsidiary that constitutes a controlled foreign
      corporation within the meaning of Section 957 of the Code.

     

    “CFC Subsidiary Holding Company” means any Subsidiary (a) that is engaged in
      no material business activities other than the holding of Equity Interests and other investments in one or more CFC Subsidiaries or other CFC Subsidiary Holding Companies or (b) that owns Equity Interests or other investments in one or more CFC
      Subsidiaries or other CFC Subsidiary Holding Companies and is disregarded for U.S. federal income tax purposes.

     

    
      

      
        

      -8-

      

    

    “Change of Control” means the occurrence of any of the following:

     

    (1)          any Transfer (other than by way of
        merger or consolidation) of all or substantially all of the assets of the Parent Guarantor and its Subsidiaries taken as a whole to any “person” (as defined in Section 13(d) of the Exchange Act) or “group” (as defined in Sections 13(d)(3) and
        14(d)(2) of the Exchange Act), other than any Transfer to the Parent Guarantor or one or more Subsidiaries of the Parent Guarantor;

     

    (2)          the adoption of a plan for the
        liquidation or dissolution the Parent Guarantor (other than in a transaction that complies with Section 5.01); or

     

    (3)          a “person” (as defined above) or
        “group” (as defined above) becomes, directly or indirectly, the “beneficial owner” (as defined in Rules 13d-3 and 13d-5 under the Exchange Act) of more than 50% of the voting power of the Voting Stock of the Parent Guarantor, other than as a result
        of (i) any transaction where the voting power of the Voting Stock of the Parent Guarantor immediately prior to such transaction constitutes or is converted into or exchanged for a majority of the voting power of the Voting Stock of such beneficial
        owner or (ii) any merger or consolidation of the Parent Guarantor with or into any “person” (as defined above) (a “Permitted Person”) or a subsidiary of a Permitted
        Person, in each case, if immediately after such transaction no person (as defined above) is the beneficial owner (as defined above), directly or indirectly, of more than 50% of the voting power of the Voting Stock of such Permitted Person.

     

    “Code” means the Internal Revenue Code of 1986, as
      amended.

     

    “Change of Control Offer” has the meaning set forth in Section 4.07(a).

     

    “Change of Control Payment” has the meaning set forth in Section 4.07(a).

     

    “Change of Control Payment Date” has the meaning set forth in Section
      4.07(a).

     

    “Commission” means the United States Securities and Exchange Commission.

     

    “Consolidated Cash Flow Available for Fixed Charges” means, with respect to
      any Person for any period:

     

    (1) the sum of, without duplication, the amounts for such period, taken as a single accounting period, of:

     

    (a)          Consolidated Net Income;

     

    (b)          Consolidated Non-cash Charges;

     

    
      

      
        

      -9-

      

    

    (c)          Consolidated Interest Expense to the
        extent the same was deducted in computing Consolidated Net Income;

     

    (d)          Consolidated Income Tax Expense
        (other than income tax expense (either positive or negative) attributable to extraordinary gains or losses);

     

    (e)          any expenses or charges related to
        any Equity Offering, any recapitalization or incurrence of Indebtedness or this offering of the Notes;

     

    (f)           the amount of any interest expense
        attributable to minority equity interests of third parties in any non-Wholly Owned Subsidiary of the Parent Guarantor to the extent the same was deducted in computing Consolidated Net Income; and

     

    (g)          any net loss from discontinued
        operations; less

     

    (2) (x) net income from discontinued operations and (y) non-cash items increasing Consolidated Net Income for such period, other than
      (a) the accrual of revenue consistent with past practice and (b) reversals of prior accruals or reserves for cash items previously excluded in the calculation of Consolidated Non-cash Charges.

     

    In calculating “Consolidated Cash Flow Available for Fixed Charges” and “Consolidated Total Assets” for any period, if any Asset Disposition or Asset
      Acquisition (whether pursuant to a stock or an asset transaction) shall have occurred since the first day of any twelve month period for which the “Consolidated Cash Flow Available for Fixed Charges” is being calculated, such calculation shall give
      pro forma effect to such Asset Disposition or Asset Acquisition including, for the avoidance of doubt, any Indebtedness incurred or repaid in connection with such Asset Disposition or Asset Acquisition.

     

    For the purposes of calculating “Consolidated Cash Flow Available for Fixed Charges,” “Asset Acquisition” means any acquisition of property or series of
      related acquisitions of property that constitutes all or substantially all of the assets of a business, unit or division of a Person or constitutes all or substantially all of the common stock (or equivalent) of a Person; and “Asset Disposition”
      means any disposition of property or series of related dispositions of property that involves all or substantially all of the assets of a business, unit or division of a Person or constitutes all or substantially all of the common stock (or
      equivalent) of a Person.

     

    

    
      

      
        

      -10-

      

    

    “Consolidated Fixed Charge Coverage Ratio” means the ratio of Consolidated
      Cash Flow Available for Fixed Charges of the Parent Guarantor and its Subsidiaries during the most recent four consecutive full fiscal quarters for which financial statements are available (the “Four-Quarter Period”) ending on or prior to the date of the transaction giving rise to the need to calculate the Consolidated Fixed Charge Coverage Ratio (the “Transaction

          Date”) to Consolidated Fixed Charges of the Parent Guarantor and its Subsidiaries for the Four-Quarter Period. Notwithstanding anything to the contrary set forth in the definitions of Consolidated Cash Flow Available for Fixed Charges
      and Consolidated Interest Expense (and all component definitions referenced in such definitions), whenever pro forma effect is to be given to the incurrence or repayment of Indebtedness or the issuance or redemption of Preferred Stock, the pro forma
      calculations shall be determined in good faith by a responsible officer of the Parent Guarantor.

     

    For purposes of this definition, Consolidated Cash Flow Available for Fixed Charges and Consolidated Fixed Charges shall be calculated after giving
      effect on a pro forma basis for the period of such calculation to the incurrence of any Indebtedness or the issuance of any Preferred Stock of the Parent Guarantor or any Subsidiary (and the application of the proceeds thereof) and any repayment of
      Indebtedness or redemption of other Preferred Stock (and the application of the proceeds therefrom) (other than the incurrence or repayment of Indebtedness in the ordinary course of business for working capital purposes pursuant to any revolving
      credit arrangement) occurring during the Four-Quarter Period or at any time subsequent to the last day of the Four-Quarter Period and on or prior to the Transaction Date, as if such incurrence, repayment, issuance or redemption, as the case may be
      (and the application of the proceeds thereof), occurred on the first day of the Four-Quarter Period.

     

    In calculating Consolidated Fixed Charges for purposes of determining the denominator (but not the numerator) of this Consolidated Fixed Charge Coverage
      Ratio:

     

    (a)          interest on outstanding Indebtedness
        determined on a fluctuating basis as of the Transaction Date and which will continue to be so determined thereafter shall be deemed to have accrued at a fixed rate per annum equal to the rate of interest on such Indebtedness in effect on the
        Transaction Date (although interest with respect to any Indebtedness for periods while the same was actually outstanding during the respective period shall be calculated using the actual rates applicable thereto while the same was actually
        outstanding);

     

    (b)          if interest on any Indebtedness
        actually incurred on the Transaction Date may optionally be determined at an interest rate based upon a factor of a prime or similar rate, a eurocurrency interbank offered rate, or other rates, then the interest rate in effect on the Transaction
        Date will be deemed to have been in effect during the Four-Quarter Period (although interest with respect to any Indebtedness for periods while the same was actually outstanding during the respective period shall be calculated using the actual
        rates applicable thereto while the same was actually outstanding); and

     

    
      (c)          notwithstanding clause (a) or (b)
          above, interest on Indebtedness determined on a fluctuating basis, to the extent such interest is covered by agreements relating to Hedging Obligations, shall be deemed to accrue at the rate per annum resulting after giving effect to the
          operation of these agreements.

       

        

    

    
      

      
        

      -11-

      

    

    “Consolidated Fixed Charges” for any period means the sum, without
      duplication, of (a) Consolidated Interest Expense of the Parent Guarantor and the Subsidiaries for such period, plus (b) the product of (a) all dividend payments on any series of Disqualified Equity Interests of the Parent Guarantor or any Subsidiary
      or any Preferred Stock of any Subsidiary (other than any such Disqualified Equity Interests or any Preferred Stock held by the Parent Guarantor or a Subsidiary or to the extent paid in Qualified Equity Interests) for such period, multiplied by (b) a
      fraction, the numerator of which is one and the denominator of which is one minus the then current combined federal, state and local statutory tax rate of the Parent Guarantor and the Subsidiaries, expressed as a decimal.

     

    “Consolidated Income Tax Expense” means, with respect to any Person for any
      period the provision for federal, state, local and foreign income taxes of such Person and its subsidiaries for such period as determined on a consolidated basis in accordance with GAAP.

     

    “Consolidated Interest Expense” means, with respect to any Person for any
      period, the interest expense of such Person and its subsidiaries for such period, on a consolidated basis, determined in accordance with GAAP (including amortization of original issue discount and deferred financing costs, non-cash interest payments,
      the interest component of all payments associated with Capitalized Lease Obligations, capitalized interest, net payments, if any, pursuant to interest rate-related Hedging Obligations and imputed interest with respect to Attributable Indebtedness but
      excluding write-offs associated with the amendment and restatement or repayment of indebtedness).

     

    “Consolidated Net Income” means, with respect to any Person, for any period,
      the consolidated net income (or loss) of such Person and its subsidiaries for such period as determined in accordance with GAAP, adjusted, to the extent included in calculating such net income, by excluding, without duplication:

     

    (1)          all extraordinary gains or losses
        (net of fees and expenses relating to the transaction giving rise thereto), income, expenses or charges;

     

    (2)          the portion of net income of such
        Person and its subsidiaries allocable to minority interests in unconsolidated Persons to the extent that cash dividends or distributions have not actually been received by such Person or one of its subsidiaries; provided that, for the avoidance of doubt, Consolidated Net Income shall be increased in amounts equal to the amounts of cash actually received;

     

    (3)          gains or losses in respect of any
        sales of Capital Stock or asset sales outside the ordinary course of business (including in a Sale and Leaseback Transaction) by such Person or one of its subsidiaries (net of fees and expenses relating to the transaction giving rise thereto);

     

    
      

      
        

      -12-

      

    

    (4)          any gain or loss realized as a result
        of the cumulative effect of a change in accounting principles;

     

    (5)          any fees, expenses and other costs
        incurred or paid (and write-offs recorded) in connection with the offering of the Notes and any subsequent exchange offer, the ABL Credit Facility or other Indebtedness;

     

    (6)          nonrecurring or unusual gains or
        losses;

     

    (7)          the net after-tax effects of
        adjustments in the inventory, property and equipment, goodwill and intangible assets line items in such Person’s consolidated financial statements pursuant to GAAP resulting from the application of purchase accounting or the amortization or
        write-off of any amounts thereof;

     

    (8)          any fees and expenses incurred (and
        write-offs recorded) during such period, or any amortization thereof for such period, in connection with any acquisition, investment, asset sale, issuance or repayment or amendment or restatement of Indebtedness, issuance of Capital Stock, stock
        options or other equity-based awards, refinancing transaction or amendment or modification of any debt instrument (including without limitation any such transaction undertaken but not completed);

     

    (9)          any gain or loss recorded in
        connection with the designation of a discontinued operation (exclusive of its operating income or loss);

     

    (10)        any non-cash compensation or other
        non-cash expenses or charges arising from the grant of or issuance or repricing of Capital Stock, stock options or other equity-based awards or any amendment, modification, substitution or change of any such Capital Stock, stock options or other
        equity-based awards;

     

    (11)        any expenses or charges related to
        any Equity Offering, Asset Disposition, merger, amalgamation, consolidation, arrangement, acquisition, disposition, recapitalization or the incurrence of Indebtedness permitted to be incurred by this Indenture (including a refinancing thereof)
        (whether or not successful);

     

    (12)        unrealized gains and losses with
        respect to Hedging Obligations; and

     

    (13)        any non-cash impairment,
        restructuring or special charge or asset write-off or write-down, and the amortization or write-off of intangibles.

     
       “Consolidated Non-cash Charges” means, with respect to any Person for any
        period, the aggregate depreciation, amortization and other non-cash expenses of the Person and its subsidiaries (including without limitation any minority interest) reducing Consolidated Net Income for such period, determined on a consolidated
        basis in accordance with GAAP.

       

      

    

    
      

      
        

      -13-

      

    

    “Consolidated Total Assets” means the total assets of the Parent Guarantor
      and its Subsidiaries as of the most recent fiscal quarter end for which an internal consolidated balance sheet of the Parent Guarantor and its Subsidiaries is available, all calculated on a consolidated basis in accordance with GAAP (which
      calculation shall give pro forma effect to any Asset Acquisition or Asset Disposition consummated by the Parent Guarantor since the date of such balance sheet and on or prior to the date of determination, as if such Asset Acquisition or Asset
      Disposition had been consummated on the date of such consolidated balance sheet).

     

    For the purposes of calculating “Consolidated Total Assets,” “Asset Acquisition” means any acquisition of property or series of related acquisitions of
      property that constitutes all or substantially all of the assets of a business, unit or division of a Person or constitutes all or substantially all of the common stock (or equivalent) of a Person; and “Asset Disposition” means any disposition of
      property or series of related dispositions of property that involves all or substantially all of the assets of a business, unit or division of a Person or constitutes all or substantially all of the common stock (or equivalent) of a Person.

     

    “Corporate Trust Office” means the office of the Trustee at which any time
      its corporate trust business in relation to this Indenture shall be administered, which at the date hereof is located at 225 W. Station Square Drive, Suite 380, Pittsburgh PA 15219, Attention: Corporate Trust Services,  or such other address as the
      Trustee may designate from time to time by notice to the Holders and the Issuer, or the principal corporate trust office of any successor Trustee (or such other address as such successor Trustee may designate from time to time by notice to the
      Holders and the Issuer).

     

    “Covenant Defeasance” has the meaning set forth in Section 9.03.

     

    “Covenant Termination Event” has the meaning set forth in Section 4.15(a).

     

    “Credit Facilities” means one or more debt facilities (including, without
      limitation, the ABL Credit Facility) or commercial paper facilities, in each case with banks or other lenders providing for revolving credit loans, term loans or letters of credit, together with all related notes, letters of credit, collateral
      documents, guarantees and any other related agreements and instruments executed and delivered in connection therewith, in each case as amended, modified, refinanced, refunded or replaced in whole or in part (including by sales of debt securities)
      from time to time including by or pursuant to any agreement(s) or instrument(s) (including an indenture) extending the maturity of or refinancing (including increasing the amount of available borrowings thereunder or adding the Parent Guarantor or
      Subsidiaries of the Parent Guarantor as borrowers or guarantors thereunder) all or any portion of the Indebtedness under such agreement(s) or instrument(s) any successor or replacement bank credit agreement(s) and whether by the same or any other
      agent, lender, group of lenders, purchasers, debt holders, creditor or group of creditors.

     

    
      

      
        

      -14-

      

    

    “Default” means (1) any Event of Default or (2) any event, act or condition
      that, after notice or the passage of time or both, would be an Event of Default.

     

    “Depositary” means, with respect to the Global Notes, The Depository Trust
      Company or another Person designated as depositary by the Issuer, which Person must be a clearing agency registered under the Exchange Act.

     

    “Depositary Custodian” means the Trustee as custodian with respect to the
      Global Notes or any successor entity thereto.

     

    “Designated Non-cash Consideration” means the fair market value of non-cash
      consideration received by the Issuer or any of the Guarantors in connection with an Asset Disposition that is designated as “Designated Non-cash Consideration” pursuant to an officer’s certificate, setting forth the basis of such valuation, less the
      amount of cash or cash equivalents received in connection with a subsequent sale, redemption or payment of, on or with respect to such Designated Non-cash Consideration.

     

    “Disqualified Equity Interests” of any Person means any class of Equity
      Interests of such Person that, by its terms, or by the terms of any related agreement or of any security into which it is convertible, puttable or exchangeable, is, or upon the happening of any event or the passage of time would be, required to be
      redeemed by such Person, whether or not at the option of the holder thereof, or matures or is mandatorily redeemable, pursuant to a sinking fund obligation or otherwise, in whole or in part on or prior to the date which is 91 days after the final
      maturity date of any outstanding Notes; provided, however, that any
      class of Equity Interests of such Person that, by its terms, authorizes such Person to satisfy in full its obligations with respect to the payment of dividends or upon maturity, redemption (pursuant to a sinking fund or otherwise) or repurchase
      thereof or otherwise by the delivery of Equity Interests that are not Disqualified Equity Interests, and that is not convertible, puttable or exchangeable for Disqualified Equity Interests or Indebtedness, will not be deemed to be Disqualified Equity
      Interests so long as such Person satisfies its obligations with respect thereto solely by the delivery of Equity Interests that are not Disqualified Equity Interests; provided,
      further, however, that any Equity Interests that would not constitute
      Disqualified Equity Interests but for provisions thereof giving holders thereof (or the holders of any security into or for which such Equity Interests are convertible, exchangeable or exercisable) the right to require the Issuer to redeem such
      Equity Interests upon the occurrence of a change of control occurring prior to the 91st day after the final maturity date of any outstanding Notes, in each case, shall not constitute Disqualified Equity Interests if the change of control provisions
      applicable to such Equity Interests are no more favorable to such holders than the provisions of Section 4.07 and such Equity Interests specifically provide that
        the Issuer will not redeem any such Equity Interests pursuant to such provisions prior to the Issuer’s purchase of each series of Notes as required pursuant to Section 4.07.

     

    
      

      
        

      -15-

      

    

     “Domestic Subsidiary” means any Subsidiary of the Issuer, other than a
      Foreign Subsidiary.

     

     “Eligible Investments” means any of the following: (1) investments in
      obligations issued or guaranteed by the U.S. government or any agency thereof; (2) demand deposits, including interest-bearing money market accounts, time deposits, trust funds, trust accounts, overnight bank deposits, interest-bearing deposits,
      certificates of deposit or bankers acceptances of depository institutions; (3) investments in commercial paper having, at the date of acquisition, a credit rating no lower than A-1 from S&P or P-1 from Moody’s; (4) investments in money market
      mutual funds having a rating in the highest investment category granted thereby from S&P or Moody’s; or (5) any investment funds or mutual funds primarily invested in any of the foregoing (including, for the avoidance of doubt, the BlackRock
      FedFund (or any successor thereto or replacement thereof)).

     

    “Equity Interests” of any Person means (1) any and all shares or other
      equity interests (including common stock, Preferred Stock, limited liability company interests and partnership interests) in such Person and (2) all rights to purchase, warrants or options (whether or not currently exercisable), participations or
      other equivalents of or interests in (however designated) such shares or other interests in such Person, but excluding any debt securities that are convertible into such shares or other interests in such Person.

     

    “Equity Offering” means a public sale for cash of common stock of the Parent
      Guarantor or any direct or indirect parent entity of the Parent Guarantor, other than (i) public offerings with respect to common stock of the Parent Guarantor or any of its direct or indirect parent entities registered on Form S-4 or Form S-8 or
      (ii) any sale to any Subsidiary of the Parent Guarantor.

     

    “Event of Default” has the meaning set forth in Section 6.01.

     

    “Excess Proceeds” has the meaning set forth in Section 4.08(c).

     

    “Exchange Act” means the Securities Exchange Act of 1934, as amended.

     

    “Fiscal Year” means the fiscal year of the Issuer, which at the date hereof
      ends on December 31.

     

     “Fixed Basket” shall mean with respect to any covenant, any exception,
      threshold or basket based on any fixed amount.

     

    
      

      
        

      -16-

      

    

    “Foreign Subsidiary” means (i) any Subsidiary of the Issuer that is
      organized under the laws of a jurisdiction other than the United States, any state thereof or the District of Columbia, (ii) any Subsidiary of the Issuer that is a CFC Subsidiary Holding Company, or (iii) any Subsidiary of the Issuer that is a direct
      or indirect subsidiary of any CFC Subsidiary or CFC Subsidiary Holding Company.

     

    “GAAP” means generally accepted accounting principles set forth in the
      opinions and pronouncements of the Accounting Principles Board of the American Institute of Certified Public Accountants and statements and pronouncements of the Financial Accounting Standards Board or in such other statements by such other entity as
      may be approved by a significant segment of the accounting profession of the United States, which are in effect on the Issue Date; provided, for the avoidance
      of doubt, that any leases that are not or would not be characterized as Capitalized Leases under GAAP as in effect on June 15, 2016 shall not be reclassified as Capitalized Leases and additional liabilities associated with such leases shall not be
      classified as Indebtedness as a result of any changes in interpretive releases or literature regarding GAAP or any requirements by the independent auditors of the Parent Guarantor.

     

    “Global Note Legend” means the legend substantially in the form set forth in
      Exhibit C.

     

    “Global Notes” has the meaning set forth in Section 2.16(a).

     

    “Guarantee” means a guarantee (other than by endorsement of negotiable
      instruments for collection in the ordinary course of business), direct or indirect, in any manner (including, without limitation, through letters of credit and reimbursement agreements in respect thereof), of all or any part of any Indebtedness.
      “Guarantee” when used as a verb shall have a corresponding meaning.

     

    “Guarantor” means:

     

    (1)          the Parent Guarantor;

     

    (2)          promptly following the consummation
        of the Merger, the Subsidiary Guarantor;

     

    (3)          each Domestic Subsidiary of the
        Issuer that executes and delivers this Indenture or a Guarantee pursuant to Section 4.14; and

     

    (4)          each Subsidiary of the Issuer that
        otherwise executes and delivers a Guarantee,

     

    in each case, until such time as such Person is released from its Guarantee in accordance with the provisions of this Indenture.

     

    
      

      
        

      -17-

      

    

    “Hedging Obligations” of any Person means the obligations of such Person
      under swap, cap, collar, forward purchase or similar agreements or arrangements dealing with interest rates, currency exchange rates or commodity prices or availability, either generally or under specific contingencies, and including both physical
      and financial settlement transactions.

     

    “Holder” or “Noteholder”
      means any registered holder, from time to time, of any series of Notes.

     

    “Incurrence-Based Basket” means, with respect to any covenant, any
      incurrence based exception, threshold or basket based on any applicable ratio or financial test.

     

    “Indebtedness” of any Person at any date means, without duplication:

     

    (a)          all liabilities, contingent or
        otherwise, of such Person for borrowed money (whether or not the recourse of the lender is to the whole of the assets of such Person or only to a portion thereof);

     

    (b)          all obligations of such Person
        evidenced by bonds, debentures, notes or other similar instruments;

     

    (c)          all reimbursement obligations of such
        Person in respect of letters of credit, letters of guaranty, bankers’ acceptances and similar credit transactions;

     

    (d)          all obligations of such Person to pay
        the deferred and unpaid purchase price of property or services due more than six months after such property is acquired or services performed, except (i) trade payables and accrued expenses, (ii) obligations to pay royalty fees or other payments
        under license agreements and (iii) accrued expenses, salary and other employee compensation obligations, in each case incurred in the ordinary course of business in connection with obtaining goods, materials or services;

     

    (e)          the maximum fixed redemption or
        repurchase price of all Disqualified Equity Interests of such Person (but excluding any accrued but unpaid dividends);

     

    (f)           all Capitalized Lease Obligations
        of such Person;

     

    (g)          all Indebtedness of others secured
        by a Security Interest on any asset of such Person, whether or not such Indebtedness is assumed by such Person;

     

    (h)          all Indebtedness of others guaranteed
        by such Person to the extent of such guarantee; provided that Indebtedness of the Parent Guarantor or any of its Subsidiaries that is guaranteed by the
        Parent Guarantor or any such Subsidiary shall only be counted once in the calculation of the amount of Indebtedness of the Parent Guarantor and its Subsidiaries on a consolidated basis;

     

    
      

      
        

      -18-

      

    

    (i)           all Attributable Indebtedness; and

     

    (j)           all obligations of such Person
        under conditional sale or other title retention agreements relating to assets purchased by such Person.

     

    The amount of Indebtedness of any Person at any date shall be the outstanding balance at such date of all unconditional obligations as described above,
      the maximum liability of such Person for any such contingent obligations at such date and, in the case of clause (g), the lesser of (a) the fair market value of any asset subject to a Security Interest securing the Indebtedness of others on the date
      that the Security Interest attaches and (b) the amount of the Indebtedness secured. For purposes of clause (e), the “maximum fixed redemption or repurchase price” of any Disqualified Equity Interests that do not have a fixed redemption or repurchase
      price shall be calculated in accordance with the terms of such Disqualified Equity Interests as if such Disqualified Equity Interests were redeemed or repurchased on any date on which an amount of Indebtedness outstanding shall be required to be
      determined pursuant to this Indenture.

     

    “Indenture” means this Indenture as amended, restated or supplemented from
      time to time.

     

    “Initial 5-Year Notes” means the first $1,500,000,000 aggregate principal
      amount of 5-Year Notes issued under this Indenture on the date hereof.

     

    “Initial 8-Year Notes” means the first $1,325,000,000 aggregate principal
      amount of 8-Year Notes issued under this Indenture on the date hereof.

     

    “Initial Notes” means the Initial 5-Year Notes and the Initial 8-Year Notes.

     

    “Initial Purchasers” means Barclays Capital Inc., CIBC World Markets Corp.,
      Fifth Third Securities, Inc., PNC Capital Markets LLC, TD Securities (USA) LLC, U.S. Bancorp Investments, Inc., Citizens Capital Markets, Inc., HSBC Securities (USA) Inc. and Scotia Capital (USA) Inc.

     

    “Initial Security Interest” has the meaning set forth in Section 4.10.

     

    “interest” means, with respect to each series of Notes, interest with
      respect thereto.

     

    “Interest Payment Date” means the stated maturity of an installment of
      interest on the Notes.

     

    
      

      
        

      -19-

      

    

    “Investment Grade Rating” means a rating equal to or higher than Baa3 (or
      the equivalent) by Moody’s and BBB- (or the equivalent) by S&P, in each case with stable outlook, or an equivalent rating by any other Rating Agency.

     

    “Issue Date” means June 12, 2020, the date on which Notes were first issued
      under this Indenture.

     

    “Issuer” has the meaning set forth in the recitals hereto.

     

    “Legal Defeasance” has the meaning set forth in Section 9.02.

     

    “Legal Holiday” has the meaning set forth in Section 11.06.

     

    “Losses” has the meaning set forth in Section 7.07.

     

     “Maturity Date” when used with respect to any Note, means the date on which
      the principal amount of such Note becomes due and payable as therein or herein provided.

     

    “Merger” means the transactions contemplated by the Agreement and Plan of
      Merger (as the same may be further amended, modified, supplemented or replaced from time to time), dated as of January 10, 2020, by and among Parent Guarantor, Warrior Merger Sub, Inc. and Anixter International Inc.

     

    “Moody’s” means Moody’s Investors Service, Inc. and any successor to its
      rating agency business.

     

    “Net Available Cash” from an Asset Disposition means cash payments received
      therefrom (including any cash payments received by way of deferred payment of principal pursuant to a note or installment receivable or otherwise, but only as and when received, but excluding any other consideration received in the form of assumption
      by the acquiring Person of Indebtedness or other obligations relating to such properties or assets or received in any other noncash form), in each case net of:

     

    (1)          all legal, accounting, investment
        banking, title and recording tax expenses, commissions and other fees (including financial and other advisory fees) and expenses incurred, and all Federal, state, provincial, foreign and local taxes required to be paid or accrued as a liability
        under GAAP, as a consequence of such Asset Disposition;

     

    (2)          all payments made on any Indebtedness
        which is secured by any assets subject to such Asset Disposition, in accordance with the terms of any lien upon or other security agreement of any kind with respect to such assets, or which must by its terms, or in order to obtain a necessary
        consent to such Asset Disposition, or by applicable law, be repaid out of the proceeds from such Asset Disposition;

     

    
      

      
        

      -20-

      

    

    (3)          all distributions and other payments
        required to be made to non-controlling interest holders in Subsidiaries or joint ventures as a result of such Asset Disposition; and

     

    (4)          appropriate amounts provided by the
        seller as a reserve, in accordance with GAAP, against any liabilities associated with the property or other assets disposed in such Asset Disposition and retained by the Parent Guarantor or any of its Subsidiaries after such Asset Disposition.

     

    “Non-U.S. Person” means a Person who is not a U.S. Person.

     

    “Notes” means, with respect to each series, the Initial Notes and the
      Additional Notes, if any.  For each series, the Initial Notes issued on the Issue Date and the Additional Notes shall be treated as a single class for all purposes under this Indenture, and unless the context otherwise requires, all references to the
      Notes shall include the Notes issued on the Issue Date and any Additional Notes.

     

    “Offer” has the meaning set forth in Section 4.08(a).

     

    “Offering Memorandum” means the Offering Memorandum of the Issuer, dated May
      29, 2020, relating to the offering of the Notes on the Issue Date.

     

    “Officer” means, with respect to any Person, the Chairman, President, Chief
      Executive Officer, Chief Financial Officer, Treasurer, Controller, any Senior Vice President, any Vice President of such Person or any other authorized officer or director of such Person.

     

    “Officer’s Certificate” means, with respect to any Person, a certificate
      signed by any Officer of such Person that shall comply with applicable provisions of this Indenture.

     

    “Opinion of Counsel” means a written opinion from legal counsel, who may be
      an employee of or counsel to the Parent Guarantor or any of its Subsidiaries, or other counsel who is reasonably acceptable to the Trustee.  Each such opinion shall include the statements provided for in Section 11.04, if and to the extent required
      by the provisions thereof.

     

    “Parent Guarantor” means WESCO International, Inc., a Delaware corporation,
      the direct parent company of the Issuer and its successors.

     

    “Pari Passu Indebtedness” means any Indebtedness of the Issuer or any
      Guarantor that ranks pari passu in right of payment with each series of Notes or the Guarantees, as applicable.

     

    “Paying Agent” has the meaning set forth in Section 2.04.

     

    “Payment Default” has the meaning set forth in Section 6.01(a).

     

    
      

      
        

      -21-

      

    

    “Permitted Security Interest” has the meaning set forth in Section 4.10.

     

    “Person” means an individual, partnership, corporation, limited liability
      company, unincorporated organization, trust or joint venture, or a governmental agency or political subdivision thereof.

     

    “Physical Notes” means certificated Notes in registered form that are not
      Global Notes.

     

    “Preferred Stock” means, with respect to any Person, any and all preferred
      or preference stock or other equity interests (however designated) of such Person having a preference or priority over other Equity Interests (however designated) of such Person, whether now outstanding or issued after the Issue Date.

     

    “principal” of a Note means the principal of the Note plus the premium, if
      any, payable on the Note which is due or overdue or is to become due at the relevant time.

     

    “Principal Facility” means any land, building, machinery or equipment, or
      leasehold interests and improvements in respect of the foregoing, owned, on the date of this Indenture or thereafter, by the Parent Guarantor or any of its Subsidiaries, which has a gross book value (without deduction for any depreciation reserves)
      at the date as of which the determination is being made of in excess of 1.0% of the Consolidated Total Assets, other than any such land, building, machinery or equipment, or leasehold interests and improvements in respect of the foregoing which, in
      the opinion of the Board of Directors of the Parent Guarantor (evidenced by a board resolution), is not of material importance to the business conducted by the Parent Guarantor and its Subsidiaries taken as a whole.

     

    “Private Placement Legend” means the legend substantially in the form set
      forth in Exhibit B.

     

    “Qualified Equity Interests” of any Person means Equity Interests of such
      Person other than Disqualified Equity Interests; provided that such Equity Interests shall not be deemed Qualified Equity Interests to the extent sold to a
      Subsidiary of such Person or financed, directly or indirectly, using funds (1) borrowed from such Person or any Subsidiary of such Person until and to the extent such borrowing is repaid or (2) contributed, extended, guaranteed or advanced by such
      Person or any Subsidiary of such Person (including, without limitation, in respect of any employee stock ownership or benefit plan). Unless otherwise specified, Qualified Equity Interests refer to Qualified Equity Interests of the Parent Guarantor.

     

    “Qualified Institutional Buyer” shall have the meaning specified in Rule
      144A promulgated under the Securities Act.

     

    
      

      
        

      -22-

      

    

    “Qualified Receivables Transaction” means any transaction or series of
      transactions that may be entered into by the Parent Guarantor or any of its Subsidiaries pursuant to which the Parent Guarantor or any of its Subsidiaries may sell, convey or otherwise transfer to:

     

    (1)          a Receivables Entity (in the case of
        a transfer by the Parent Guarantor or any of its Subsidiaries); or

     

    (2)          any other Person (in the case of a
        transfer by a Receivables Entity),

     

    or may grant a security interest in, any accounts receivable (whether now existing or arising in the future) of the Parent Guarantor or any of its Subsidiaries, and any
      assets related thereto, including all collateral securing such accounts receivable, all contracts and all Guarantees or other obligations in respect of such accounts receivable, proceeds of such accounts receivable and other assets which are
      customarily transferred or in respect of which security interests are customarily granted in connection with asset securitization transactions involving accounts receivable; provided, however, that the financing terms, covenants, termination events and other provisions thereof shall be market terms in all material
      respects at the time of such transaction (as determined in good faith by the Parent Guarantor). The grant of a Security Interest in any accounts receivable of the Parent Guarantor or any of its Subsidiaries to secure Indebtedness under Credit
      Facilities shall not be deemed a Qualified Receivables Transaction.

     

    “Rating Agencies” means Moody’s and S&P or if Moody’s or S&P or both
      shall not make a rating on the Notes publicly available, a nationally recognized statistical rating agency or agencies, as the case may be, selected by the Issuer which shall be substituted for Moody’s or S&P or both, as the case may be.

     

    “Receivables Entity” means (a) a Wholly Owned Subsidiary of the Parent
      Guarantor that is designated by the Board of Directors of the Parent Guarantor (as provided below) as a Receivables Entity or (b) another Person engaging in a Qualified Receivables Transaction with the Parent Guarantor, which Person engages in the
      business of the financing of accounts receivable, and in the case of either clause (a) or (b):

     

    (1)          no portion of the Indebtedness or any
        other obligations (contingent or otherwise) of such entity:

     

    (A)         is Guaranteed by the Parent Guarantor
        or any Subsidiary of the Parent Guarantor (excluding Guarantees of obligations (other than the principal of, and interest on, Indebtedness) pursuant to Standard Securitization Undertakings),

     

    
      

      
        

      -23-

      

    

    (B)          is recourse to or obligates the
        Parent Guarantor or any Subsidiary of the Parent Guarantor in any way (other than pursuant to Standard Securitization Undertakings), or

     

    (C)         subjects any property or asset of the
        Parent Guarantor or any Subsidiary of the Parent Guarantor, directly or indirectly, contingently or otherwise, to the satisfaction thereof (other than pursuant to Standard Securitization Undertakings);

     

    (2)          the entity is not an Affiliate of the
        Parent Guarantor or is an entity with which neither the Parent Guarantor nor any Subsidiary of the Parent Guarantor has any material contract, agreement, arrangement or understanding other than on terms that the Parent Guarantor reasonably believes
        to be no less favorable to the Parent Guarantor or such Subsidiary than those that might be obtained at the time from Persons that are not Affiliates of the Parent Guarantor; and

     

    (3)          is an entity to which neither the
        Parent Guarantor nor any Subsidiary of the Parent Guarantor has any obligation to maintain or preserve such entity’s financial condition or cause such entity to achieve certain levels of operating results.

     

    Any such designation by the Board of Directors of the Parent Guarantor shall be evidenced to the Trustee by filing with the Trustee a certified copy of
      the resolution of the Board of Directors of the Parent Guarantor giving effect to such designation and an Officer’s Certificate certifying that such designation complied with the foregoing conditions.

     

    “Redemption Date” when used with respect to any Note to be redeemed pursuant
      to paragraph 5 of the Notes means the date fixed for such redemption pursuant to the terms of this Indenture and the Notes.

     

    “Registrar” has the meaning set forth in Section 2.04.

     

    “Regulation S” means Regulation S promulgated under the Securities Act.

     

    “Regulation S Global Note” has the meaning set forth in Section 2.16(a).

     

    “Regulation S Legend” means the legend substantially in the form set forth
      in Exhibit D.

     

    “Regulation S Notes” has the meaning set forth in Section 2.02.

     

    “Responsible Officer” shall mean, when used with respect to the Trustee, any
      officer in the Corporate Trust Department of the Trustee including any vice president, assistant vice president or any other officer of the Trustee who customarily performs functions similar to those performed by the Persons who at the time shall be
      such officers, respectively, in each case having direct responsibility for the administration of this Indenture, and any other officer to whom any corporate trust matter is referred because of such officer’s knowledge of and familiarity with the
      particular subject.

     

    
      

      
        

      -24-

      

    

    “Restricted Global Note” means a Global Note that is a Restricted Note.

     

    “Restricted Note” has the same meaning as “restricted security” set forth in
      Rule 144(a)(3) promulgated under the Securities Act; provided that the Trustee shall be entitled to request (at the expense of the Issuer) and conclusively
      rely upon an Opinion of Counsel with respect to whether any Note is a Restricted Note.

     

    “Restricted Payment” means any of the following:

     

    (a)          the declaration or payment of any
        dividend or any other distribution on Equity Interests of the Parent Guarantor or any payment made to the direct or indirect holders (in their capacities as such) of Equity Interests of the Parent Guarantor, including, without limitation, any
        payment in connection with any merger or consolidation involving the Parent Guarantor but excluding dividends or distributions payable solely in Qualified Equity Interests of the Parent Guarantor or through accretion or accumulation of such
        dividends on such Equity Interests; or

     

    (b)          the repurchase or redemption of any
        Equity Interests of the Parent Guarantor, including, without limitation, any payment in connection with any merger or consolidation involving the Parent Guarantor

     

    “Restricted Payments Basket” has the meaning set forth in Section 4.09(c).

     

    “Restricted Period” has the meaning set forth in Section 2.17(b)(i).

     

    “Restricted Physical Note” means a Physical Note that is a Restricted Note.

     

    “Rule 144” means Rule 144 promulgated under the Securities Act.

     

    “Rule 144A” means Rule 144A promulgated under the Securities Act.

     

    “Rule 144A Global Note” has the meaning set forth in Section 2.16(a).

     

    “Rule 144A Notes” has the meaning set forth in Section 2.02.

     

    “S&P” means Standard & Poor’s Ratings Group, a division of The
      McGraw-Hill Companies, Inc., and any successor to its rating agency business

     

    
      

      
        

      -25-

      

    

    “Sale and Leaseback Transaction” means any sale or transfer made by the
      Parent Guarantor or one or more of its Subsidiaries (except a sale or transfer made to the Parent Guarantor or one or more of its Subsidiaries) of any Principal Facility that (in the case of a Principal Facility which is a building or equipment) has
      been in operation, use or commercial production (exclusive of test and start-up periods) by the Parent Guarantor or any of its Subsidiaries for more than 180 days prior to such sale or transfer, or that (in the case of a Principal Facility that is a
      parcel of real property not containing a building) has been owned by the Parent Guarantor or any of its Subsidiaries for more than 180 days prior to such sale or transfer, if such sale or transfer is made with the intention of leasing, or as part of
      an arrangement involving the lease of such Principal Facility to the Parent Guarantor or any of its Subsidiaries (except a lease for a period not exceeding 36 months made with the intention that the use of the leased Principal Facility by the Parent
      Guarantor or such Subsidiary will be discontinued on or before the expiration of such period); provided, however, the creation of any Secured Debt permitted under Section 4.10 shall not be deemed to create or be considered a Sale and Leaseback Transaction.

     

    “Secured Debt” means outstanding Indebtedness of the Parent Guarantor or any
      of its Subsidiaries which is secured by (a) a Security Interest in any property or assets of the Parent Guarantor or any of its Subsidiaries, or (b) a Security Interest in any shares of Capital Stock owned directly or indirectly by the Parent
      Guarantor in a Subsidiary. The securing in the foregoing manner of any previously unsecured debt shall be deemed to be the creation of Secured Debt at the time such security is given. The amount of Secured Debt at any time outstanding shall be the
      aggregate principal amount then owing thereon by the Parent Guarantor and its Subsidiaries.

     

    “Securities Act” means the Securities Act of 1933, as amended.

     

    “Security Interest” means any mortgage, pledge, lien, encumbrance or other
      security interest which secures payment or performance of an obligation.

     

    “Senior Secured Leverage Ratio” means, as of the date of determination, the
      ratio of (a) Total Debt secured by a Security Interest to (b) Consolidated Cash Flow Available for Fixed Charges for the most recently ended four fiscal quarter period ending immediately prior to such date for which financial statements are
      available. In the event that the Parent Guarantor or any of its Subsidiaries incurs, redeems, retires, defeases or extinguishes any Total Debt (other than Indebtedness under a revolving credit facility unless such Indebtedness has been permanently
      paid and not replaced) subsequent to the commencement of the period for which the Senior Secured Leverage Ratio is being calculated but prior to or simultaneously with the event for which the calculation of the Senior Secured Leverage Ratio is made,
      then the Senior Secured Leverage Ratio shall be calculated giving pro forma effect to such incurrence, redemption, retirement, defeasance or extinguishment of Total Debt as if the same had occurred at the beginning of the applicable four-quarter
      period. Notwithstanding anything to the contrary set forth in the definition of Consolidated Cash Flow Available for Fixed Charges (and all component definitions referenced in such definitions), whenever pro forma effect is to be given to Asset
      Acquisition, Asset Disposition or incurrence, redemption, retirement, defeasance or extinguishment of Total Debt, the pro forma calculations shall be determined in good faith by a responsible officer of the Issuer.

     

    
      

      
        

      -26-

      

    

    “Significant Subsidiary” means any Subsidiary that would be a “significant
      subsidiary” as defined in Article 1, Rule 1-02 of Regulation S-X, promulgated pursuant to the Securities Act, as such Regulation is in effect on the Issue Date.

     

    “Special Mandatory Redemption” has the meaning set forth in Section 3.07(a).

     

    “Special Mandatory Redemption Date” has the meaning set forth in Section
      3.07(b).

     

    “Special Mandatory Redemption Price” has the meaning set forth in Section
      3.07(a).

     

    “Special Mandatory Redemption Trigger Date” has the meaning set forth in
      Section 3.07(a).

     

    “Standard Securitization Undertakings” means representations, warranties,
      covenants and indemnities entered into by the Parent Guarantor or any Subsidiary of the Parent Guarantor that, taken as a whole, are customary in an accounts receivable transaction.

     

     “subsidiary” of any Person means a corporation, association, partnership,
      limited liability company or other entity of which more than 50% of the outstanding Voting Stock is owned, directly or indirectly, by such Person or one or more of the other subsidiaries of such Person (or a combination thereof).  For purposes of
      this Indenture, any reference to a “Subsidiary” is a subsidiary of the Parent Guarantor or the Issuer, as applicable.

     

    “Subsidiary Guarantor” means Anixter Inc, a Delaware corporation, and its
      successors.

     

    “Terminated Covenants” has the meaning set forth in Section 4.15(a).

     

    “Third Party Claim” has the meaning set forth in Section 7.07.

     

    “TIA” or “Trust

          Indenture Act” means the Trust Indenture Act of 1939, as amended (15 U.S. Code §§ 77aaa-77bbbb) as in effect on the date of this Indenture (except as amended to the extent required by law).

     

    “Total Debt” means, at any date of determination, the aggregate amount of
      all outstanding Indebtedness of the Parent Guarantor and its Subsidiaries determined on a consolidated basis in accordance with GAAP. Notwithstanding the foregoing, for purposes of Section 4.10, a binding commitment to lend under a revolving credit
      facility shall be deemed to be an incurrence of Indebtedness in the full amount of such commitment on the date that such commitment is entered into, regardless of whether the full amount of such revolving credit facility is actually borrowed, and
      thereafter the amount of such commitment shall be deemed fully borrowed at all times.

     

    
      

      
        

      -27-

      

    

    “Total Leverage Ratio” means, as of the date of determination, the ratio of
      (a) Total Debt to (b) Consolidated Cash Flow Available for Fixed Charges for the most recently ended four fiscal quarter period ending immediately prior to such date for which financial statements are available. In the event that the Parent Guarantor
      or any Subsidiary incurs, redeems, retires, defeases or extinguishes any Total Debt (other than Indebtedness under a revolving credit facility unless such Indebtedness has been permanently paid and not replaced) subsequent to the commencement of the
      period for which the Total Leverage Ratio is being calculated but prior to or simultaneously with the event for which the calculation of the Total Leverage Ratio is made, then the Total Leverage Ratio shall be calculated giving pro forma effect to
      such incurrence, redemption, retirement, defeasance or extinguishment of Total Debt as if the same had occurred at the beginning of the applicable four-quarter period. Notwithstanding anything to the contrary set forth in the definition of
      Consolidated Cash Flow Available for Fixed Charges (and all component definitions referenced in such definitions), whenever pro forma effect is to be given to Asset Acquisition, Asset Disposition or incurrence, redemption, retirement, defeasance or
      extinguishment of Total Debt, the pro forma calculations shall be determined in good faith by a responsible officer of the Issuer.

     

    “Transactions” means the Merger, the issuance of the Notes and the other
      Transactions (as defined in the Offering Memorandum).

     

    “Transfer” means to sell, assign, transfer, lease (other than pursuant to an
      operating lease entered into in the ordinary course of business), convey or otherwise dispose of, including by a Sale and Leaseback Transaction, consolidation, merger, liquidation, dissolution or otherwise, in one transaction or a series of
      transactions.

     

    “Treasury Management Arrangement” means any agreement or other arrangement
      governing the provision of treasury or cash management services, including deposit accounts, overdraft, credit or debit card, funds transfer, automated clearinghouse, zero balance accounts, returned check concentration, controlled disbursement,
      lockbox, account reconciliation and reporting and trade finance services and other cash management services.

     

    “Trustee” means the party named as such in this Indenture until a successor
      replaces it pursuant to this Indenture and thereafter means the successor.

     

    “Unrestricted Global Note” means a Global Note that is not a Restricted
      Note.

     

    “Unrestricted Physical Note” means a Physical Note that is not a Restricted
      Note.

     

    
      

      
        

      -28-

      

    

    “U.S. Government Obligations” means marketable direct obligations issued by,
      or unconditionally guaranteed as to full and timely payment by, the United States Government or issued by any agency or instrumentality thereof and backed by the full faith and credit of the United States of America that, in each case, mature within
      one year from the date of acquisition thereof and are not callable or redeemable at the option of the issuer thereof.

     

    “U.S. Person” means a “U.S. person” as defined in Rule 902(k) under the
      Securities Act.

     

    “Usage Date” has the meaning set forth in Section 4.11.

     

    “Voting Stock” means any class or classes of Capital Stock pursuant to which
      the holders thereof have power to vote in the election of directors, managers or trustees of any Person (irrespective of whether or not, at the time, stock of any other class or classes shall have, or might have, voting power by reason of the
      happening of any contingency).

     

    “Wholly Owned Subsidiary” of any Person means a subsidiary of such Person
      all of the outstanding Capital Stock or other ownership interests of which (other than directors’ qualifying shares) shall at the time be owned by such Person or by one or more Wholly Owned Subsidiaries of such Person or by such Person and one or
      more Wholly Owned Subsidiaries of such Person.

     

    	SECTION 1.02.	
            No Incorporation by Reference of Trust Indenture Act.

          

     

    This Indenture is not qualified under the TIA, and the TIA shall not apply to or in any way govern the terms of this Indenture. As a result, no
      provisions of the TIA are incorporated into this Indenture unless expressly incorporated pursuant to this Indenture.

     

    	SECTION 1.03.	
            Rules of Construction.

          

     

    Unless the context otherwise requires:

     

    (1)          a term has the meaning assigned to it
        herein, whether defined expressly or by reference;

     

    (2)          “or” is not exclusive;

     

    (3)          words in the singular include the
        plural, and in the plural include the singular;

     

    (4)          words used herein implying any gender
        shall apply to both genders;

     

    (5)          “herein,” “hereof” and other words of
        similar import refer to this Indenture as a whole and not to any particular Article, Section or other clause;

     

    
      

      
        

      -29-

      

    

    (6)          unless otherwise specified herein,
        all accounting terms used herein shall be interpreted, all accounting determinations hereunder shall be made, and all financial statements required to be delivered hereunder shall be prepared in accordance with GAAP;

     

    (7)          “$” and “U.S. Dollars” each refer to
        United States dollars, or such other money of the United States of America that at the time of payment is legal tender for payment of public and private debts;

     

    (8)          “will” shall be interpreted to
        express a command; and

     

    (9)          “including” means including without
        limitation.

     

    ARTICLE TWO

     

    THE SECURITIES

     

    	SECTION 2.01.	
            Amount of Notes.

          

     

    The Trustee shall initially authenticate the Initial Notes for original issue on the Issue Date upon a written order of the Issuer signed by one Officer,
      together with an Officer’s Certificate of the Issuer.  The Trustee shall authenticate Additional Notes thereafter in unlimited amount for original issue upon a written order of the Issuer in the form of an Officer’s Certificate in aggregate principal
      amount as specified in such order.  The Trustee shall also authenticate (i) replacement Notes as provided in Section 2.08,  (ii) temporary Notes as provided in Section 2.11, (iii) Notes issued in connection with certain transfers and exchanges as
      provided in Sections 2.07, 2.16 and 2.17, (iv) Notes issued in connection with a partial redemption of the Notes as provided in Section 3.06 or a partial repurchase of a Note as provided in Section 4.07 and (v) Notes exchanged as provided in Section
      8.04, in each case upon a written order of the Issuer in the form of an Officer’s Certificate in aggregate principal amount as specified in such order.  Each such written order shall specify the principal amount of Notes to be authenticated and the
      date on which the Notes are to be authenticated.

     

    	SECTION 2.02.	
            Form and Dating; Legends.

          

     

    The Notes and the Trustee’s certificate of authentication with respect thereto shall be substantially in the form set forth in Exhibit A-1 (in the case of the 5-Year Notes) and Exhibit A‐2 (in the case of 8-Year Notes), each of which is
      incorporated in and forms a part of this Indenture.  Each Note shall be dated the date of its authentication.

     

    
      

      
        

      -30-

      

    

    The Notes may have notations, legends or endorsements required by law, rule or usage to which the Issuer is subject.  Without limiting the generality of
      the foregoing, Notes offered and sold to Qualified Institutional Buyers in reliance on Rule 144A (“Rule 144A Notes”), Notes offered and sold in offshore transactions in
      reliance on Regulation S (“Regulation S Notes”) and all other Restricted Notes shall bear the Private Placement Legend.  All Global Notes shall bear the Global Note Legend.
      Regulation S Notes shall bear the Regulation S Legend.

     

    The terms and provisions contained in the Notes shall constitute, and are expressly made, a part of this Indenture and, to the extent applicable, the
      Issuer, the Guarantors and the Trustee, by their execution and delivery of this Indenture, expressly agree to such terms and provisions and agree to be bound thereby.  If there is a conflict between the terms of the Notes and this Indenture, the
      terms of this Indenture shall govern.

     

    The Notes may be presented for registration of transfer and exchange at the offices of the Registrar.

     

    	SECTION 2.03.	
            Execution and Authentication.

          

     

    The Notes shall be executed on behalf of the Issuer by an Officer of the Issuer.  The signature of any of these Officers on the Notes may be manual or
      facsimile.

     

    If an Officer whose signature is on a Note was an Officer at the time of such execution but no longer holds that office at the time the Trustee
      authenticates the Note, the Note shall be valid nevertheless.

     

    No Note shall be entitled to any benefit under this Indenture or be valid or obligatory for any purpose unless there appears on such Note a certificate
      of authentication substantially in the form provided for herein executed by the Trustee by manual signature, and such certificate upon any Note shall be conclusive evidence, and the only evidence, that such Note has been duly authenticated and
      delivered hereunder.  Notwithstanding the foregoing, if any Note shall have been authenticated and delivered hereunder but never issued and sold by the Issuer, and the Issuer shall deliver such Note to the Trustee for cancellation as provided in
      Section 2.12, for all purposes of this Indenture such Note shall be deemed never to have been authenticated and delivered hereunder and shall never be entitled to the benefits of this Indenture.

     

    The Trustee may appoint one or more authenticating agents reasonably acceptable to the Issuer to authenticate the Notes.  Unless otherwise provided in
      the appointment, an authenticating agent may authenticate the Notes whenever the Trustee may do so.  Each reference in this Indenture to authentication by the Trustee includes authentication by such agent.  An authenticating agent has the same rights
      as an Agent to deal with the Issuer and Affiliates of the Issuer.  Each Paying Agent is designated as an authenticating agent for purposes of this Indenture.

     

    
      

      
        

      -31-

      

    

    Each series of Notes shall be issuable only in registered form without coupons in denominations of $2,000 and integral multiples of $1,000 in excess of
      $2,000.

     

    	SECTION 2.04.	
            Registrar and Paying Agent.

          

     

    The Issuer shall maintain (a) an office or agency where Notes may be presented for registration of transfer or for exchange (the “Registrar”), (b) an office or agency in the city in the United States in which the Trustee’s Corporate Trust Office is located, where Notes may be presented for payment (the “Paying Agent”) and (c) an office or agency where notices and demands to or upon the Issuer, if any, in respect of the Notes and this Indenture may be served.  The Registrar
      shall keep a register of the Notes and of their transfer and exchange.  The Registrar shall provide a copy of such register from time to time upon request of the Issuer.  The Issuer may appoint one or more co-registrars and one or more additional
      Paying Agents.  The term “Registrar” includes any co-registrars.  The term “Paying Agents” means the Paying Agent and any additional Paying Agents.  The Issuer or any Affiliate thereof may act as Registrar or a Paying Agent.

     

    The Issuer shall enter into an appropriate agency agreement with any Agent that is not a party to this Indenture.  The agreement shall implement the
      provisions of this Indenture that relate to such Agent.  The Issuer shall notify the Trustee of the name and address of any such Agent.  If the Issuer fails to maintain a Registrar or any required co-registrar or Paying Agent, or fails to give the
      foregoing notice, the Trustee shall act as such and shall be entitled to appropriate compensation in accordance with Section 7.07.

     

    The Issuer initially appoints the Trustee as Registrar, Paying Agent and Depositary Custodian.

     

    The Issuer initially appoints The Depository Trust Company to act as Depositary with respect to the Global Notes.  The Issuer may change the Depositary
      at any time without notice to any Holder, but the Issuer will notify the Trustee of the name and address of any new Depositary.

     

    The Issuer shall be responsible for making calculations called for under the Notes, including but not limited to determination of redemption price,
      premium, if any, and any additional amounts or other amounts payable on the Notes.  The Issuer will make the calculations in good faith and, absent manifest error, its calculations will be final and binding on the Holders.  The Issuer will provide a
      schedule of its calculations to the Trustee when reasonably requested by the Trustee, and the Trustee is entitled to rely conclusively on the accuracy of the Issuer’s calculations without independent verification. The Trustee shall forward the
      Issuer’s calculations referred to above in this paragraph to any Holder of the Notes upon the written request of such Holder.

     

    
      

      
        

      -32-

      

    

    	SECTION 2.05.	
            Paying Agent To Hold Money in Trust.

          

     

    The Paying Agent shall hold in trust for the benefit of the Noteholders or the Trustee all money held by the Paying Agent for the payment of principal of
      or premium or interest on the Notes (whether such money has been paid to it by the Issuer, one or more of the Guarantors or any other obligor on the Notes), and the Issuer and the Paying Agent shall notify the Trustee of any default by the Issuer (or
      any other obligor on the Notes) in making any such payment.  Money held in trust by a Paying Agent need not be segregated except as required by law and in no event shall a Paying Agent be liable for any interest on any money received by it
      hereunder.  The Issuer at any time may require a Paying Agent to pay all money held by it to the Trustee and account for any funds disbursed and the Trustee may at any time during the continuance of any Event of Default specified in Section 6.01(1)
      or (2), upon written request to a Paying Agent, require such Paying Agent to pay forthwith all money so held by it to the Trustee and to account for any funds disbursed.  Upon making such payment, such Paying Agent shall have no further liability for
      the money delivered to the Trustee.

     

    	SECTION 2.06.	
            Noteholder Lists.

          

     

    The Trustee shall preserve in as current a form as is reasonably practicable the most recent list available to it of the names and addresses of the
      Noteholders.  If the Trustee is not the Registrar, the Issuer shall furnish to the Trustee at least five Business Days before each Interest Payment Date, and at such other times as the Trustee may request in writing, a list in such form and as of
      such date as the Trustee may reasonably require of the names and addresses of the Noteholders.

     

    	SECTION 2.07.	
            Transfer and Exchange.

          

     

    Subject to Sections 2.16 and 2.17, when Notes are presented to the Registrar with a request from the Holder of such Notes to register a transfer or to
      exchange them for an equal principal amount of Notes of other authorized denominations, the Registrar shall register the transfer as requested.  Every Note presented or surrendered for registration of transfer or exchange shall be duly endorsed or be
      accompanied by a written instrument of transfer in form satisfactory to the Issuer and the Registrar, duly executed by the Holder thereof or his attorneys duly authorized in writing.  To permit registrations of transfers and exchanges, the Issuer
      shall issue and execute and, upon receipt of a written order of the Issuer in the form of an Officer’s Certificate in accordance with Section 2.01, the Trustee shall authenticate new Notes (and the Guarantors shall execute the Guarantees thereon)
      evidencing such transfer or exchange at the Registrar’s request.  No service charge shall be made to the Noteholder for any registration of transfer or exchange.  The Issuer or the Trustee may require from the Noteholder payment of a sum sufficient
      to cover any transfer taxes or other governmental charge that may be imposed in relation to a transfer or exchange, but this provision shall not apply to any exchange pursuant to Section 2.11, 3.06, 3.07, 4.07 or 8.04 (in which events the Issuer
      shall be responsible for the payment of such taxes).  The Registrar shall not be required to exchange or register a transfer of any Note for a period of 15 days immediately preceding the mailing of notice of redemption of Notes to be redeemed or of
      any Note selected, called or being called for redemption except the unredeemed portion of any Note being redeemed in part.

     

    
      

      
        

      -33-

      

    

    Any Holder of a Global Note shall, by acceptance of such Global Note, agree that transfers of the beneficial interests in such Global Note may be
      effected only through a book-entry system maintained by the Holder of such Global Note (or its agent), and that ownership of a beneficial interest in the Global Note shall be required to be reflected in a book entry.  By its acceptance of any Note
      bearing the Private Placement Legend, each Holder of such Note acknowledges the restrictions on transfer of such Note set forth in this Indenture and in the Private Placement Legend and agrees that it will transfer such Note only as provided in this
      Indenture.

     

    	SECTION 2.08.	
            Replacement Notes.

          

     

    If a mutilated Note is surrendered to the Registrar or the Trustee, or if the Holder of a Note claims that the Note has been lost, destroyed or
      wrongfully taken, the Issuer shall issue and, upon receipt of a written order of the Issuer in the form of an Officer’s Certificate in accordance with Section 2.01, the Trustee shall authenticate a replacement Note (and the Guarantors shall execute
      the Guarantees thereon) if the Holder of such Note furnishes to the Issuer and the Trustee evidence reasonably acceptable to them of the ownership and the destruction, loss or theft of such Note and if the requirements of Section 8‐405 of the New
      York Uniform Commercial Code as in effect on the date of this Indenture are met.  If required by the Trustee or the Issuer, an indemnity bond shall be posted, sufficient in the judgment of all to protect the Issuer, the Guarantors, the Trustee, the
      Registrar and any Paying Agent from any loss that any of them may suffer if such Note is replaced.  The Issuer may charge such Holder for the Issuer’s reasonable out-of-pocket expenses in replacing such Note and the Trustee may charge the Issuer for
      the Trustee’s reasonable out-of-pocket expenses (including, without limitation, attorneys’ fees and disbursements) in replacing such Note and may require the payment of a sum sufficient to cover any tax, assessment, fee or other charge that may be
      imposed in relation thereto and any other expenses (including the reasonable out-of-pocket fees and expenses of the Trustee) connected therewith.  Every replacement Note shall constitute a contractual obligation of the Issuer.  The provisions of this
      Section 2.08 are exclusive and will preclude (to the extent lawful) all other rights and remedies with respect to the replacement or payment of lost, destroyed, mutilated or wrongfully taken Notes.

     

    	SECTION 2.09.	
            Outstanding Notes.

          

     

    The Notes outstanding at any time are all Notes that have been authenticated by the Trustee except for (a) those canceled by or on behalf of the Trustee,
      (b) those accepted by the Trustee for cancellation, (c) to the extent set forth in Sections 9.01 and 9.02, on or after the date on which the conditions set forth in Section 9.01 or 9.02 have been satisfied, those Notes theretofore authenticated by
      the Trustee hereunder and (d) those described in this Section 2.09 as not outstanding.  Subject to Section 2.10, a Note does not cease to be outstanding because the Issuer or one of its Affiliates holds the Note.

     

    
      

      
        

      -34-

      

    

    If a Note is replaced pursuant to Section 2.08, it ceases to be outstanding unless the Trustee receives proof satisfactory to the Issuer that the
      replaced Note is held by a bona fide purchaser in whose hands such Note is a legal, valid and binding obligation of the Issuer.

     

    If a Paying Agent holds, in its capacity as such, on any Maturity Date, U.S. Dollars sufficient to pay all accrued interest and principal with respect to
      the Notes payable on that date, then on and after that date such Notes shall cease to be outstanding and interest on them shall cease to accrue.

     

    	SECTION 2.10.	
            Treasury Notes.

          

     

    In determining whether the Holders of the required principal amount of Notes have concurred in any declaration of acceleration or notice of default or
      direction, waiver or consent or any amendment, modification or other change to this Indenture, Notes owned by the Issuer or any other Affiliate of the Issuer shall be disregarded as though they were not outstanding, except that for the purposes of
      determining whether the Trustee shall be protected in relying on any such direction, waiver or consent or any amendment, modification or other change to this Indenture, only Notes as to which a Responsible Officer of the Trustee has actually received
      an Officer’s Certificate stating that such Notes are so owned shall be so disregarded.  Notes so owned which have been pledged in good faith shall not be disregarded if the pledgee established to the satisfaction of the Trustee the pledgee’s right so
      to act with respect to the Notes and that the pledgee is not the Issuer, a Guarantor, any other obligor on the Notes or any of their respective Affiliates.

     

    	SECTION 2.11.	
            Temporary Notes.

          

     

    Until definitive Notes are prepared and ready for delivery, the Issuer may prepare and, upon receipt of a written order of the Issuer in the form of an
      Officer’s Certificate in accordance with Section 2.01, the Trustee shall authenticate temporary Notes.  Temporary Notes shall be substantially in the form of definitive Notes but may have variations that the Issuer considers appropriate for temporary
      Notes.  Without unreasonable delay, the Issuer shall prepare and, upon receipt of a written order of the Issuer in the form of an Officer’s Certificate in accordance with Section 2.01, the Trustee shall authenticate definitive Notes in exchange for
      temporary Notes.  Until such exchange, temporary Notes shall be entitled to the same rights, benefits and privileges as definitive Notes.

     

    
      

      
        

      -35-

      

    

    	SECTION 2.12.	
            Cancellation.

          

     

    The Issuer at any time may deliver Notes to the Trustee for cancellation.  The Registrar and the Paying Agent shall forward to the Trustee any Notes
      surrendered to them for registration of transfer, exchange or payment.  The Trustee shall cancel all Notes surrendered for registration of transfer, exchange, payment, replacement or cancellation and shall dispose of such canceled Notes in its
      customary manner.  The Issuer may not reissue or resell or issue new Notes to replace Notes that the Issuer has redeemed or paid, or that have been delivered to the Trustee for cancellation.

     

    	SECTION 2.13.	
            Defaulted Interest.

          

     

    If the Issuer defaults on a payment of interest on the Notes, the Issuer shall pay the defaulted interest then borne by the Notes plus (to the extent
      permitted by law) any interest payable on the defaulted interest, in accordance with the terms hereof, to the Persons who are Holders thereof on a subsequent special record date, which date shall be at least five Business Days prior to the payment
      date.  If such default continues for thirty (30) days, the Issuer shall fix such special record date and payment date in a manner satisfactory to the Trustee.  At least 10 days before such special record date, the Issuer (or upon the written request
      of the Issuer, the Trustee, in the name and at the expense of the Issuer) shall mail to each affected Noteholder a notice that states the special record date, the payment date and the amount of defaulted interest, and interest payable on defaulted
      interest, if any, to be paid.  The Issuer may make payment of any defaulted interest in any other lawful manner not inconsistent with the requirements (if applicable) of any securities exchange on which the Notes may be listed and, upon such notice
      as may be required by such exchange, if, after written notice given by the Issuer to the Trustee of the proposed payment pursuant to this sentence, such manner of payment shall be deemed practicable by the Trustee.  If the Issuer elects for the
      Trustee to send such notice to the Holders then the Issuer shall provide such notice to the Trustee at least five (5) days (or such  shorter time as may be agreed by the Trustee in its discretion) before such notice is required to be mailed to the
      Holders.

     

    Notwithstanding the foregoing, any interest which is paid prior to the expiration of the 30-day period set forth in Section 6.01(1) shall be paid to
      Holders as of the record date for the Interest Payment Date for which interest has not been paid.

     

    	SECTION 2.14.	
            CUSIP and ISIN Numbers.

          

     

    The Issuer in issuing the Notes may use “CUSIP” and “ISIN” numbers, and if so used, such CUSIP and ISIN numbers shall be included in notices as a
      convenience to Holders; provided that any such notice may state that no representation is made as to the correctness or accuracy of the CUSIP or ISIN numbers
      printed in the notice or on the Notes, that reliance may be placed only on the other identification numbers printed on the Notes, and any such notice shall not be affected by any defect in or omission of such CUSIP or ISIN numbers.  The Issuer shall
      promptly notify the Trustee, in writing, of any such CUSIP or ISIN number used by the Issuer in connection with the issuance of the Notes and of any change in any such CUSIP or ISIN number.

     

    
      

      
        

      -36-

      

    

    	SECTION 2.15.	
            Deposit of Moneys.

          

     

    Prior to 10:00 A.M., New York City time, on each Interest Payment Date and Maturity Date, the Issuer shall have deposited with the Paying Agent in
      immediately available funds U.S. Dollars sufficient to make cash payments, if any, due on such Interest Payment Date or Maturity Date, as the case may be, in a timely manner which permits such Paying Agents to remit payment to the Holders on such
      Interest Payment Date or Maturity Date, as the case may be.  The principal and interest on Global Notes shall be payable to the Depositary or its nominee, as the case may be, as the sole registered owner and the sole Holder of the Global Notes
      represented thereby.  The principal and interest on Physical Notes shall be payable, either in person, by wire transfer or by mail, at the office of the Paying Agent.  Final payment of principal at maturity will only be made by the Trustee upon
      surrender of the related Note to the Trustee at its Corporate Trust Office.

     

    	SECTION 2.16.	
            Book-Entry Provisions for Global Notes.

          

     

    (a)          Rule 144A Notes initially shall be represented by one or
        more Notes in registered, global form without interest coupons (collectively, the “Rule 144A Global Note”).  Regulation S Notes initially shall be represented by one or
        more Notes in registered, global form without interest coupons (collectively, the “Regulation S Global Note”).  The term “Global Notes” means the Rule 144A Global Note and the Regulation S Global Note.  The Global Notes shall bear the Global Note Legend.  The Global Notes initially shall (i) be registered in the name of the Depositary or
        the nominee of such Depositary, in each case for credit to an account of an Agent Member, (ii) be delivered to the Trustee as custodian for such Depositary and (iii) bear the Private Placement Legend.

     

    Members of, or direct or indirect participants in, the Depositary (“Agent Members”)

      shall have no rights under this Indenture with respect to any Global Note held on their behalf by the Depositary or under the Global Notes.  The Depositary may be treated by the Issuer, the Trustee and any agent of the Issuer or the Trustee as the
      absolute owner of the Global Notes for all purposes whatsoever.  Notwithstanding the foregoing, nothing herein shall prevent the Issuer, the Trustee or any agent of the Issuer or the Trustee from giving effect to any written certification, proxy or
      other authorization furnished by the Depositary or impair, as between the Depositary and its Agent Members, the operation of customary practices governing the exercise of the rights of a Holder of any Note.  None of the Issuer, the Trustee, the
      Paying Agent nor the Registrar shall have any responsibility or liability for any acts or omissions of the Depositary with respect to such Global Note, for the records of the Depositary, including records in respect of the beneficial owners of any
      such Global Note, for any transactions between the Depositary and any Agent Member or between or among the Depositary, any such Agent Member and/or any Holder or beneficial owner of such Global Note, or for any transfers of beneficial interests in
      any such Global Note.

     

    
      

      
        

      -37-

      

    

    (b)          Transfers of Global Notes shall be limited to transfer
        in whole, but not in part, to the Depositary, its successors or their respective nominees.  Interests of beneficial owners in the Global Notes may be transferred or exchanged for Physical Notes only in accordance with the applicable rules and
        procedures of the Depositary and the provisions of Section 2.17.  In addition, a Global Note shall be exchangeable for Physical Notes (i) if requested by a holder of such interests upon receipt by the Trustee of written instructions from the
        Depositary or its nominee on behalf of any beneficial owner and in accordance with the rules and procedures of the Depositary and provisions of this Section 2.16 or (ii) if the Depositary notifies the Issuer that it is unwilling or unable to
        continue as depositary for such Global Note and the Issuer thereupon fail to appoint a successor depositary within 90 days or (iii) if the Depositary has ceased to be a clearing agency registered under the Exchange Act or (iv) if there shall have
        occurred and be continuing an Event of Default with respect to such Global Note and the Depository has requested such exchange.  In all cases, Physical Notes delivered in exchange for any Global Note or beneficial interests therein shall be
        registered in the names, and issued in any approved denominations, requested by or on behalf of the Depositary in accordance with its customary procedures.

     

    (c)          In connection with the transfer of a Global Note as an
        entirety to beneficial owners pursuant to clause (b) of this Section 2.16, such Global Note shall be deemed to be surrendered to the Trustee for cancellation, and the Issuer shall execute and, upon receipt of a written order of the Issuer in the
        form of an Officer’s Certificate in accordance with Section 2.01, the Trustee shall authenticate and deliver, to each beneficial owner identified by the Depositary in writing in exchange for its beneficial interest in such Global Note, an equal
        aggregate principal amount of Physical Notes of authorized denominations.

     

    (d)          Any Restricted Physical Note delivered in exchange for
        an interest in a Global Note pursuant to Section 2.17 shall, except as otherwise provided in Section 2.17, bear the Private Placement Legend.

     

    (e)          The Holder of any Global Note may grant proxies and
        otherwise authorize any Person, including Agent Members and Persons that may hold interests through Agent Members, to take any action which a Holder is entitled to take under this Indenture or the Notes.

     

    	SECTION 2.17.	
            Transfer and Exchange of Notes.

          

     

    (a)          Transfer and Exchange of Global Notes.  A Global Note may not be transferred as a whole except as set forth in Section 2.16(b).  Global Notes will not be exchanged by the Issuer for Physical Notes except under the
        circumstances described in Section in Section 2.16(b).  Global Notes also may be exchanged or replaced, in whole or in part, as provided in Sections 2.08 and 2.11.  Beneficial interests in a Global Note may be transferred and exchanged as provided
        in Section 2.17(b) or 2.17(f).

     

    
      

      
        

      -38-

      

    

    (b)          Transfer and Exchange of Beneficial Interests in Global Notes.  The transfer and exchange of beneficial interests in the Global Notes shall be effected through the Depositary, in accordance with the provisions of this
        Indenture and the applicable rules and procedures of the Depositary.  Beneficial interests in Restricted Global Notes shall be subject to restrictions on transfer comparable to those set forth herein to the extent required by the Securities Act. 
        Beneficial interests in Global Notes shall be transferred or exchanged only for beneficial interests in Global Notes.  Transfers and exchanges of beneficial interests in the Global Notes also shall require compliance with either subparagraph (i) or
        (ii) below, as applicable, as well as one or more of the other following subparagraphs, as applicable:

     

    (i)           Transfer of Beneficial Interests in the Same Global Note.  Beneficial interests in any Restricted Global Note may be transferred to Persons who take delivery thereof in the form of a beneficial
        interest in the same Restricted Global Note in accordance with the transfer restrictions set forth in the Private Placement Legend; provided, however, that prior to the 40th day after the later of the commencement of the offering of the Notes represented by a Regulation S Global Note and the issue date
        of such Notes (such period through and including such 40th day, the “Restricted Period”), transfers of beneficial interests in a Regulation S Global Note may not be made
        to a U.S. Person or for the account or benefit of a U.S. Person (other than an Initial Purchaser).  A beneficial interest in an Unrestricted Global Note may be transferred to Persons who take delivery thereof in the form of a beneficial interest in
        an Unrestricted Global Note.  No written orders or instructions shall be required to be delivered to the Registrar to effect the transfers described in this Section 2.17(b)(i).

     

    (ii)          All Other Transfers and Exchanges of Beneficial Interests in Global Notes.  In connection with all transfers and exchanges of beneficial interests in any Global Note that is not subject to Section
        2.17(b)(i), the transferor of such beneficial interest must deliver to the Registrar (1) a written order from an Agent Member given to the Depositary in accordance with the applicable rules and procedures of the Depositary directing the Depositary
        to credit or cause to be credited a beneficial interest in another Global Note in an amount equal to the beneficial interest to be transferred or exchanged and (2) instructions given in accordance with the applicable rules and procedures of the
        Depositary containing information regarding the Agent Member account to be credited with such increase.  Upon satisfaction of all of the requirements for transfer or exchange of beneficial interests in Global Notes contained in this Indenture and
        the Notes, the Trustee shall adjust the principal amount of the relevant Global Note(s) pursuant to Section 2.17(f).

     

    
      

      
        

      -39-

      

    

    (iii)         Transfer of Beneficial Interests to Another Restricted Global Note.  A beneficial interest in a Restricted Global Note may be transferred to a Person who takes delivery thereof in the form of a
        beneficial interest in another Restricted Global Note if the transfer complies with the requirements of Section 2.17(b)(ii) above and the Registrar receives the following:

     

    (A)         if the transferee will take delivery
        in the form of a beneficial interest in a Rule 144A Global Note, then the transferor must deliver a certificate in the form of Exhibit E, including the certifications in
        item (1) thereof; and

     

    (B)          if the transferee will take delivery
        in the form of a beneficial interest in a Regulation S Global Note, then the transferor must deliver a certificate in the form of Exhibit E, including the certifications
        in item (2) thereof.

     

    (iv)         Transfer and Exchange of Beneficial Interests in a Restricted Global Note for Beneficial Interests in an Unrestricted Global Note.  A beneficial interest in a Restricted Global Note may be exchanged
        by any holder thereof for a beneficial interest in an Unrestricted Global Note or transferred to a Person who takes delivery thereof in the form of a beneficial interest in an Unrestricted Global Note if the exchange or transfer complies with the
        requirements of Section 2.17(b)(ii) above and the Registrar receives the following:

     

    (A)          if the holder of such beneficial
        interest in a Restricted Global Note proposes to exchange such beneficial interest for a beneficial interest in an Unrestricted Global Note, a certificate from such holder in the form of Exhibit F, including the certifications in item (1)(a) thereof; or

     

    (B)          if the holder of such beneficial
        interest in a Restricted Global Note proposes to transfer such beneficial interest to a Person who shall take delivery thereof in the form of a beneficial interest in an Unrestricted Global Note, a certificate from such holder in the form of Exhibit E, including the certifications in item (4) thereof,

     

    and, in each such case, an Opinion of Counsel in form reasonably acceptable to the Registrar to the effect that such exchange or transfer is in
      compliance with the Securities Act and that the restrictions on transfer contained herein and in the Private Placement Legend are no longer required in order to maintain compliance with the Securities Act.  If any such transfer or exchange is
      effected pursuant to this subparagraph (iv) at a time when an Unrestricted Global Note has not yet been issued, the Issuer shall issue and, upon receipt of a written order of the Issuer in the form of an Officer’s Certificate in accordance with
      Section 2.01, the Trustee shall authenticate one or more Unrestricted Global Notes in an aggregate principal amount equal to the aggregate principal amount of beneficial interests transferred or exchanged pursuant to this subparagraph (iv).

     

    
      

      
        

      -40-

      

    

    (v)           Transfer and Exchange of Beneficial Interests in an Unrestricted Global Note for Beneficial Interests in a Restricted Global Note.  Beneficial interests in an Unrestricted Global Note cannot be
        exchanged for, or transferred to Persons who take delivery thereof in the form of, a beneficial interest in a Restricted Global Note.

     

    (c)          Transfer and Exchange of Beneficial Interests in Global Notes for Physical Notes.  A beneficial interest in a Global Note may not be exchanged for a Physical Note except under the circumstances described in Section
        2.16(b).  A beneficial interest in a Global Note may not be transferred to a Person who takes delivery thereof in the form of a Physical Note except under the circumstances described in Section 2.16(b).

     

    (d)          Transfer and Exchange of Physical Notes for Beneficial Interests in Global Notes.  Transfers and exchanges of beneficial interests in the Global Notes also shall require compliance with either subparagraph (i), (ii) or
        (iii) below, as applicable:

     

    (i)           Restricted Physical Notes to Beneficial Interests in Restricted Global Notes.  If any Holder of a Restricted Physical Note proposes to exchange such Restricted Physical Note for a beneficial interest
        in a Restricted Global Note or to transfer such Restricted Physical Note to a Person who takes delivery thereof in the form of a beneficial interest in a Restricted Global Note, then, upon receipt by the Registrar of the following documentation:

     

    (A)          if the Holder of such Restricted
        Physical Note proposes to exchange such Restricted Physical Note for a beneficial interest in a Restricted Global Note, a certificate from such Holder in the form of Exhibit F,
        including the certifications in item (2)(a) thereof;

     

    (B)          if such Restricted Physical Note is
        being transferred to a Qualified Institutional Buyer in accordance with Rule 144A under the Securities Act, a certificate to the effect set forth in Exhibit E, including
        the certifications in item (1) thereof;

     

    (C)          if such Restricted Physical Note is
        being transferred to a Non-U.S. Person in an offshore transaction in accordance with Rule 903 or Rule 904 under the Securities Act, a certificate to the effect set forth in Exhibit
            E, including the certifications in item (2) thereof;

     

    (D)          if such Restricted Physical Note is
        being transferred pursuant to an exemption from the registration requirements of the Securities Act in accordance with Rule 144 under the Securities Act, a certificate to the effect set forth in Exhibit E, including the certifications in item (3)(a) thereof; or

     

    
      

      
        

      -41-

      

    

    (E)          if such Restricted Physical Note is
        being transferred to the Issuer or a Subsidiary thereof, a certificate to the effect set forth in Exhibit E, including the certifications in item (3)(b) thereof,

     

    the Trustee shall cancel the Restricted Physical Note, and increase or cause to be increased the aggregate principal amount of  the appropriate
      Restricted Global Note.

     

    (ii)          Restricted Physical Notes to Beneficial Interests in Unrestricted Global Notes.  A Holder of a Restricted Physical Note may exchange such Restricted Physical Note for a beneficial interest in an
        Unrestricted Global Note or transfer such Restricted Physical Note to a Person who takes delivery thereof in the form of a beneficial interest in an Unrestricted Global Note only if the Registrar receives the following:

     

    (A)         if the Holder of such Restricted
        Physical Note proposes to exchange such Restricted Physical Note for a beneficial interest in an Unrestricted Global Note, a certificate from such Holder in the form of Exhibit F,
        including the certifications in item (1)(b) thereof; or

     

    (B)          if the Holder of such Restricted
        Physical Notes proposes to transfer such Restricted Physical Note to a Person who shall take delivery thereof in the form of a beneficial interest in an Unrestricted Global Note, a certificate from such Holder in the form of Exhibit E, including the certifications in item (4) thereof,

     

    and, in each such case, an Opinion of Counsel in form reasonably acceptable to the Registrar to the effect that such exchange or transfer is in
      compliance with the Securities Act and that the restrictions on transfer contained herein and in the Private Placement Legend are no longer required in order to maintain compliance with the Securities Act.  Upon satisfaction of the conditions of this
      subparagraph (ii), the Trustee shall cancel the Restricted Physical Notes and increase or cause to be increased the aggregate principal amount of the Unrestricted Global Note.  If any such transfer or exchange is effected pursuant to this
      subparagraph (ii) at a time when an Unrestricted Global Note has not yet been issued, the Issuer shall issue and, upon receipt of a written order of the Issuer in the form of an Officer’s Certificate in accordance with Section 2.01, the Trustee shall
      authenticate one or more Unrestricted Global Notes in an aggregate principal amount equal to the aggregate principal amount of Restricted Physical Notes transferred or exchanged pursuant to this subparagraph (ii).

     

    
      

      
        

      -42-

      

    

    (iii)         Unrestricted Physical Notes to Beneficial Interests in Unrestricted Global Notes.  A Holder of an Unrestricted Physical Note may exchange such Unrestricted Physical Note for a beneficial interest in
        an Unrestricted Global Note or transfer such Unrestricted Physical Note to a Person who takes delivery thereof in the form of a beneficial interest in an Unrestricted Global Note at any time.  Upon receipt of a request for such an exchange or
        transfer, the Trustee shall cancel the applicable Unrestricted Physical Note and increase or cause to be increased the aggregate principal amount of one of the Unrestricted Global Notes.  If any such transfer or exchange is effected pursuant to
        this subparagraph (iii) at a time when an Unrestricted Global Note has not yet been issued, the Issuer shall issue and, upon receipt of a written order of the Issuer in the form of an Officer’s Certificate in accordance with Section 2.01, the
        Trustee shall authenticate one or more Unrestricted Global Notes in an aggregate principal amount equal to the aggregate principal amount of Unrestricted Physical Notes transferred or exchanged pursuant to this subparagraph (iii).

     

    (iv)         Unrestricted Physical Notes to Beneficial Interests in Restricted Global Notes.  An Unrestricted Physical Note cannot be exchanged for, or transferred to a Person who takes delivery thereof in the
        form of, a beneficial interest in a Restricted Global Note.

     

    (e)          Transfer and Exchange of Physical Notes for Physical Notes.  Upon request by a Holder of Physical Notes and such Holder’s compliance with the provisions of this Section 2.17(e), the Registrar shall register the transfer or
        exchange of Physical Notes.  Prior to such registration of transfer or exchange, the requesting Holder shall present or surrender to the Registrar the Physical Notes duly endorsed or accompanied by a written instruction of transfer in form
        satisfactory to the Registrar duly executed by such Holder or by its attorney, duly authorized in writing.  In addition, the requesting Holder shall provide any additional certifications, documents and information, as applicable, required pursuant
        to the following provisions of this Section 2.17(e).

     

    (i)           Restricted Physical Notes to Restricted Physical Notes.  A Restricted Physical Note may be transferred to and registered in the name of a Person who takes delivery thereof in the form of a Restricted
        Physical Note if the Registrar receives the following:

     

    (A)          if the transfer will be made pursuant
        to Rule 144A under the Securities Act, then the transferor must deliver a certificate in the form of Exhibit E, including the certifications in item (1) thereof;

     

    (B)          if the transfer will be made pursuant
        to Rule 903 or Rule 904 under the Securities Act, then the transferor must deliver a certificate in the form of Exhibit E, including the certifications in item (2)
        thereof;

     

    (C)          if the transfer will be made pursuant
        to an exemption from the registration requirements of the Securities Act in accordance with Rule 144 under the Securities Act, a certificate to the effect set forth in Exhibit E,
        including the certifications in item (3)(a) thereof; and

     

    
      

      
        

      -43-

      

    

    (D)         if such transfer will be made to the
        Issuer or a Subsidiary thereof, a certificate to the effect set forth in Exhibit E, including the certifications in item (3)(b) thereof.

     

    (ii)          Restricted Physical Notes to Unrestricted Physical Notes.  Any Restricted Physical Note may be exchanged by the Holder thereof for an Unrestricted Physical Note or transferred to a Person who takes
        delivery thereof in the form of an Unrestricted Physical Note if the Registrar receives the following:

     

    (1)          if the Holder of such Restricted
        Physical Note proposes to exchange such Restricted Physical Note for an Unrestricted Physical Note, a certificate from such Holder in the form of Exhibit F, including the
        certifications in item (1)(c) thereof; or

     

    (2)          if the Holder of such Restricted
        Physical Note proposes to transfer such Notes to a Person who shall take delivery thereof in the form of an Unrestricted Physical Note, a certificate from such Holder in the form of Exhibit

            E, including the certifications in item (4) thereof,

     

    and, in each such case, an Opinion of Counsel in form reasonably acceptable to the Issuer to the effect that such exchange or transfer is in compliance
      with the Securities Act and that the restrictions on transfer contained herein and in the Private Placement Legend are no longer required in order to maintain compliance with the Securities Act.

     

    (iii)         Unrestricted Physical Notes to Unrestricted Physical Notes.  A Holder of an Unrestricted Physical Note may transfer such Unrestricted Physical Notes to a Person who takes delivery thereof in the form
        of an Unrestricted Physical Note at any time.  Upon receipt of a request to register such a transfer, the Registrar shall register the Unrestricted Physical Notes pursuant to the instructions from the Holder thereof.

     

    (iv)         Unrestricted Physical Notes to Restricted Physical Notes.  An Unrestricted Physical Note cannot be exchanged for, or transferred to a Person who takes delivery thereof in the form of, a Restricted
        Physical Note.

     

    (f)           Cancellation and/or Adjustment of Global Notes.  At such time as all beneficial interests in a particular Global Note have been exchanged for Physical Notes or a particular Global Note has been redeemed, repurchased or
        canceled in whole and not in part, each such Global Note shall be returned to or retained and canceled by the Trustee in accordance with Section 2.12.  At any time prior to such cancellation, if any beneficial interest in a Global Note is exchanged
        for or transferred to a Person who will take delivery thereof in the form of a beneficial interest in another Global Note or for Physical Notes, the principal amount of Notes represented by such Global Note shall be reduced accordingly and an
        endorsement shall be made on such Global Note by the Trustee or by the Depositary at the direction of the Trustee to reflect such reduction; and if the beneficial interest is being exchanged for or transferred to a Person who will take delivery
        thereof in the form of a beneficial interest in another Global Note, such other Global Note shall be increased accordingly and an endorsement shall be made on such Global Note by the Trustee or by the Depositary at the direction of the Trustee to
        reflect such increase.

     

    
      

      
        

      -44-

      

    

    (g)          Private Placement Legend.  Upon the registration of transfer, exchange or replacement of Notes not bearing the Private Placement Legend, the Registrar shall deliver Notes that do not bear the Private Placement Legend.  Upon
        the registration of transfer, exchange or replacement of Notes bearing the Private Placement Legend, the Registrar shall deliver only Notes that bear the Private Placement Legend unless (i) there is delivered to the Registrar an Opinion of Counsel
        reasonably satisfactory to the Issuer and the Trustee to the effect that neither such legend nor the related restrictions on transfer are required in order to maintain compliance with the provisions of the Securities Act or (ii) such Note has been
        sold pursuant to an effective registration statement under the Securities Act and the Registrar has received an Officer’s Certificate from the Issuer to such effect.

     

    (h)          General.  All Global Notes and Physical Notes issued upon any registration of transfer or exchange of Global Notes or Physical Notes shall be the valid obligations of the Issuer, evidencing the same debt, and entitled to
        the same benefits under this Indenture, as the Global Notes or Physical Notes surrendered upon such registration of transfer or exchange.

     

    The Registrar shall retain for a period of two years copies of all letters, notices and other written communications received pursuant to Section 2.16 or
      this Section 2.17.  The Issuer shall have the right to inspect and make copies of all such letters, notices or other written communications at any reasonable time upon the giving of reasonable notice to the Registrar.

     

    None of the Issuer, the Trustee, Paying Agent nor any Agent of the Issuer shall have any responsibility or liability in any respect of the records
      relating to or payment made on account of beneficial interests in a Global Note, or for maintaining, supervising or reviewing any records relating to such beneficial ownership interests.

     

    Neither the Trustee nor the Registrar shall have any obligation or duty to monitor, determine or inquire as to compliance with any restrictions on
      transfer imposed under this Indenture or under applicable law with respect to any transfer of any interest in any Note (including any transfers between or among Agent Members or beneficial owners of interests in any Global Note) other than to require
      delivery of such certificates and other documentation or evidence as are expressly required by, and to do so if and when expressly required by the terms of, this Indenture, and to examine the same to determine substantial compliance as to form with
      the express requirements hereof.

     

    
      

      
        

      -45-

      

    

    	SECTION 2.18.	
            Computation of Interest.

          

     

    Interest on the Notes shall be computed on the basis of a 360-day year of twelve 30-day months and actual days elapsed.

     

    ARTICLE THREE

     

    REDEMPTION

     

    	SECTION 3.01.	
            Election To Redeem; Notices to Trustee.

          

     

    If the Issuer elects to redeem Notes pursuant to paragraph 5 of each series of Notes, at least 10 days prior to the Redemption Date, the Issuer shall
      notify the Trustee in writing of the Redemption Date, the principal amount of such Notes to be redeemed and the redemption price(s), and deliver to the Trustee an Officer’s Certificate stating that such redemption will comply with the conditions
      contained in paragraph 5 of such Notes.  Notice given to the Trustee pursuant to this Section 3.01 may not be revoked after the time that notice is given to Noteholders pursuant to Section 3.03, but it may be conditional as set forth in Section
      3.03.  If the redemption price is not known at the time such notice is to be given, the actual redemption price, calculated as described in the terms of such Notes, will be set forth in an Officer’s Certificate delivered to the Trustee no later than
      two Business Days prior to the redemption date.

     

    	SECTION 3.02.	
            Selection by Trustee of Notes To Be Redeemed.

          

     

    If less than all of the Notes of any series are to be redeemed at any time, selection of Notes for redemption will be made by the Trustee on a pro rata basis to the extent practicable (or, in the case of Global Notes, the Notes will be selected for redemption based on the Depositary’s applicable
      procedures); provided that no Notes with a principal amount of $2,000 or less shall be redeemed in part.  For all purposes of this Indenture unless the context
      otherwise requires, provisions of this Indenture that apply to Notes called for redemption also apply to portions of Notes called for redemption. Redemption amounts shall only be paid upon presentation and surrender of any such Notes to be redeemed
      to the Trustee at its Corporate Trust Office.

     

    	SECTION 3.03.	
            Notice of Redemption.

          

     

    At least 10 days, and no more than 60 days, before a Redemption Date, the Issuer shall send, or cause to be sent, a notice of redemption electronically
      or by first-class mail to each Holder of Notes to be redeemed at his or her last address as the same appears on the registry books maintained by the Registrar pursuant to Section 2.06.

     

    
      

      
        

      -46-

      

    

    The notice shall identify the Notes to be redeemed (including the CUSIP and/or ISIN numbers thereof) and shall state:

     

    (1)          the Redemption Date;

     

    (2)          the redemption price and the amount
        of premium and accrued interest to be paid;

     

    (3)          if any series of Notes is being
        redeemed in part, the portion of the principal amount of such Note to be redeemed and that, after the Redemption Date and upon surrender of such Note, a new Note or Notes in principal amount equal to the unredeemed portion will be issued;

     

    (4)          the name and address of the Paying
        Agent;

     

    (5)          that Notes called for redemption must
        be surrendered to the Paying Agent to collect the redemption price;

     

    (6)          that unless the Issuer defaults in
        making the redemption payment, interest on Notes called for redemption ceases to accrue on and after the Redemption Date;

     

    (7)          that paragraph 5 of the Notes is the
        provision of the Notes pursuant to which the redemption is occurring;

     

    (8)          the aggregate principal amount of
        Notes that are being redeemed;

     

    (9)          any conditions precedent to such
        redemption in reasonable detail; and

     

    (10)        that no representation is made as to
        the correctness or accuracy of the CUSIP or ISIN numbers printed in the notice or on the Notes, and that reliance may be placed only on the other identification numbers printed on the Notes.

     

    At the Issuer’s written request made at least five Business Days prior to the date on which notice is to be given (unless a shorter notice shall be
      agreed to in writing by the Trustee), together with the notice of redemption to be given, the Trustee shall give the notice of redemption in the Issuer’s name and at the Issuer’s sole expense.

     

    
      

      
        

      -47-

      

    

    Any notice of redemption may, at the Issuer’s discretion, be subject to one or more conditions precedent with respect to completion of a corporate
      transaction (including, but not limited to, any merger, acquisition, disposition, asset sale or corporate restructuring or reorganization) or financing (including, but not limited to, any incurrence of Indebtedness (or entering into a commitment with
      respect thereto), Sale and Leaseback Transaction, issuance of securities, equity offering or contribution, liability management transaction or other capital raise) and may be given prior to the completion thereof. If any notice of redemption is
      subject to one or more conditions precedent, the notice shall describe each condition, and the notice may be rescinded in the event that any or all of the conditions shall not have been satisfied by the Redemption Date if the Issuer delivers an
      Officer’s Certificate to the Trustee describing the failure of the condition in reasonable detail and rescinding the redemption.  The Issuer may provide in such notice that payment of the redemption price and performance of the Issuer’s obligations
      with respect to such redemption may be performed by another Person. The Trustee shall promptly provide a copy of such Officer’s Certificate to the Holders in the same manner in which the notice of redemption was given.

     

    	SECTION 3.04.	
            Effect of Notice of Redemption.

          

     

    Once the notice of redemption described in Section 3.03 is sent and subject to the proviso to this sentence, the series of Notes called for redemption
      become due and payable on the Redemption Date and at the redemption price, including any premium, plus interest accrued to the Redemption Date; provided, however, that any redemption and notice thereof pursuant to this Indenture may, in the Issuer’s discretion, be subject to one or more conditions precedent, and the
      notice may be rescinded in the event that any or all of the conditions shall not have been satisfied by the Redemption Date and the Issuer shall have no obligation to redeem Notes on such Redemption Date.  Upon surrender to the Paying Agent, such
      Notes shall be paid at the redemption price, including any premium, plus interest accrued to the Redemption Date; provided that if the Redemption Date is after
      a regular record date and on or prior to the Interest Payment Date, the accrued interest shall be payable to the Holder of the redeemed Notes registered on the relevant record date; and provided, further, that if a Redemption Date is a Legal Holiday, payment shall be made on the next succeeding Business Day and no
      interest shall accrue for the period from such Redemption Date to such succeeding Business Day.

     

    	SECTION 3.05.	
            Deposit of Redemption Price.

          

     

    On or prior to 10:00 A.M., New York City time, on each Redemption Date, the Issuer shall deposit with the Paying Agent U.S. Dollars sufficient to pay the
      redemption price of, including premium, if any, and accrued interest on any and all Notes to be redeemed on that date (other than Notes or portions thereof called for redemption on that date which have been delivered by the Issuer to the Trustee for
      cancellation).

     

    On and after any Redemption Date, if money sufficient to pay the redemption price of, including premium, if any, and accrued interest on all Notes called
      for redemption shall have been made available in accordance with the immediately preceding paragraph, the Notes called for redemption will cease to accrue interest and the only right of the Holders of such Notes will be to receive payment of the
      redemption price of and, subject to the first proviso in Section 3.04, accrued and unpaid interest on such Notes to the Redemption Date.  If any Note surrendered for redemption shall not be so paid, interest will be paid, from the Redemption Date
      until such redemption payment is made, on the unpaid principal of the Note and (to the extent permitted by applicable law) any interest not paid on such unpaid principal, in each case at the rate and in the manner provided in the Notes.

     

    
      

      
        

      -48-

      

    

    	SECTION 3.06.	
            Notes Redeemed in Part.

          

     

    Upon surrender of a Note that is redeemed in part, the Issuer shall execute and, upon receipt of a written order of the Issuer in the form of an
      Officer’s Certificate in accordance with Section 2.01, the Trustee shall authenticate for the Holder thereof a new Note equal in principal amount to the unredeemed portion of the Note surrendered.

     

    	SECTION 3.07.	
            Special Mandatory Redemption.

          

     

    (a)          If (i) the consummation of the Merger does not occur on
        or before April 14, 2021 or (ii) the Issuer notifies the Trustee that the Issuer will not pursue the consummation of the Merger (any such date, the “Special Mandatory Redemption
            Trigger Date”), the Issuer will be required to redeem each series of Notes then outstanding (such redemption, the “Special Mandatory Redemption”) at a
        redemption price equal to 100% of the principal amount of such series of Notes plus accrued and unpaid interest, if any, to, but excluding, the Special Mandatory Redemption Date (the “Special

            Mandatory Redemption Price”).

     

    (b)          In the event that the Issuer becomes obligated to redeem
        each series of Notes pursuant to the Special Mandatory Redemption, the Issuer will promptly, and in any event not more than 10 Business Days after the Special Mandatory Redemption Trigger Date, deliver notice to the Trustee of the Special Mandatory
        Redemption and the date upon which each series of Notes will be redeemed (the “Special Mandatory Redemption Date,” which date shall be no later than the third Business Day
        following the date of such notice) together with a notice of Special Mandatory Redemption for the Trustee to deliver to each registered Holder of each series of Notes. The Trustee will then promptly mail, or electronically deliver, according to the
        procedures of DTC, such notice of Special Mandatory Redemption to each registered Holder of each series of Notes. Unless the Issuer defaults in payment of the Special Mandatory Redemption Price, on and after such Special Mandatory Redemption Date,
        interest will cease to accrue on each series of Notes.

     

    (c)          Notwithstanding the foregoing, installments of interest
        on each series of Notes that are due and payable on Interest Payment Dates falling on or prior to the Special Mandatory Redemption Date will be payable on such interest payment dates to the applicable registered Holders as of the close of business
        on the relevant record dates in accordance with the Notes and this Indenture. Upon the deposit of funds sufficient to pay the Special Mandatory Redemption Price of all Notes to be redeemed on the Special Mandatory Redemption Date with the Trustee
        before such Special Mandatory Redemption Date, all rights of Holders under each series of Notes shall terminate (other than the right of Holders to receive the Special Mandatory Redemption Price on the Special Mandatory Redemption Date).

     

    
      

      
        

      -49-

      

    

    (d)          Notwithstanding anything to the contrary herein, the
        provisions in this Section 3.07 may be waived or modified with the consent of the Holders of at least a majority in aggregate principal amount of each series of the then outstanding Notes issued under this Indenture voting as a single class.

     

    ARTICLE FOUR

     

    COVENANTS

     

    	SECTION 4.01.	
            Payment of Notes.

          

     

    The Issuer shall pay the principal of and interest on the Notes on the dates and in the manner provided in the Notes and this Indenture.  An installment
      of principal or interest shall be considered paid on the date it is due if the Trustee or the Paying Agents hold by 10:00 A.M. Eastern Time on that date U.S. Dollars designated for and sufficient to pay such installment.

     

    The Issuer shall pay interest on overdue principal (including post-petition interest in a proceeding under any Bankruptcy Law), and overdue interest, to
      the extent lawful, at the rate specified in the Notes.

     

    	SECTION 4.02.	
            Maintenance of Office or Agency.

          

     

    (a)          The Issuer shall maintain an office or agency (which may
        be an office of the Trustee or an Affiliate of the Trustee or Registrar) where Notes may be surrendered for registration of transfer or for exchange and where notices and demands to or upon the Issuer in respect of the Notes and this Indenture may
        be served.  The Issuer shall give prompt written notice to the Trustee of the location, and any change in the location, of such office or agency.  If at any time the Issuer shall fail to maintain any such required office or agency or shall fail to
        furnish the Trustee with the address thereof, such presentations, surrenders, notices and demands may be made or served at the Corporate Trust Office of the Trustee.

     

    (b)          The Issuer may also from time to time designate one or
        more other offices or agencies where the Notes may be presented or surrendered for any or all such purposes and may from time to time rescind such designations.  The Issuer shall give prompt written notice to the Trustee of any such designation or
        rescission and of any change in the location of any such other office or agency.

     

    
      

      
        

      -50-

      

    

    	SECTION 4.03.	
            Legal Existence.

          

     

    Except as permitted by Article Five, the Issuer shall do or cause to be done all things necessary to preserve and keep in full force and effect (i) its
      legal existence, and the corporate, partnership or other existence of each Subsidiary, in accordance with the respective organizational documents (as the same may be amended from time to time) of the Issuer and each such Subsidiary, and (ii) the
      material rights (charter and statutory) and franchises of the Issuer and such Subsidiaries; provided that the Issuer shall not be required to preserve any such
      right, franchise, or the corporate, partnership or other existence of any of its Subsidiaries if the Board of Directors of the Issuer or such Subsidiary shall determine that the preservation thereof is no longer desirable in the conduct of the
      business of the Issuer and its Subsidiaries, taken as a whole, and that the loss thereof is not adverse in any material respect to the Holders.

     

    	SECTION 4.04.	
            Waiver of Stay, Extension or Usury Laws.

          

     

    Each of the Issuer and the Guarantors covenants (to the extent that it may lawfully do so) that it shall not at any time insist upon, or plead (as a
      defense or otherwise) or in any manner whatsoever claim or take the benefit or advantage of, any stay or extension law or any usury law or other law which would prohibit or forgive the Issuer and the Guarantors from paying all or any portion of the
      principal of, premium, if any, and/or interest on the Notes as contemplated herein, wherever enacted, now or at any time hereafter in force, or which may affect the covenants or the performance of this Indenture; and (to the extent that they may
      lawfully do so) the Issuer and the Guarantors hereby expressly waives all benefit or advantage of any such law, and covenants that it will not hinder, delay or impede the execution of any power herein granted to the Trustee, but will suffer and
      permit the execution of every such power as though no such law had been enacted.

     

    	SECTION 4.05.	
            Compliance Certificate.

          

     

    (a)          The Issuer shall deliver to the Trustee, within 120 days
        after the end of each Fiscal Year,  an Officer’s Certificate (as enumerated by and in compliance with Section 314(a)(4) of the TIA) stating that such Officer has conducted or supervised a review of the activities the Issuer and its Subsidiaries and
        the Issuer’s and its Subsidiaries’ performance under this Indenture during such Fiscal Year, and further stating that, to such Officer’s knowledge, based upon such review, the Issuer has fulfilled all obligations under this Indenture or, if there
        has been a Default under this Indenture that is continuing, a description of the event and what action the Issuer is taking or propose to take with respect thereto.

     

    (b)          The Issuer shall deliver to the Trustee, within ten
        Business Days after an executive officer of the Issuer becomes aware of any Default or Event of Default, a statement specifying such Default or Event of Default.

     

    (c)          The Issuer shall provide written notice to the Trustee
        of any change in the Issuer’s Fiscal Year.

     

    
      

      
        

      -51-

      

    

    	SECTION 4.06.	
            Taxes.

          

     

    The Issuer shall, and shall cause each of its Subsidiaries to, pay prior to delinquency all material taxes, assessments, and governmental levies; provided, however, that, neither the Issuer nor any of its Subsidiaries
      shall be required to pay or discharge or cause to be paid or discharged any such tax, assessment, charge or claim whose amount, applicability or validity is being contested in good faith by appropriate proceedings.

     

    	SECTION 4.07.	
            Repurchase at the Option of Holders upon Change of Control.

          

     

    (a)          Upon the occurrence of a Change of Control or, at the
        Issuer’s option, prior to the consummation of a Change of Control but after a transaction that would constitute a Change of Control upon consummation is publicly announced, the Issuer will make an offer, as described below (the “Change of Control Offer”), to the Holders of all of each series of outstanding Notes at an offer price in cash equal to 101% of the principal amount tendered, plus accrued and
        unpaid interest, if any, thereon to, but not including, the date of purchase (the “Change of Control Payment”).

     

    (b)          Within 30 days following any Change of Control or, at
        the Issuer’s option, prior to the consummation of such Change of Control but after the public announcement of a transaction that would constitute a Change of Control upon consummation thereof, the Issuer will mail (or to the extent permitted or
        required by applicable Depositary procedures or regulations with respect to each series of global Notes, send electronically) a notice to each Holder and the Trustee.  The notice shall describe the transaction or transactions that constitute, or
        are expected to constitute, the Change of Control and offer to repurchase each series of Notes on the purchase date specified in such notice (which must be no earlier than 10 days nor later than 60 days from the date such notice is mailed or sent
        electronically, other than as required by law) (the “Change of Control Payment Date”) pursuant to the procedures required by this Indenture and described in such notice. 
        Such obligation will not continue after a discharge of the Issuer or defeasance from its obligations with respect to each series of Notes.  Such notice shall state:

     

    (1)          that the Change of Control Offer is
        being made pursuant to this Section 4.07 and that all Notes validly tendered and not validly withdrawn will be accepted for payment;

     

    (2)          the Change of Control Payment and the
        Change of Control Payment Date (which shall be no earlier than 30 days nor later than 60 days from the date such notice is sent, other than as may be required by law);

     

    (3)          that any Note not tendered will
        continue to accrue interest;

     

    
      

      
        

      -52-

      

    

    (4)          that, unless the Issuer defaults in
        making payment therefor, any Note accepted for payment pursuant to the Change of Control Offer shall cease to accrue interest after the Change of Control Payment Date;

     

    (5)          that Holders electing to have a Note
        purchased pursuant to the Change of Control Offer will be required to surrender the Note, with the form entitled “Option of Holder to Elect Purchase” on the reverse of the Note completed, to the Paying Agent and Registrar for the Note at the
        address specified in the notice prior to the close of business on the Business Day prior to the Change of Control Payment Date;

     

    (6)          that Holders will be entitled to
        withdraw their election if the Paying Agent receives, not later than the third Business Day prior to the Change of Control Payment Date, a telegram, telex, facsimile transmission or letter setting forth the name of the Holder, the principal amount
        of the Notes the Holder delivered for purchase and a statement that such Holder is withdrawing its election to have such Note purchased;

     

    (7)          that Holders whose Notes are
        purchased only in part will be issued new Notes in a principal amount equal to the unpurchased portion of the Notes surrendered; provided, however, that each Note purchased and each new Note issued shall be in a principal amount of $2,000 or integral multiples of $1,000 in excess of $2,000; and

     

    (8)          the circumstances and relevant facts
        regarding such Change of Control.

     

    (c)          On the Change of Control Payment Date, the Issuer shall,
        to the extent lawful:

     

    (1)          accept for payment all Notes or
        portions thereof (in minimum amounts of $2,000 or an integral multiple of $1,000 in excess thereof) properly tendered pursuant to the Change of Control Offer;

     

    (2)          deposit with the Paying Agent an
        amount equal to the Change of Control Payment in respect of all Notes or portions thereof so tendered; and

     

    (3)          deliver or cause to be delivered to
        the Trustee for cancellation all Notes so accepted together with an Officer’s Certificate stating the aggregate principal amount of Notes (or portions thereof) being purchased by the Issuer.

     

    
      

      
        

      -53-

      

    

    Promptly following the deposit with the Paying Agent of the moneys described in Section 4.07(c)(2) above and the delivery of the Officer’s Certificate
      described in Section 4.07(c)(3) above, the Paying Agent will remit to each Holder of Notes so tendered the Change of Control Payment for such Notes, and the Issuer will execute and, upon receipt of a written order of the Issuer in the form of an
      Officer’s Certificate in accordance with Section 2.01, the Trustee will promptly authenticate and deliver (or cause to be transferred by book entry) to each Holder of Notes a new Note equal in principal amount to any unpurchased portion of the Notes
      surrendered, if any; provided that each such new Note will be in a principal amount of $2,000 or an integral multiple of $1,000 in excess thereof. The Issuer
      will publicly announce the results of the Change of Control Offer on or as soon as reasonably practicable after the Change of Control Payment Date.

     

    If Holders of not less than 90% in aggregate principal amount of the then outstanding Notes of a series validly tender and do not withdraw such Notes in
      a Change of Control Offer and the Issuer, or any other Person making a Change of Control Offer in lieu of the Issuer as described below, purchases all of the applicable Notes validly tendered and not withdrawn by such holders, the Issuer will have
      the right, upon not less than 10 nor more than 30 days’ prior notice, given not more than 10 days following such purchase pursuant to the Change of Control Offer described above, to redeem all such series of Notes that remain outstanding following
      such purchase at a redemption price in cash equal to the applicable Change of Control Payment plus, to the extent not included in the Change of Control Payment, accrued and unpaid interest to, but not including, the redemption date.

     

    Upon the payment of the Change of Control Payment, the Trustee shall, subject to the provisions of Section 2.16, return the Notes purchased to the Issuer
      for cancellation.  The Trustee may act as the Paying Agent for purposes of any Change of Control Offer.

     

    (d)          The Issuer will not be required to make a Change of
        Control Offer upon a Change of Control if (1) a third party makes the Change of Control Offer in the manner, at the times and otherwise in compliance with the requirements set forth in this Section 4.07 with respect to a Change of Control Offer
        made by the Issuer and purchases all Notes validly tendered and not withdrawn under such Change of Control Offer or (2) notice of redemption has been given or will be given pursuant to this Indenture as described in Article Three, prior to the date
        the Issuer is required to send notice of the Change of Control Offer to the Holders of the Notes, unless and until there is a default in payment of the applicable redemption price.  Notwithstanding anything to the contrary contained herein, a
        Change of Control Offer may be made in advance of a Change of Control, conditioned upon the consummation of such Change of Control, if a definitive agreement is in place for the Change of Control at the time the Change of Control Offer is made and
        such Change of Control Offer is otherwise made in compliance with the provisions of this Section 4.07.

     

    (e)          The Issuer will comply with the requirements of Rule
        14e-1 under the Exchange Act and any other securities laws and regulations thereunder to the extent such laws and regulations are applicable in connection with the repurchase of the Notes as a result of a Change of Control. To the extent that the
        provisions of any securities laws or regulations conflict with provisions of this Section 4.07, the Issuer will comply with the applicable securities laws and regulations and will not be deemed to have breached its obligations under this paragraph
        by virtue of its compliance with such securities laws or regulations.

     

    
      

      
        

      -54-

      

    

    	SECTION 4.08.	
            Limitation on Asset Disposition.

          

     

    (a)          The Parent Guarantor shall not, and shall not permit any
        of its Subsidiaries to, directly or indirectly, consummate any Asset Disposition unless:

     

    (1)          the Parent Guarantor or such
        Subsidiary receives consideration at least equal to the fair market value (such fair market value to be determined in good faith by the Issuer on the date of contractually agreeing to such Asset Disposition) of the equity or assets subject to such
        Asset Disposition;

     

    (2)          at least 75% of the consideration
        received by the Parent Guarantor or such Subsidiary is in the form of cash or cash equivalents, Additional Assets or any combination thereof (collectively, the “Cash Consideration”);

        and

     

    (3)          within 365 days, including the 365th
        day, from the later of the date of such Asset Disposition or the receipt of such Net Available Cash, an amount equal to 100% of the Net Available Cash from such Asset Disposition is applied by the Parent Guarantor (or such Subsidiary, as the case
        may be) at its option:

     

    (A)          to prepay, repay, redeem or purchase
        Secured Debt of the Issuer or any Guarantor or Indebtedness of a Wholly Owned Subsidiary of the Parent Guarantor that is not a Guarantor (in each case other than Indebtedness owed to the Issuer or an Affiliate of the Issuer); provided that such prepayment, repayment, redemption or purchase permanently retires, or reduces the related loan commitment (if any) for, such Indebtedness in an
        amount equal to the principal amount so prepaid, repaid, redeemed or purchased;

     

    (B)          to acquire Additional Assets or to
        make any other capital expenditures (provided that this requirement shall be deemed satisfied if the Parent Guarantor (or such Subsidiary, as the case may be)
        by the end of such 365-day period has entered into a binding agreement under which it is contractually committed to acquire Additional Assets and such acquisition is consummated within 180 days from the end of the 365-day period);

     

    (C)          to make an offer to the Holders of
        each series of Notes (and to holders of other Pari Passu Indebtedness of the Issuer designated by the Issuer) to purchase such series of Notes (and such other Pari Passu Indebtedness of the Issuer) pursuant to and subject to the conditions
        contained herein, as set forth below (other than with respect to Excess Proceeds and that such offer may be made at any time prior to the end of such 365-day period), and in the instruments governing such Pari Passu Indebtedness; and

     

    
      

      
        

      -55-

      

    

    (D)          to the extent of the balance of such
        Net Available Cash after application in accordance with clauses (A), (B) and (C), for any purpose permitted by the terms of this Indenture.

     

    Pending application of Net Available Cash pursuant to this Section 4.08, such Net Available Cash shall be applied to temporarily reduce revolving credit
      Indebtedness or in any manner not prohibited by this Indenture.

     

    (b)          For the purposes of this Section 4.08, the following are
        deemed to be Cash Consideration:

     

    (1)          any liabilities, as shown on the
        Parent Guarantor’s or any of its Subsidiaries’ most recent balance sheet (or in the footnotes thereto or if incurred, accrued or increased subsequent to the date of such balance sheet, such liabilities that would have been reflected on the Parent
        Guarantor’s or such Subsidiary’s balance sheet or in the footnotes thereto if such incurrence, accrual or increase had taken place on or prior to the date of such balance sheet, as determined by the Parent Guarantor), of the Parent Guarantor or
        such Subsidiary that are assumed by the transferee of any such assets either by operation of law or pursuant to (A) a customary novation agreement that releases the Parent Guarantor or such Subsidiary from further liability or (B) an assignment
        agreement that includes, in lieu of such a release, the agreement of the transferee or its parent company to indemnify and hold harmless the Issuer or such Subsidiary from and against any loss, liability or cost in respect of such assumed
        liability;

     

    (2)          any securities, notes or other
        obligations received by the Parent Guarantor or any of its Subsidiaries from such transferee that are converted by the Parent Guarantor or such Subsidiary into cash or cash equivalents within 360 days after such Asset Disposition, to the extent of
        the cash and cash equivalents received in that conversion; and

     

    (3)          any Designated Non-cash Consideration
        received by the Parent Guarantor or any of its Subsidiaries in such Asset Disposition having an aggregate fair market value, taken together with all other Designated Non-cash Consideration received pursuant to this clause that has at that time not
        been converted into cash or a cash equivalent, not to exceed the greater of (x) $100.0 million and (y) 2.0% of Consolidated Total Assets at the time of the receipt of such Designated Non-cash Consideration (with the fair market value of each item
        of Designated Non-cash Consideration being measured at the time received and without giving effect to subsequent changes in value).

     

    
      

      
        

      -56-

      

    

    (c)          The amount of Net Available Cash not applied or invested
        as provided above will constitute “Excess Proceeds” (other than any Net Available Cash remaining after the Issuer has made an offer to purchase each series of Notes
        pursuant to clause (C) above).  Within ten Business Days of the date that the aggregate amount of Excess Proceeds equals or exceeds $100.0 million, the Issuer shall make an offer to purchase each series of Notes (each, an “Offer”), and shall purchase the series of Notes tendered pursuant to an Offer by the Issuer for the applicable series of Notes and other Pari Passu Indebtedness that contemporaneously requires
        the purchase, prepayment or redemption of such Indebtedness with the proceeds of sales of assets at a purchase price of 100% of their principal amount without premium, plus accrued but unpaid interest (or, in respect of such other Pari Passu
        Indebtedness, such lesser price, if any, as may be provided for by the terms of such Pari Passu Indebtedness) to, but excluding, the date such Offer is consummated, in accordance with the procedures (including prorating in the event of
        oversubscription) set forth in this Indenture and the terms of such other Pari Passu Indebtedness. If any Excess Proceeds remain after consummation of an Offer and the contemporaneous offer with respect to any other Pari Passu Indebtedness
        contemplated above, the Issuer may use those Excess Proceeds for any purpose not otherwise prohibited by this Indenture. If the aggregate purchase price of the securities tendered exceeds the amount of Excess Proceeds, the Issuer shall allocate the
        Excess Proceeds between such securities on a pro rata basis and will select the Notes to be purchased on a pro rata basis but in denominations of $2,000 principal amount or integral multiples of $1,000 in excess thereof. The remainder of the Excess
        Proceeds allocable to the other Pari Passu Indebtedness will be repurchased as provided pursuant to the terms of such Indebtedness. Upon completion of such an Offer to purchase, Excess Proceeds will be deemed to be reset to zero.

     

    (d)          The Issuer shall comply, to the extent applicable, with
        the requirements of Rule 14e-1 under the Exchange Act and any other securities laws and regulations thereunder to the extent such laws and regulations are applicable in connection with the repurchase of Notes pursuant to this Section 4.08. To the
        extent that the provisions of any securities laws or regulations conflict with provisions of this Section 4.08, the Issuer shall comply with the applicable securities laws and regulations and shall not be deemed to have breached its obligations
        under this Section 4.08 by virtue of its compliance with such securities laws or regulations.

     

    	SECTION 4.09.	
            Limitation on Restricted Payments.

          

     

    The Parent Guarantor will not, and will not permit any of its Subsidiaries to, directly or indirectly, make any Restricted Payment if at the time of such
      Restricted Payment:

     

    (a)          a Default shall have occurred and be
        continuing or shall occur as a consequence thereof;

     

    (b)          after giving effect to such
        Restricted Payment (including, without limitation, the incurrence of any Indebtedness to finance such Restricted Payment), the Consolidated Fixed Charge Coverage Ratio would be less than 2.00 to 1.00; or

     

    
      

      
        

      -57-

      

    

    (c)          the amount of such Restricted
        Payment, when added to the aggregate amount of all other Restricted Payments made after November 26, 2013 (other than Restricted Payments made pursuant to clause (b), (c), (d), (e), (f), (g) or (h) of the next paragraph), exceeds the sum (the “Restricted Payments Basket”) of (without duplication):

     

    (1)          50% of Consolidated Net Income of the
        Parent Guarantor and its Subsidiaries determined in accordance with GAAP for the period (taken as one accounting period) commencing on July 1, 2013 to and including the last day of the fiscal quarter ended immediately prior to the date of such
        calculation for which consolidated financial statements are available (or, if such Consolidated Net Income shall be a deficit, minus 100% of such aggregate deficit), plus

     

    (2)          100% of the aggregate net cash
        proceeds and the fair market value, as determined in good faith by the Parent Guarantor, of property and marketable securities received by the Parent Guarantor from the issuance and sale of Qualified Equity Interests of the Parent Guarantor after
        November 26, 2013 or from the issue or sale of convertible or exchangeable Disqualified Equity Interests of the Parent Guarantor or convertible or exchangeable debt securities of the Parent Guarantor, in each case that have been converted into or
        exchanged for Qualified Equity Interests of the Parent Guarantor, other than (A) any such proceeds which are used to redeem any series of Notes in accordance with paragraph 5 of each of the Notes or (B) any such proceeds or assets received from a
        Subsidiary of the Parent Guarantor, plus

     

    (3)          the aggregate amount by which
        Indebtedness incurred by the Parent Guarantor or any of its Subsidiaries subsequent to November 26, 2013 is reduced on the Parent Guarantor’s consolidated balance sheet upon the conversion or exchange (other than by a Subsidiary of the Parent
        Guarantor) into Qualified Equity Interests of the Parent Guarantor (less the amount of any cash, or the fair value of assets, distributed by the Parent Guarantor or any Subsidiary upon such conversion or exchange), plus

     

    (4)          50% of any cash dividends or
        distributions received by the Parent Guarantor or any of its Subsidiaries after November 26, 2013 from any unconsolidated Person, to the extent that such dividends or distributions were not otherwise included in Consolidated Net Income.

     

    The foregoing provisions will not prohibit:

     

    (a)          the payment by the Parent Guarantor
        of any dividend or the consummation of any redemption within 60 days after the date of declaration thereof or the giving of the redemption notice, as the case may be, if on the date of declaration or notice, the dividend or redemption payment would
        have complied with the provisions of this Indenture;

     

    
      

      
        

      -58-

      

    

    (b)          the repurchase or redemption of any
        Equity Interests of the Parent Guarantor in exchange for, or out of the proceeds of the substantially concurrent issuance and sale of, Qualified Equity Interests;

     

    (c)          payments by the Parent Guarantor to
        redeem Equity Interests of the Parent Guarantor held by officers, directors or employees or former officers, directors or employees (or their transferees, estates or beneficiaries under their estates) of the Parent Guarantor or its Subsidiaries,
        upon their death, disability, retirement, severance or termination of employment or service or other repurchase event pursuant to any management equity plan or stock option plan, shareholders’ agreement or any other management or employee benefit
        plan or agreement or arrangement; provided that the aggregate cash consideration paid for all such redemptions shall not exceed (A) $10.0 million in any
        calendar year (with unused amounts in any calendar year being permitted to be carried over to succeeding calendar years subject to a maximum of $20.0 million in any calendar year); plus (B) the amount of any net cash proceeds received by the Parent
        Guarantor from the issuance and sale after November 26, 2013 of Qualified Equity Interests of the Parent Guarantor to officers, directors or employees of the Parent Guarantor or its Subsidiaries that have not been applied to the payment of
        Restricted Payments pursuant to this clause (c), plus (C) the net cash proceeds of any “key-man” life insurance policies that have not been applied to the payment of Restricted Payments pursuant to this clause (c); provided that neither (x) cancellation of Indebtedness owing to the Parent Guarantor from any current or former officer, director or employee (or any permitted transferees thereof) of
        the Parent Guarantor or any of its Subsidiaries (or any direct or indirect parent company thereof), in connection with a repurchase of Equity Interests of the Parent Guarantor from such Persons nor (y) any payments or other obligations arising in
        respect of Equity Interests of the Parent Guarantor held by officers, directors or employees or former officers, directors or employees (or their transferees, estates or beneficiaries under their estates) in connection with or resulting from the
        announcement or consummation of a Change of Control, will be deemed to constitute a Restricted Payment for purposes of this Section 4.09 or any other provisions of this Indenture;

     

    (d)          repurchases, acquisitions or
        retirements for value of Equity Interests (i) deemed to occur upon the exercise of stock options, warrants, rights to acquire Equity Interests or other convertible securities if the Equity Interests represent a portion of the exercise price
        thereof, or in connection with the withholding of a portion of the Equity Interests granted or awarded to an employee to pay for the taxes payable by such employee upon such grant or award or (ii) upon cancellation or forfeiture of stock options,
        warrants, rights to acquire Equity Interests or other convertible securities;

     

    
      

      
        

      -59-

      

    

    (e)          Restricted Payments to allow the
        payment of cash in lieu of the issuance of fractional shares upon (i) the exercise of options or warrants or (ii) the conversion or exchange of Equity Interests of any Person (including in a merger, consolidation, amalgamation or similar
        transaction) and payments of cash to dissenting shareholders in connection with a merger, consolidation, amalgamation, transfer of assets;

     

    (f)           the payment of any dividend (or, in
        the case of any partnership or limited liability company, any similar distribution) by a Subsidiary of the Parent Guarantor to the holders of its Equity Interests on a pro rata basis;

     

    (g)          Restricted Payments in an amount not
        to exceed $200.0 million since the Issue Date (provided, however,
        that any Restricted Payment made under (i) clause (g) of the second paragraph of Section 4.10 of the 2021 Indenture on or after November 26, 2013 and prior to the Issue Date and (ii) clause (g) of the second paragraph of Section 4.10 of the 2024
        Indenture on or after June 15, 2016 and prior to the Issue Date, in each case, shall be treated as a utilization of this clause (g));

     

    (h)          (i) the repurchase or redemption of
        common stock or Preferred Stock purchase rights of the Parent Guarantor issued in connection with any stockholders rights plan and (ii) so long as no Default under clauses (1) or (2) of the definition of “Event of Default” shall have occurred and
        be continuing or shall occur as consequence thereof, Restricted Payments with respect to Preferred Stock in an aggregate amount not to exceed $73.0 million in each calendar year; and

     

    (i)           other Restricted Payments if, at
        the time of the making of such payments, and after giving effect thereto (including, without limitation, the incurrence of any Indebtedness to finance such payment), the Total Leverage Ratio would not exceed 3.00 to 1.00,

     

    provided that (a) in the case of any Restricted Payment pursuant to clause (g) or
      (i) of this Section 4.09, no Default shall have occurred and be continuing or shall occur as a consequence thereof and (b) no issuance and sale of Qualified Equity Interests that are used to make a payment pursuant to clauses (b) or (c)(B) of this
      Section 4.09 shall increase the Restricted Payments Basket.

     

    
      

      
        

      -60-

      

    

    For purposes of determining compliance with this Section 4.09, in the event that a payment or other action meets the criteria of more than one of the
      exceptions described in clauses (a) through (i) above, or is entitled to be made pursuant to the first paragraph of this Section 4.09, the Issuer will be permitted to classify such payment or other action on the date of its occurrence in any manner
      that complies with this Section 4.09. Payments or other actions permitted by this Section 4.09 need not be permitted solely by reference to one provision permitting such payment or other action, but may be permitted in part by one such provision and
      in part by one or more other provisions of this Section 4.09 permitting payment or other action, including, for the avoidance of doubt, in the event that any Fixed Baskets are intended to be utilized together with any Incurrence-Based Baskets in a
      single transaction or a series of related transactions, (1) compliance with or satisfaction of any applicable financial ratios or tests for the portion of such Restricted Payment or other applicable transaction or action to be incurred under any
      Incurrence-Based Baskets shall first be calculated without giving effect to amounts being utilized pursuant to any Fixed Baskets, but giving full pro forma effect to all applicable and related transactions (including, subject to the foregoing with
      respect to Fixed Baskets, any incurrence and any repayment of Indebtedness and any related Liens) and all other permitted pro forma adjustments and (2) thereafter, incurrence of the portion of such Restricted Payment to be incurred under any Fixed
      Baskets shall be calculated.

     

    If the Parent Guarantor or any of its Subsidiaries makes a Restricted Payment which, at the time of the making of such Restricted Payment, in the good
      faith determination of the Parent Guarantor or such Subsidiary, would be permitted under the requirements of this Indenture, such Restricted Payment shall be deemed to have been made in compliance with this Indenture notwithstanding any subsequent
      adjustment made in good faith to the Parent Guarantor’s financial statements affecting Consolidated Net Income.

     

    	SECTION 4.10.	
            Limitation on Liens.

          

     

    The Parent Guarantor will not at any time create, incur, assume or guarantee, and will not cause or permit any of its Subsidiaries to create, incur,
      assume or guarantee, any Secured Debt (the “Initial Security Interest”), and the Parent Guarantor will not at any time create, and will not cause or permit any of its
      Subsidiaries to create, any Security Interest securing any Indebtedness existing on the date hereof that would constitute Secured Debt if it were secured by a Security Interest, without first making effective provision whereby each series of Notes
      shall be secured by the Security Interest securing such Secured Debt equally and ratably with, or prior to, any and all other obligations and indebtedness so secured, so long as such other obligations and indebtedness shall be so secured; provided, however, that the foregoing prohibition will not prevent the
      creation, incurrence, assumption or guarantee of the following permitted Security Interests (the “Permitted Security Interests”):

     

    (1)          Security Interests on property
        acquired, constructed, developed or improved after the date of this Indenture by the Parent Guarantor or any of its Subsidiaries and created prior to or contemporaneously with, or within 180 days after the acquisition, construction, development or
        improvement of property that is a parcel of real property, a building, machinery or equipment;

     

    
      

      
        

      -61-

      

    

    (2)          Security Interests on property at the
        time of acquisition which secure obligations assumed by the Parent Guarantor or any of its Subsidiaries, or on the property or on the outstanding shares or Indebtedness of a corporation or firm at the time it becomes a Subsidiary or is merged into
        or consolidated with the Parent Guarantor or any of its Subsidiaries, or on properties of a corporation or firm acquired by the Parent Guarantor or any of its Subsidiaries as an entirety or substantially as an entirety; provided that the Security Interests may not extend to any other property of the Parent Guarantor or such Subsidiary other than proceeds and products of such property, shares or
        Indebtedness and accessions thereto;

     

    (3)          Security Interests arising from
        conditional sales agreements or title retention agreements with respect to property acquired by the Parent Guarantor or any of its Subsidiaries;

     

    (4)          Security Interests securing
        Indebtedness of a Subsidiary of the Parent Guarantor owing to the Parent Guarantor or to another of the Parent Guarantor’s Subsidiaries;

     

    (5)          Security Interests (a) to secure
        obligations under Credit Facilities or (b) in accounts receivable and related assets of the types specified in the definition of “Qualified Receivables Transaction” incurred in connection with a Qualified Receivables Transaction, in an aggregate
        principal amount under clauses (a) and (b) combined not to exceed the greater of (x) $3,000.0 million and (y) the maximum amount that would not cause the Senior Secured Leverage Ratio to exceed 3.00 to 1.00 after giving pro forma effect to the
        incurrence of the obligations to be secured by such Security Interests and the application of the proceeds therefrom;

     

    (6)          Security Interests existing on the
        Issue Date and extensions, renewals and replacements of any such Security Interests so long as such Security Interests are not extended to any other property of the Parent Guarantor or any of its Subsidiaries;

     

    (7)          any Security Interest arising by
        reason of deposits with, or the giving of any form of security to, any governmental agency or any body created or approved by law or governmental regulations, which is required by law or governmental regulation as a condition to the transaction of
        any business, or the exercise of any privilege, franchise or license;

     

    (8)          carriers’, warehousemen’s, mechanics’
        and other statutory liens arising in the ordinary course of business (including construction of facilities) in respect of obligations that are not due or that are being contested in good faith;

     

    (9)          Security Interests for taxes,
        assessments or governmental charges not yet delinquent or for taxes, assessments or governmental charges that are being contested in good faith;

     

    
      

      
        

      -62-

      

    

    (10)        Security Interests (including
        judgment liens) arising in connection with legal proceedings so long as such proceedings are being contested in good faith and, in the case of judgment liens, execution thereon is stayed or not giving rise to an Event of Default;

     

    (11)        landlords’ liens on fixtures on
        premises leased in the ordinary course of business;

     

    (12)        Security Interests to secure the
        performance of statutory obligations, insurance, surety or appeal bonds, performance bonds, or other obligations of a like nature incurred in the ordinary course of business (including Security Interests to secure letters of credit issued to assure
        payment of such obligations);

     

    (13)        Security Interests on assets of the
        Parent Guarantor or any of its Subsidiaries securing Indebtedness consisting of Hedging Obligations or Treasury Management Arrangements;

     

    (14)        survey exceptions, easements or
        reservations of, or rights of others for, licenses, rights-of-way, sewers, electric lines, telegraph and telephone lines and other similar purposes, or zoning or other restrictions as to the use of real property that were not incurred in connection
        with Indebtedness and that do not in the aggregate materially impair the use of said properties in the operation of the business of the Parent Guarantor and its Subsidiaries;

     

    (15)        Security Interests in favor of
        customs or revenue authorities arising as a matter of law to secure payment of customs duties in connection with the importation of goods incurred in the ordinary course of business;

     

    (16)        Security Interests on insurance
        policies and proceeds thereof, or other deposits, to secure insurance premium financings;

     

    (17)        filing of Uniform Commercial Code
        financing statements as a precautionary measure in connection with operating leases;

     

    (18)        bankers’ liens and rights of setoff;

     

    (19)        Security Interests in cash, cash
        equivalents or other property arising in connection with the defeasance, discharge or redemption of Indebtedness;

     

    (20)        Security Interests on specific items
        of inventory or other goods (and the proceeds thereof) of the Parent Guarantor or any of its Subsidiaries securing such Person’s obligations in respect of bankers’ acceptances or trade-related letters of credit issued or created in the ordinary
        course of business for the account of such Person to facilitate the purchase, shipment or storage of such inventory or other goods;

     

    
      

      
        

      -63-

      

    

    (21)        grants of intellectual property
        licenses (including software and other technology licenses) in the ordinary course of business;

     

    (22)        Security Interests incurred or
        pledges or deposits made in the ordinary course of business in connection with workers’ compensation, unemployment insurance and other types of social security and employee health and disability benefits (including pledges or deposits securing
        liability to insurance carriers under insurance or self-insurance arrangements);

     

    (23)        deposits made in the ordinary course
        of business to secure liability to insurance carriers;

     

    (24)        Security Interests to secure partial,
        progress, advance or other payments or any Indebtedness incurred for the purpose of financing all or any part of the purchase price or the cost of construction, development, or substantial repair, alteration or improvement of the property subject
        to such Security Interests if the commitment for the financing is obtained not later than 180 days after the later of the completion of or the placing into operation (exclusive of test and start-up periods) of such property;

     

    (25)        options, put and call arrangements,
        rights of first refusal and similar rights relating to investments in joint ventures, partnerships and the like;

     

    (26)        other Security Interests securing
        Indebtedness, in an aggregate principal amount for the Parent Guarantor and its Subsidiaries, together with the amount of Attributable Indebtedness incurred in connection with Sale and Leaseback Transactions, not exceeding at the time such Security
        Interest is created or assumed the greater of (x) $200.0 million and (y) 4.0% of Consolidated Total Assets; or

     

    (27)        Security Interests on cash proceeds
        of Indebtedness (and on the related escrow accounts) in connection with the issuance of such Indebtedness into (and pending the release from) a customary escrow arrangement, to the extent such Indebtedness is otherwise Incurred in compliance with
        this Indenture.

     

    Additionally, such permitted Secured Debt includes (with certain limitations) any extension, renewal or refunding, in whole or in part, of any Secured
      Debt permitted at the time of the original incurrence thereof.

     

    Any Security Interest created for the benefit of the Holders of each series of Notes pursuant to this Section 4.10 shall provide by its terms that such
      Security Interest shall be unconditionally and automatically released and discharged upon the release and discharge of the Initial Security Interest.

     

    
      

      
        

      -64-

      

    

    For purposes of determining compliance with this Section 4.10, a Security Interest securing an item of Secured Debt need not be permitted solely by one
      category of Permitted Security Interest but may be permitted in part under any combination thereof, and if a Permitted Security Interest meets the criteria or more than one of the exceptions described in clauses (1) through (27) of this Section 4.10,
      the Parent Guarantor may, in its sole discretion, classify the Permitted Security Interest in any manner that complies with this Section 4.10, including, for the avoidance of doubt, in the event that any Fixed Baskets are intended to be utilized
      together with any Incurrence-Based Baskets in a single transaction or a series of related transactions, (1) compliance with or satisfaction of any applicable financial ratios or tests for the portion of such Liens or other applicable transaction or
      action to be incurred under any Incurrence-Based Baskets shall first be calculated without giving effect to amounts being utilized pursuant to any Fixed Baskets, but giving full pro forma effect to all applicable and related transactions (including,
      subject to the foregoing with respect to Fixed Baskets, any incurrence and any repayment of Indebtedness and any related Liens) and all other permitted pro forma adjustments and (2) thereafter, incurrence of the portion of such Liens to be incurred
      under any Fixed Baskets shall be calculated.

     

    	SECTION 4.11.	
            Activities Limiting Use of Proceeds Prior to the Merger.

          

     

    Subject to the immediately following sentence, prior to the earlier of (i) the date of the consummation of the Merger and (ii) the Special Mandatory
      Redemption Date (the “Usage Date”), the gross proceeds of each series of Notes shall not be used for any purpose and shall remain in a bank account reasonably acceptable to
      the Initial Purchasers. Notwithstanding the foregoing, prior to the Usage Date, the gross proceeds of each series of Notes may be invested in Eligible Investments and nothing herein shall prevent the Issuer and the Parent Guarantor from using the
      gross proceeds (x) to consummate the Transactions as described in the “Use of Proceeds” section in the Offering Memorandum or (y) to redeem the applicable series of Notes pursuant to a Special Mandatory Redemption.

    

    

    	SECTION 4.12.	
            Limitation on Sale and Leaseback Transactions.

          

     

    The Parent Guarantor will not, and will not permit any of its Subsidiaries to, engage in any Sale and Leaseback Transaction unless:

     

    (1)          the Parent Guarantor or such
        Subsidiary would be entitled to incur Secured Debt pursuant to Section 4.10 equal in amount to the net proceeds of the property sold or transferred or to be sold or to be transferred pursuant to such Sale and Leaseback Transaction and secured by a
        Security Interest on the property to be leased, without equally and ratably securing the debt securities outstanding under this Indenture as provided under Section 4.10; or

     

    
      

      
        

      -65-

      

    

    (2)          the Parent Guarantor or such
        Subsidiary shall apply, within 180 days after the effective date of such sale or transfer, an amount equal to such net proceeds to (i) the acquisition, construction, development or improvement of properties, facilities or equipment that are, or
        upon such acquisition, construction, development or improvement will be, a Principal Facility or Facilities or a part thereof or (ii) the repurchase or redemption of Notes or to the repayment or redemption of Indebtedness of the Parent Guarantor or
        of any of its Subsidiaries, or in part to such acquisition, construction, development or improvement and in part to such redemption and/or repayment. In lieu of applying an amount equal to such net proceeds to such repurchase or redemption, the
        Parent Guarantor or any of its Subsidiaries may, within 180 days after such sale or transfer, deliver to the Trustee or any other applicable trustee or comparable Person, Notes or Indebtedness for cancellation and thereby reduce the amount to be
        applied to the repurchase or redemption of such Notes or Indebtedness by an amount equivalent to the aggregate principal amount of Notes or Indebtedness.

     

    	SECTION 4.13.	
            Reports to Holders.

          

     

    (a)          Whether or not required by the rules and regulations of
        the Commission, so long as any Notes are outstanding hereunder, the Issuer shall furnish to the Trustee and Holders the following:

     

    (1)          all quarterly and annual financial
        information required to be filed by the Parent Guarantor with the Commission on Forms 10-Q and 10-K, and, with respect to the annual information only, a report thereon by the Parent Guarantor’s certified independent accountants; and

     

    (2)          all current reports required to be
        filed by the Parent Guarantor with the Commission on Form 8-K (during any period in which the Parent Guarantor is not required to file reports with the Commission, such current reports need only be prepared or delivered if the Parent Guarantor
        determines in good faith that the information to be reported is material to the Holders of each series of Notes or the business, operations, assets, liabilities or financial position of the Parent Guarantor and its Subsidiaries, taken as a whole),

     

    in each case, within the time periods specified in the Commission’s rules and regulations, including any extension as would be permitted by Rule 12b-25 under the Exchange
      Act (and, during any period in which the Parent Guarantor is not required to file reports with the Commission, within the time periods specified in the Commission’s rules and regulations applicable to a “non-accelerated filer”).

     

    
      

      
        

      -66-

      

    

    (b)          In addition, whether or not required by the rules and
        regulations of the Commission, the Parent Guarantor will make all such information publicly available (including via a non-password protected website) within the time periods specified in the Commission’s rules and regulations, including any
        extension as would be permitted by Rule 12b-25 under the Exchange Act (unless the Commission will not accept such a filing), and make such information available to Holders of each series of Notes upon request. In addition, to the extent not
        satisfied by the foregoing, the Parent Guarantor shall, for so long as any Notes remain outstanding, furnish to the Holders of such series of Notes and to securities analysts and prospective investors, upon their request, the information required
        to be delivered pursuant to Rule 144A(d)(4) under the Securities Act.

     

    (c)          Whether the Parent Guarantor files such reports with the
        Commission or posts its reports on its website, the public filing of such reports with the SEC or the public posting of such reports shall satisfy any requirement hereunder to deliver such reports to the Trustee and the Holders. The terms of this
        Indenture shall not impose any duty on the Parent Guarantor under the Sarbanes-Oxley Act of 2002 and the related Commission rules that would not otherwise be applicable to it.

     

    (d)          Delivery of such reports and information to the Trustee
        shall be for informational purposes only, and the Trustee’s receipt of them shall not constitute constructive notice of any information contained therein or determinable from information contained therein (including the Issuer’s compliance with any
        of its covenants hereunder as to which the Trustee is entitled to rely exclusively on Officer’s Certificates delivered pursuant to this Indenture, including Officer’s Certificates delivered pursuant to Section 4.05(a)).

     

    	SECTION 4.14.	
            Additional Guarantees.

          

     

    If, on or after the Issue Date:

     

    (1)          the Issuer or any of its Subsidiaries
        acquires or creates another Domestic Subsidiary (other than a Receivables Entity) that incurs any Indebtedness under Credit Facilities (other than the ABL Credit Facility) or any syndicated loan or capital markets debt securities or guarantees any
        such Indebtedness of the Parent Guarantor or any of its Domestic Subsidiaries; or

     

    (2)          any Domestic Subsidiary (other than a
        Receivables Entity) of the Issuer incurs Indebtedness under Credit Facilities (other than the ABL Credit Facility) or any syndicated loan or capital markets debt securities or guarantees any such Indebtedness of the Issuer or any of its Domestic
        Subsidiaries and that Domestic Subsidiary was not a Guarantor immediately prior to such incurrence or guarantee (an “Additional Obligor”),

     

    
      

      
        

      -67-

      

    

    
      then that newly acquired or created Domestic Subsidiary or Additional Obligor, as the case may be, shall become a Guarantor and execute a supplemental indenture
        substantially in the form of Exhibit H to this Indenture within 30 Business Days of the date on which it was acquired or created or became an Additional Obligor.

       

      

    

    In addition, the Issuer shall have delivered to the Trustee an Officer’s Certificate and an Opinion of Counsel, each stating that such supplemental
      Indenture complies with the applicable provisions of this Indenture, that all conditions precedent in this Indenture relating to the entry into such supplemental indenture have been satisfied, and such Opinion of Counsel shall additionally state that
      such supplemental indenture is enforceable against the new Guarantor, subject to customary qualifications.

     

    	SECTION 4.15.	
            Termination of Certain Covenants When Notes are Rated Investment Grade.

          

     

    (a)          If on any date following the Issue Date (i) the Notes
        have Investment Grade Ratings from both Rating Agencies, and (ii) no Default has occurred and is continuing under this Indenture (the occurrence of the events described in the foregoing clauses (i) and (ii) being collectively referred to as a “Covenant Termination Event”), the Parent Guarantor and its Subsidiaries will not be subject to Sections 4.08, 4.09, 4.12(2) and 4.14 hereof (collectively, the “Terminated Covenants”).

     

    (b)          In the event that a Covenant Termination Event occurs,
        the Parent Guarantor and its Subsidiaries will no longer be subject to the Terminated Covenants, regardless of whether on any subsequent date one or both Rating Agencies withdraw their Investment Grade Rating or downgrade the rating assigned to the
        Notes below an Investment Grade Rating.

     

    (c)          The Issuer, in an Officer’s Certificate, will provide
        the Trustee notice of any Covenant Termination Event.  The Trustee will have no obligation to (i) independently determine or verify if such events have occurred or (ii) notify the Holders of a Covenant Termination Event.  The Trustee may deliver a
        copy of any such Officer’s Certificate to the Holders upon request.

     

    ARTICLE FIVE

     

    SUCCESSOR OBLIGOR

     

    	SECTION 5.01.	
            Merger, Consolidation or Sale of Assets.

          

     

    The Parent Guarantor will not (i) consolidate or merge with or into any other Person or Transfer all or substantially all of the properties or assets of
      the Parent Guarantor and its Subsidiaries, taken as a whole or (ii) permit any of its Subsidiaries to, in a single transaction or a series of related transactions, Transfer all or substantially all of the properties or assets of the Parent Guarantor
      and its Subsidiaries, taken as a whole, in each case, to, another Person unless:

     

    
      

      
        

      -68-

      

    

    (1)          the Parent Guarantor is the
        continuing Person, or the successor or Person to whom all or substantially all of the properties or assets are transferred to is a corporation, limited liability company, partnership or trust organized and existing under the laws of the United
        States or a state thereof;

     

    (2)           the successor Person or Person to
        whom all or substantially all of the properties or assets are transferred to expressly assumes, by a supplemental indenture or amendment of the relevant documents, the Parent Guarantor’s obligations under each series of Notes and this Indenture;
        and

     

    (3)          after giving effect to the
        transaction, no Event of Default, and no event which, after notice or lapse of time or both, would become an Event of Default, shall have occurred or be continuing.

     

    A Guarantor (other than the Parent Guarantor) may not sell or otherwise dispose of all or substantially all of its assets to, or consolidate with or
      merge with or into, another Person, other than the Parent Guarantor, the Issuer or another Guarantor, unless:

     

    	

          	(1)	
            the successor or Person to whom all or substantially all of the properties or assets are transferred to is a corporation, limited liability company, partnership or trust organized
              and existing under the laws of the United States or a state thereof;

          

     

    	

          	(2)	
            the successor Person or Person to whom all or substantially all of the properties or assets are transferred to expressly assumes, by a supplemental indenture or amendment of the
              relevant documents, the Guarantor’s obligations under each series of Notes and this Indenture; and

          

     

    	

          	(3)	
            after giving effect to the transaction, no Event of Default, and no event which, after notice or lapse of time or both, would become an Event of Default, shall have occurred or be
              continuing.

          

     

    The Issuer shall deliver, or cause to be delivered, to the Trustee an Officer’s Certificate and an Opinion of Counsel, each to the effect that such
      consolidation, merger, sale, conveyance, assignment, transfer, lease or other disposition complies with the requirements of this Indenture.

     

    
      

      
        

      -69-

      

    

    This Section 5.01 will not apply to any Transfer of assets between or among the Parent Guarantor and any one or more of its Subsidiaries or between or
      among any one or more of the Parent Guarantor’s Subsidiaries. Clause (2) of the first paragraph of this Section 5.01 will not apply to: (1) any merger or consolidation of the Parent Guarantor with or into one of its Subsidiaries for any purpose or
      (2) any merger or consolidation of the Parent Guarantor or any of its Subsidiaries solely for the purpose of reincorporating the Parent Guarantor or such Subsidiary in another jurisdiction.

     

    	SECTION 5.02.	
            Successor Person Substituted.

          

     

    Upon any consolidation, combination or merger of the Parent Guarantor, or any Transfer of all or substantially all of the assets of the Parent Guarantor
      and its Subsidiaries, taken as a whole, in accordance with the foregoing provisions of Section 5.01, in which the Issuer is not the continuing obligor under each series of Notes, the surviving entity formed by such consolidation or into which the
      Parent Guarantor is merged or to which such Transfer of all or substantially all of the assets of the Parent Guarantor and its Subsidiaries, taken as a whole, is made, will succeed to, and be substituted for, and may exercise every right and power of
      the Issuer under this Indenture and each series of Notes with the same effect as if such surviving entity had been named therein as the Issuer and, the Issuer and all of the Guarantors will be released from the obligation to pay the principal of and
      interest on such series of Notes or in respect of its related Guarantee, as the case may be, and all of the Issuer’s or such Guarantor’s other obligations and covenants under such Notes, this Indenture and its related Guarantee, if applicable.

     

    ARTICLE SIX

     

    DEFAULTS AND REMEDIES

     

    	SECTION 6.01.	
            Events of Default.

          

     

    Each of the following constitutes an “Event of Default” with respect to the
      Notes:

     

    (1)          default for 30 consecutive days in
        the payment when due of interest with respect to the Notes;

     

    (2)          default in payment when due of
        principal or premium, if any, on the applicable series of Notes at maturity, upon redemption or otherwise;

     

    (3)          failure by the Issuer for 60
        consecutive days after receipt of notice from the Trustee or Holders of at least 25% in aggregate principal amount of the applicable series of Notes then outstanding under this Indenture (with a copy to the Trustee) to comply with the provisions
        under Section 4.07;

     

    
      

      
        

      -70-

      

    

    (4)          failure by the Parent Guarantor or
        any Subsidiary of the Parent Guarantor for 60 consecutive days (120 days with respect to Section 4.13) after receipt of notice from the Trustee or the Holders of at least 25% in aggregate principal amount of the applicable series of Notes then
        outstanding under this Indenture (with a copy to the Trustee) to comply with any covenant or agreement contained in this Indenture (other than the covenants and agreements specified in clauses (1) through (3) of this Section 6.01);

     

    (5)          default under any mortgage, indenture
        or instrument under which there may be issued or by which there may be secured or evidenced any Indebtedness of the Parent Guarantor or any of its Subsidiaries (other than Indebtedness owed to the Parent Guarantor or any of its Subsidiaries),
        whether such Indebtedness now exists or is created after the Issue Date, which default (a) is caused by a failure to pay when due at final stated maturity (giving effect to any grace period related thereto) principal of such Indebtedness (a “Payment Default”) or (b) results in the acceleration of such Indebtedness prior to its stated maturity, and, in each case, the principal amount of any such Indebtedness,
        together with the principal amount of any such Indebtedness under which there has been a Payment Default or the maturity of which has been so accelerated, aggregates $100.0 million or more; and, in each case, the Issuer has received notice
        specifying the default from the Trustee or Holders of at least 25% in aggregate principal amount of the applicable series of Notes then outstanding (with a copy to the Trustee) and does not cure the default within 30 days; provided, however, that this clause (5) shall not apply to any default with respect to
        Indebtedness that is (A) remedied by the Parent Guarantor of any of its Subsidiaries prior to the acceleration of Notes, including by the discharge of such Indebtedness or (B) waived (including in the form of amendment or consent) by the required
        holders of the applicable item of Indebtedness prior to the acceleration of Notes, in each case, if the Issuer delivers an Officer’s Certificate to the Trustee certifying to the matters in clause (A) or this clause (B), as applicable;

     

    (6)          failure by the Parent Guarantor or
        any of its Subsidiaries to pay final and non-appealable judgments (net of any amounts covered by insurance and as to which such insurer has not denied responsibility or coverage in writing) aggregating $100.0 million or more, which judgments are
        not paid, discharged, bonded, stayed or waived within 60 days after such judgment becomes final, and in the event such judgment is covered in full by insurance, an enforcement proceeding has been commenced by any creditor upon such judgment or
        decree which is not promptly stayed;

     

      

    
      
        

      -71-

      

    

    
    
       (7)          (A) a court having jurisdiction over the Issuer, the Parent Guarantor or any Subsidiary enters (x) a decree or
        order for relief in respect of the Issuer, the Parent Guarantor or any Subsidiary that is a Significant Subsidiary or group of Subsidiaries of the Parent Guarantor that, taken together, would constitute a Significant Subsidiary in an involuntary
        case or proceeding under any Bankruptcy Law or (y) a decree or order adjudging the Issuer, the Parent Guarantor or any Subsidiary that is a Significant Subsidiary or group of Subsidiaries of the Parent Guarantor that, taken together, would
        constitute a Significant Subsidiary as bankrupt or insolvent, or approving as properly filed a petition seeking reorganization, arrangement, adjustment or composition of or in respect of the Issuer, the Parent Guarantor or any Subsidiary or group
        of Subsidiaries under any Bankruptcy Law, or appointing a custodian, receiver, liquidator, assignee, trustee, sequestrator or other similar official of the Issuer, the Parent Guarantor or any such Subsidiary or group of Subsidiaries or of any
        substantial part of its property, or ordering the winding up or liquidation of its affairs, and the continuance of any such decree or order for relief or any such other decree or order unstayed and in effect for a period of 60 consecutive days or
        (B) the Issuer, the Parent Guarantor or any Subsidiary that is a Significant Subsidiary or group of Subsidiaries of the Parent Guarantor that, taken together, would constitute a Significant Subsidiary (i) commences a voluntary case under any
        Bankruptcy Law or consents to the entry of an order for relief in an involuntary case under any Bankruptcy Law, (ii) consents to the appointment of or taking possession by a receiver, liquidator, assignee, custodian, trustee, sequestrator or
        similar official of the Issuer, the Parent Guarantor or any such Subsidiary or group of Subsidiaries or for all or substantially all the property and assets of the Issuer, the Parent Guarantor or any such Subsidiary or group of Subsidiaries, (iii)
        effects any general assignment for the benefit of creditors or (iv) generally is not paying its debts as they become due; and 

      

      

      (8)          any Guarantee of any Guarantor that is a Significant Subsidiary ceases to be in full force and effect in all material respects (other than in accordance with the terms of such Guarantee
        and this Indenture) or is declared null and void and unenforceable or found to be invalid or any Guarantor denies its liability under its Guarantee (other than by reason of release of a Guarantor from its Guarantee in accordance with the terms of
        this Indenture and such Guarantee).

      

      

      	SECTION 6.02.	
              Acceleration of Maturity; Rescission.

            

      

      

      If any Event of Default under this Indenture occurs and is continuing, either the Trustee or the Holders of at least 25% in aggregate principal amount of the applicable series of Notes then outstanding, may declare all
        such series of Notes to be due and payable by notice in writing to the Issuer and the Trustee, in the case of notice by Holders, specifying the respective Event of Default and that it is a “notice of acceleration” and the same will become
        immediately due and payable; provided, however, that, notwithstanding the foregoing, if an Event of Default specified in Section 6.01(7) occurs with respect to the
        Issuer or the Parent Guarantor, all outstanding Notes shall become due and payable without further action or notice.

       

      

      
        
          

        -72-

      

      
      Notwithstanding the foregoing, if after such acceleration but before a judgment or decree based on such acceleration is obtained by the Trustee, the Holders of a majority in aggregate principal amount of the applicable
        series of outstanding Notes may rescind and annul such acceleration if:

      

      

      (1)          all Events of Default, other than nonpayment of principal, premium, if any, or interest that has become due solely because of the acceleration, have been cured or waived;

      

      

      (2)          to the extent the payment of such interest is lawful, interest on overdue installments of interest and overdue principal, which has become due otherwise than by such declaration of
        acceleration, has been paid;

      

      

      (3)           the Issuer has paid the Trustee its reasonable compensation and reimbursed the Trustee for its expenses, disbursements, indemnities and advances; and

      

      

      (4)          in the event of the cure or waiver of an Event of Default of the type described in Section 6.01(7), the Trustee shall have received an Officer’s Certificate and an Opinion of Counsel
        that such Event of Default has been cured or waived.

      

      

      No such rescission shall affect any subsequent Default or impair any right consequent thereto.

      

      

      	SECTION 6.03.	
              Other Remedies.

            

      

      

      If an Event of Default occurs and is continuing, the Trustee may pursue any available remedy by proceeding at law or in equity to collect the payment of principal of, or premium, if any, and interest on the applicable
        series of Notes or to enforce the performance of any provision of the Notes or this Indenture and may take any necessary action requested by the Holders of a majority of the principal amount outstanding of the applicable series of Notes to settle,
        compromise, adjust or otherwise conclude any proceedings to which it is a party.

      

      

      The Trustee may maintain a proceeding even if it does not possess any of the Notes or does not produce any of them in the proceeding.  A delay or omission by the Trustee or any Noteholder in exercising any right or
        remedy accruing upon an Event of Default shall not impair the right or remedy or constitute a waiver of or acquiescence in the Event of Default.  No remedy is exclusive of any other remedy.  All available remedies are cumulative.  Any costs
        associated with actions taken by the Trustee under this Section 6.03 shall be reimbursed to the Trustee by the Issuer and the Guarantors.

       

      

      
        
          

        -73-

      

      	SECTION 6.04.	
              Waiver of Existing Defaults and Events of Default.

            

      

      

      (a)          Subject to Sections 2.10, 6.02, 6.08 and 8.02, the Holders of a majority in principal amount of each series of Notes then outstanding shall have the right to waive past Defaults and Events of Default under
        this Indenture except a continuing Default or Event of Default in the payment of the principal of, or interest or premium, if any, on any Note as specified in clauses (1) and (2) of Section 6.01 or in
        respect of a covenant or a provision which cannot be modified or amended without the consent of all Holders as provided for in Section 8.02, which shall require the consent of all of the Holders of the applicable series of Notes then Outstanding. 
        The Issuer shall deliver to the Trustee an Officer’s Certificate stating that the requisite percentage of Holders have consented to such waiver and attaching copies of such consents.  In case of any such waiver, the Issuer, the Trustee and the
        Holders shall be restored to their former positions and rights hereunder and under the Notes, respectively.

      

      

      (b)          Upon any such waiver, such Default or Event of Default, as applicable, shall cease to exist, and, with respect to any waived Default, any Event of Default arising therefrom shall be deemed to have been
        cured for every purpose of this Indenture, but no such waiver shall extend to any subsequent or other Default or Event of Default or impair any right consequent thereto.

      

      

      	SECTION 6.05.	
              Control by Majority.

            

      

      

      Subject to Sections 2.10 and 7.01, the Holders of a majority in aggregate principal amount of the applicable series of outstanding Notes have the right to direct the time, method and place of conducting any proceeding
        for exercising any remedy available to the Trustee or exercising any trust or power conferred on the Trustee by this Indenture.  The Trustee, however, may refuse to follow any direction that conflicts with law or this Indenture or that the Trustee
        determines may be unduly prejudicial to the rights of another Holder not taking part in such direction, and the Trustee shall have the right to decline to follow any such direction (it being understood that the Trustee does not have an affirmative
        duty to ascertain whether or not any such directions are unduly prejudicial to such Holders) if the Trustee, being advised by counsel, determines that the action so directed may not lawfully be taken or if the Trustee in good faith shall, by a
        Responsible Officer, determine that the proceedings so directed may involve it in personal liability; provided that the Trustee may take any other action deemed proper by the Trustee which is not
        inconsistent with such direction.  In the event the Trustee takes any action or follows any direction pursuant to this Indenture, the Trustee shall be entitled to indemnification reasonably satisfactory to it against any cost, liability or expense
        that might be caused by taking such action or following such direction.

      

      

      	SECTION 6.06.	
              Limitation on Suits.

            

      

      

      A Holder may not pursue any remedy with respect to this Indenture or the Notes unless:

       

      

      
        
          

        -74-

      

      (1)          the Holder has given the Trustee written notice of a continuing Event of Default;

      

      

      (2)          the Holders of at least 25% in principal amount of applicable series of Notes then outstanding make a written request to the Trustee to pursue the remedy;

      

      

      (3)          such Holder or Holders offer the Trustee security or indemnity satisfactory to the Trustee against any costs, liability or expense;

      

      

      (4)          the Trustee does not comply with the request within 60 days after receipt of the request and the offer of security or indemnity against any cost, liability or expense that might be
        caused by complying with such request; and

      

      

      (5)          during such 60-day period, the Holders of a majority in aggregate principal amount of the applicable series of outstanding Notes do not give the Trustee a direction that is inconsistent
        with the request.

      

      

      A Noteholder may not use any provision of this Indenture to disturb or prejudice the rights of another Noteholder or to obtain a preference or priority over another Noteholder.

      

      

      	SECTION 6.07.	
              No Personal Liability of Directors, Officers, Employees and Stockholders.

            

      

      

      No director, officer, employee, incorporator or stockholder of the Parent Guarantor or of any Subsidiary of the Parent Guarantor, as such, shall have any liability for any obligations of the Issuer or the Guarantors
        under each series of Notes, this Indenture, the Guarantees or for any claim based on, in respect of, or by reason of, such obligations or their creation. Each Holder of each series of Notes by accepting a Note waives and releases all such
        liability. The waiver may not be effective to waive liabilities under the federal securities laws.

      

      

      	SECTION 6.08.	
              Rights of Holders To Receive Payment.

            

      

      

      Notwithstanding any other provision of this Indenture, the right of any Holder of a Note to receive payment of the principal of or premium, if any, or interest, if any, on such Note on or after the respective due dates
        expressed in such Note, or to bring suit for the enforcement of any such payment, on or after such respective due dates, is absolute and unconditional and shall not be impaired or affected without the consent of the Holder.

      

      

      	SECTION 6.09.	
              Collection Suit by Trustee.

            

      

      

      If an Event of Default occurs and is continuing, the Trustee may recover judgment in its own name and as trustee of an express trust against the Issuer or any Guarantor (or any other obligor on the Notes) for the whole
        amount of unpaid principal and accrued interest remaining unpaid, together with interest on overdue principal and, to the extent that payment of such interest is lawful, interest on overdue installments of interest, in each case at the rate set
        forth in each series of Notes, and such further amounts as shall be sufficient to cover the costs and expenses of collection, including the reasonable compensation, expenses, disbursements and advances of the Trustee, its agents and counsel.

       

      

      
        
          

        -75-

      

      	SECTION 6.10.	
              Trustee May File Proofs of Claim.

            

      

      

      The Trustee may file such proofs of claim and other papers or documents as may be necessary or advisable in order to have the claims of the Trustee (including any claim for the reasonable compensation, expenses,
        disbursements and advances of the Trustee, its agents and counsel, and any other amounts due the Trustee under Section 7.07) and the Noteholders allowed in any judicial proceedings relative to the Issuer or any Guarantor (or any other obligor upon
        the Notes), its creditors or its property and shall be entitled and empowered to collect and receive any monies or other property payable or deliverable on any such claims and to distribute the same after deduction of its charges and expenses to
        the extent that any such charges and expenses are not paid out of the estate in any such proceedings and any custodian in any such judicial proceeding is hereby authorized by each Noteholder to make such payments to the Trustee, and in the event
        that the Trustee shall consent to the making of such payments directly to the Noteholders, to pay to the Trustee any amount due to it for the reasonable compensation, expenses, disbursements and advances of the Trustee, its agents and counsel, and
        any other amounts due the Trustee under Section 7.07.

      

      

      Nothing herein contained shall be deemed to authorize the Trustee to authorize or consent to or accept or adopt on behalf of any Noteholder any plan or reorganization, arrangement, adjustment or composition affecting
        the Notes or the rights of any Noteholder thereof, or to authorize the Trustee to vote in respect of the claim of any Noteholder in any such proceedings.

      

      

      	SECTION 6.11.	
              Priorities.

            

      

      

      If the Trustee collects any money or property pursuant to this Article Six, and after an Event of Default any money or other property distributable in respect of the Company’s or Guarantors’ obligations under this
        Indenture, such money or property shall  be paid out or distributed in the following order:

      

      

      FIRST:  to the Trustee and any predecessor Trustee for amounts due under Section 7.07;

      

      

      SECOND:  to Noteholders for amounts due and unpaid on each series of Notes for principal, premium, if any, and interest, ratably, without preference or priority of any kind, according to the amounts
        due and payable on the Notes; and

       

      

      
        
          

        -76-

      

      THIRD:  to the Issuer or, to the extent the Trustee collects any amount from any Guarantor, to such Guarantor.

      

      

      The Trustee may fix a record date and payment date for any payment to Noteholders pursuant to this Section 6.11.

      

      

      	SECTION 6.12.	
              Undertaking for Costs.

            

      

      

      In any suit for the enforcement of any right or remedy under this Indenture or in any suit against the Trustee for any action taken or omitted by it as Trustee, a court in its discretion may require the filing by any
        party litigant in the suit of an undertaking to pay the costs of the suit, and the court in its discretion may assess reasonable costs, including reasonable attorneys’ fees and expenses, against any party litigant in the suit, having due regard to
        the merits and good faith of the claims or defenses made by the party litigant.  This Section 6.12 does not apply to a suit by the Trustee, a suit by a Noteholder pursuant to Section 6.08 or a suit by Noteholders of more than 10% in principal
        amount of the applicable series of Notes then outstanding.

      

      

      ARTICLE SEVEN

      

      

      TRUSTEE

      

      

      	SECTION 7.01.	
              Duties of Trustee.

            

      

      

      (a)          If a Default or Event of Default actually known to a Responsible Officer of the Trustee has occurred and is continuing, the Trustee shall exercise such of the rights and powers vested in it by this
        Indenture and use the same degree of care and skill in their exercise as a prudent person under the circumstances would exercise or use under the same circumstances in the conduct of his or her own affairs.

      

      

      Except for an Event of Default pursuant to Section 6.01(1) or 6.01(2) (upon the occurrence of which the Trustee if then acting as Paying Agent will be deemed to have knowledge thereof), the
        Trustee shall not be deemed to have notice or be charged with knowledge of any Default or Event of Default unless a Responsible Officer of the Trustee has received written notice of any event which is in fact such a Default or Event of Default by
        the Issuer or by the Holders of at least 25% of the aggregate principal amount of the applicable series of Notes by written notice of such event sent to the Trustee in accordance with Section 11.01 at the Corporate Trust Office of the Trustee, and
        such notice references the Notes and this Indenture.

        

      

      
        
          

        -77-

      

      (b)          Except during the continuance of a Default or Event of Default of which a Responsible Officer of the Trustee has actual knowledge:

      

      

      (1)          The Trustee need perform only those duties that are specifically set forth in this Indenture and no others, and no implied covenants or obligations shall be read into this Indenture
        against the Trustee.

      

      

      (2)          In the absence of bad faith on its part, the Trustee may conclusively rely, as to the truth of the statements and the correctness of the opinions expressed therein, upon certificates or
        opinions furnished to the Trustee and conforming to the requirements of this Indenture but, in the case of any such certificates or opinions which by any provision hereof are specifically required to be furnished to the Trustee, the Trustee shall
        be under a duty to examine the same to determine whether or not they conform on their face to the requirements of this Indenture (but need not confirm or investigate the accuracy of mathematical calculations or other facts stated therein). 
        Whenever in the administration of this Indenture the Trustee shall deem it desirable that a matter be proved or established prior to taking, suffering or omitting any action hereunder, the Trustee (unless other evidence be herein specifically
        prescribed) may require and, in the absence of bad faith on its part, conclusively rely upon an Officer’s Certificate, subject to the requirement in the preceding sentence, if applicable.

      

      

      (c)          The Trustee may not be relieved from liability for its own negligent action, its own negligent failure to act, or its own willful misconduct, except that:

      

      

      (1)          This paragraph does not limit the effect of clause (b) of this Section 7.01.

      

      

      (2)          The Trustee shall not be liable for any error of judgment made in good faith by a Responsible Officer, unless it is proved that the Trustee was negligent in ascertaining the pertinent
        facts.

      

      

      (3)          The Trustee shall not be liable with respect to any action it takes or omits to take in good faith in accordance with a direction received by it from a majority in aggregate principal
        amount of the applicable series of Notes outstanding pursuant to the terms of this Indenture.

      

      

      (d)          Whether or not therein expressly so provided, clauses (a), (b), (c) and (e) of this Section 7.01 shall govern every provision of this Indenture that in any way relates to the Trustee.

       

      

      
        
          

        -78-

      

      The Trustee shall be under no obligation to exercise any of the rights or powers vested in it by this Indenture at the request or direction of any of the Holders pursuant to this Indenture, unless such Holders shall
        have offered to the Trustee security or indemnity satisfactory to the Trustee against the costs, expenses and liabilities which might be incurred by it in compliance with such request or direction (including, but in no way limited to, the fees and
        disbursements of agents and attorneys).  The Trustee’s fees, expenses and indemnities (including, but in no way limited to, the fees and disbursements of agents and attorneys) are included in the amounts guaranteed by the Guarantees.

      

      

      (e)          The Trustee shall not be liable for interest on any money received by it except as the Trustee may agree in writing with the Issuer or any Guarantor.  Money held in trust by the Trustee need not be
        segregated from other funds except to the extent required by the law.  The Trustee shall not be accountable for any diminution in the value of any investments deposited with the Trustee, or any losses incurred upon any authorized disposition
        thereof.

      

      

      (f)           No provision of this Indenture shall require the Trustee to expend or risk its own funds or otherwise incur any financial liability in the performance of any of its rights, powers or duties. The Trustee
        shall not be required to give any bond or surety in respect of the performance of its powers or duties hereunder.

      

      

      	SECTION 7.02.	
              Rights of Trustee.

            

      

      

      Subject to Section 7.01:

      

      

      (1)          The Trustee may conclusively rely on any document (whether in its original or facsimile form) reasonably believed by it to be genuine and to have been signed or presented by the proper
        person.  The Trustee need not investigate any fact or matter stated in the document.

      

      

      (2)          Before the Trustee acts or refrains from acting, it may require and shall be entitled to receive an Officer’s Certificate or an Opinion of Counsel, or both, which shall conform to the
        provisions of Section 11.04.  The Trustee shall be protected and shall not be liable for any action it takes or omits to take in good faith in reliance on such certificate or opinion.

      

      

      (3)          The Trustee may act through its attorneys and agents and shall not be responsible for the misconduct or negligence of any attorney or agent appointed by it with due care.

      

      

      (4)          The Trustee shall not be liable for any action it takes or omits to take in good faith which it reasonably believes to be authorized or within its rights or powers; provided that the Trustee’s conduct does not constitute negligence or willful misconduct.

       

      

      
        
          

        -79-

      

      (5)          The Trustee may consult with counsel of its selection, and the advice or opinion of such counsel as to matters of law shall be full and complete authorization and protection from
        liability in respect of any action taken, omitted or suffered by it hereunder in good faith and in reliance on the advice or opinion of such counsel.

      

      

      (6)          The rights, privileges, protections, immunities and benefits given to the Trustee, including, without limitation, its right to be compensated, reimbursed and indemnified, are extended
        to, and shall be enforceable by, the Trustee in each of its capacities hereunder (including but not limited to as Registrar, Paying Agent and Depositary Custodian), and each agent, custodian and other person employed to act hereunder.

      

      

      (7)          The right of the Trustee to perform any discretionary act enumerated in this Indenture shall not be construed as a duty, and the Trustee shall not be answerable for other than its own
        negligence or willful misconduct in the performance of such act.

      

      

      (8)          The Trustee may from time to time request that the Issuer deliver an Officer’s Certificate setting forth the names of individuals and/or titles of officers authorized at such time to
        take specified actions pursuant to this Indenture, which Officer’s Certificate may be signed by any persons authorized to sign an Officer’s Certificate, including any person specified as so authorized in any such certificate previously delivered
        and not superseded.

      

      

      (9)          In no event shall the Trustee be responsible or liable for special, indirect, punitive or consequential loss or damage of any kind whatsoever (including, but not limited to, loss of
        profit) irrespective of whether the Trustee has been advised of the likelihood of such loss or damage and regardless of the form of action.

      

      

      (10)        The Trustee will not be bound to make any investigation into the facts or matters stated in any resolution, certificate, statement, instrument, opinion, report, notice, request,
        direction, consent, order, bond, debenture, note, other evidence of indebtedness, or other paper or document, or inquire as to the performance by the Issuer or the Guarantors of any of their covenants in this Indenture.

      

      

      	SECTION 7.03.	
              Individual Rights of Trustee.

            

      

      

      The Trustee in its individual or any other capacity may become the owner or pledgee of Notes and may make loans to, accept deposits from, perform services for or otherwise deal with either the Issuer or any Guarantor,
        or any Affiliates thereof, with the same rights it would have if it were not Trustee. Any Agent may do the same with like rights.  The Trustee shall also be subject to Sections 7.10 and 7.11.

       

      

      
        
          

        -80-

      

      	SECTION 7.04.	
              Trustee’s Disclaimer.

            

      

      

      The Trustee shall not be responsible for and makes no representation as to the validity or adequacy of this Indenture or the Notes or any Guarantee, it shall not be accountable for the Issuer’s or any Guarantor’s use
        of the proceeds from the sale of Notes, it will not be responsible for the use or application of any money received by any Paying Agent (other than itself as Paying Agent) or any money paid to the Issuer or any Guarantor pursuant to the terms of
        this Indenture and it shall not be responsible for any statement in the Notes, the Guarantees or this Indenture other than its certificate of authentication.  The Trustee shall not be responsible for any statement in the Offering Memorandum or any
        other document utilized by the Issuer in connection with the sale of the Notes, shall not be responsible for compliance with securities laws in connection with the issuance and sale of the Notes, and shall not be responsible for any rating on the
        Notes or any action or omission of any Rating Agency.

      

      

      	SECTION 7.05.	
              Notice of Defaults.

            

      

      

      If a Default or Event of Default occurs and is continuing (which shall not be cured or waived) and if it is known to the Trustee (pursuant to Section 7.01(a) hereof), the Trustee shall give to each Noteholder a notice
        of the Default or Event of Default within 90 days after it occurs in the manner as provided in this Indenture.  Except in the case of a Default or Event of Default relating to the payment of the principal of or interest on any Note (including
        payments pursuant to a redemption or repurchase of the Notes pursuant to the provisions of this Indenture), the Trustee may withhold the notice if and so long as the board of directors, the executive committee or a trust committee of directors or
        Responsible Officers of the Trustee in good faith determines that withholding the notice is in the interests of Holders.

      

      

      	SECTION 7.06.	
              [reserved].

            

      

      

      	SECTION 7.07.	
              Compensation and Indemnity.

            

      

      

      The Issuer and the Guarantors shall pay to the Trustee from time to time compensation as agreed upon for its services hereunder (which compensation shall not be limited by any provision of law in regard to the
        compensation of a trustee of an express trust).  The Issuer and the Guarantors shall reimburse the Trustee upon request for all reasonable disbursements, expenses and advances incurred or made by it in connection with the Trustee’s duties under
        this Indenture, including the reasonable compensation, disbursements and expenses of the Trustee’s agents and external counsel.

       

      

      
        
          

        -81-

      

      The Issuer and the Guarantors, jointly and severally, shall indemnify each of the Trustee and its agents, employees, stockholders, directors and officers and any predecessor Trustee for, and hold each of them harmless
        against, any and all loss, damage, claim, liability or expense, including without limitation taxes (other than taxes based on the income of the Trustee) and reasonable attorneys’ fees and expenses (collectively, “Losses”) incurred by each of
        them in connection with the acceptance or administration of this Indenture or the performance of its duties under this Indenture or the exercise of its rights and powers under the Notes and the Guarantees, including the costs and expenses of
        enforcing this Indenture (including this Section 7.07), the Notes and the Guarantees or otherwise arising under this Indenture and including the reasonable costs and expenses of defending itself against any claim (whether asserted by any Holder,
        the Issuer, any Guarantor or otherwise) or liability in connection with the exercise or performance of any of its rights, powers or duties hereunder (including, without limitation, settlement costs).  The Trustee shall notify the Issuer and the
        Guarantors in writing promptly of any third party claim of which a Responsible Officer of the Trustee has actual knowledge asserted against the Trustee for which it may seek indemnity (each, a “Third Party Claim”); provided that the failure by the Trustee to so notify the Issuer and the Guarantors shall not relieve the Issuer and Guarantors of their obligations hereunder except to the extent the Issuer and the Guarantors are actually
        prejudiced thereby.  Neither the Issuer nor any Guarantor need pay for any settlement or provide any indemnification for any other Losses associated therewith to the extent such settlement is made in connection with any Third Party Claim without
        its consent, which consent may be withheld in its sole discretion.  The Trustee shall have the right to its own counsel and the Issuer shall pay the reasonable fees and expenses of such counsel in connection with any Third Party Claim to the extent
        the Trustee reasonably determines that a conflict of interest exists or is required in connection with the performance of its duties under this Indenture.

      

      

      Notwithstanding the foregoing, the Issuer and the Guarantors need not reimburse the Trustee for any expense or indemnify it against any loss or liability to have been incurred by the Trustee through its own negligence,
        bad faith or willful misconduct.

      

      

      To secure the payment obligations of the Issuer and the Guarantors in this Section 7.07, the Trustee shall have a lien prior to each series of Notes on all money or property held or collected by the Trustee except for
        such money or property held in trust to pay principal of and interest on particular Notes.  Such lien shall survive the satisfaction and discharge of this Indenture.

      

      

      The obligations of the Issuer and the Guarantors under this Section 7.07 to compensate and indemnify the Trustee and each predecessor Trustee and to pay or reimburse the Trustee and each predecessor Trustee for
        expenses, disbursements and advances shall be joint and several liabilities of the Issuer and each of the Guarantors and shall survive the resignation or removal of the Trustee and the satisfaction, discharge or other termination of this Indenture,
        including any termination or rejection hereof under any Bankruptcy Law.

      

      

      When the Trustee incurs expenses or renders services after an Event of Default specified in Section 6.01(7) occurs, the expenses and the compensation for the services are intended to constitute expenses of
        administration under any applicable Bankruptcy Law.

       

      

      
        
          

        -82-

      

      For purposes of this Section 7.07, the term “Trustee” shall include any trustee appointed pursuant to this Article Seven, provided, however, that the negligence, willful
        misconduct or bad faith of any Trustee hereunder shall not affect the rights of any other Trustee hereunder.  The provisions of this Section 7.07 shall apply to Trustee in its capacity as Paying Agent, Registrar and any other Agent under this
        Indenture.

      

      

      	SECTION 7.08.	
              Replacement of Trustee.

            

      

      

      The Trustee may resign at any time by so notifying the Issuer and the Guarantors in writing.  The Holders of a majority in principal amount of each series of outstanding Notes may remove the Trustee by notifying the
        Issuer and the removed Trustee in writing and may appoint a successor Trustee with the Issuer’s written consent, which consent shall not be unreasonably withheld.  The Issuer may remove the Trustee at its election if:

      

      

      (1)          the Trustee fails to comply with Section 7.10;

      

      

      (2)          the Trustee is adjudged a bankrupt or an insolvent or an order for relief is entered with respect to the Trustee under any Bankruptcy Law;

      

      

      (3)          a receiver or other public officer takes charge of the Trustee or its property; or

      

      

      (4)          the Trustee otherwise becomes incapable of acting.

      

      

      If the Trustee resigns or is removed or if a vacancy exists in the office of Trustee for any reason, the Issuer shall promptly appoint a successor Trustee.

      

      

      If a successor Trustee does not take office within 60 days after the retiring Trustee resigns or is removed, the retiring Trustee, the Issuer or the Holders of a majority in principal amount of each series of
        outstanding Notes may petition at the expense of the Issuer any court of competent jurisdiction for the appointment of a successor Trustee.

      

      

      If the Trustee fails to comply with Section 7.10, Noteholders holding at least 10% in principal amount of the Notes may petition any court of competent jurisdiction for the removal of the Trustee and the appointment of
        a successor Trustee.

      

      

      A successor Trustee shall deliver a written acceptance of its appointment to the retiring Trustee and to the Issuer.  Immediately following such delivery, the retiring Trustee shall, subject to its rights under Section
        7.07, transfer all property held by it as Trustee to the successor Trustee, the resignation or removal of the retiring Trustee shall become effective, and the successor Trustee shall have all the rights, powers and duties of the Trustee under this
        Indenture.  A successor Trustee shall mail notice of its succession to each Noteholder.  Notwithstanding replacement of the Trustee pursuant to this Section 7.08, the Issuer’s obligations under Section 7.07 shall continue for the benefit of the
        retiring Trustee.

       

      

      
        
          

        -83-

      

      	SECTION 7.09.	
              Successor Trustee by Consolidation, Merger, etc.

            

      

      

      If the Trustee consolidates with, merges or converts into, or transfers all or substantially all of its corporate trust assets to, another corporation, subject to Section 7.10, the successor corporation without any
        further act shall be the successor Trustee; provided that such entity shall be otherwise qualified and eligible under this Article Seven.

      

      

      	SECTION 7.10.	
              Eligibility; Disqualification.

            

      

      

      There will at all times be a Trustee hereunder that is a corporation organized and doing business under the laws of the United States of America or of any state thereof that is authorized under such laws to exercise
        corporate trustee power, that is subject to supervision or examination by federal or state authorities and that has a combined capital and surplus of at least $100.0 million as set forth in its most recent published annual report of condition.

      

      

      	SECTION 7.11.	
              Paying Agents.

            

      

      

      The Issuer shall cause each Paying Agent other than the Trustee to execute and deliver to it and the Trustee an instrument in which such Paying Agent shall agree with the Trustee, subject to the provisions of this
        Section 7.11:

      

      

      (A)         that it will hold all sums held by it as agent for the payment of principal of, or premium, if any, or interest on, the Notes (whether such sums have been paid to it by the Issuer or by
        any obligor on the Notes) in trust for the benefit of Holders of the Notes or the Trustee;

      

      

      (B)          that it will at any time during the continuance of any Event of Default, upon written request from the Trustee, deliver to the Trustee all sums so held in trust by it together with a
        full accounting thereof; and

      

      

      (C)          that it will give the Trustee written notice within three Business Days of any failure of the Issuer (or by any obligor on the Notes) in the payment of any installment of the principal
        of, premium, if any, or interest on, the Notes when the same shall be due and payable.

       

      

      
        
          

        -84-

      

      ARTICLE EIGHT

      

      

      AMENDMENT, SUPPLEMENT AND WAIVER

      

      

      	SECTION 8.01.	
              Without Consent of Noteholders.

            

      

      

      Notwithstanding Section 8.02, the Issuer, the Guarantors (except that any existing Guarantors need not execute a supplemental indenture entered into pursuant to clause (5) below) and the Trustee may amend or supplement
        this Indenture, each series of Notes or the Guarantees without the consent of any Holder for any of the following purposes:

      

      

      (1)          to cure any ambiguity, omission, defect or inconsistency;

      

      

      (2)          to provide for uncertificated Notes in addition to or in place of Physical Notes;

      

      

      (3)          to provide for the assumption of the Issuer’s or any Guarantor’s obligations to the Holders of such Notes in the case of a merger, consolidation, or Transfer of all or substantially all
        of the Issuer’s or such Guarantor’s assets;

      

      

      (4)          to secure the Notes;

      

      

      (5)          to add any Guarantor or release any Guarantor from its Guarantee if such release is in accordance with the terms of this Indenture;

      

      

      (6)          to conform the text of this Indenture, the Notes, or the Guarantees to any provision of the “Description of Notes” set forth in the Offering Memorandum to the extent that such provision
        in the “Description of Notes” set forth in the Offering Memorandum was intended to be a verbatim recitation of a provision of this Indenture, the Notes, or the Guarantees, which intent may be evidenced by an Officer’s Certificate to that effect;

      

      

      (7)          to provide for the issuance of Additional Notes in accordance with the limitations set forth in this Indenture as of the date hereof;

      

      

      (8)          to make any change that would provide any additional rights or benefits to the Holders of such Notes or that does not adversely affect the rights under this Indenture of any Holder in
        any material respect; or

      

      

      (9)          add customary provisions allowing for the issuance of Additional Notes into escrow.

       

      

      
        
          

        -85-

      

      	SECTION 8.02.	
              With Consent of Noteholders.

            

      

      

      (a)          Except to the extent provided in Section 8.01 and clause (b) of this Section 8.02, this Indenture, the Notes or any Guarantee may be amended with the consent of the Holders of at least a majority in
        aggregate principal amount of the then outstanding Notes voting as a single class (including, without limitation, consents obtained in connection with a purchase of, tender offer or exchange offer for Notes), and any existing Default or compliance
        with any provision of this Indenture, the Notes or any Guarantee may be waived with the consent of the Holders of a majority in aggregate principal amount of the then outstanding Notes voting as a single class (including, without limitation,
        consents obtained in connection with a purchase of, tender offer or exchange offer for Notes); provided that (x) if any such amendment, supplement or waiver will only affect one series of Notes (or less than all series of Notes) then outstanding
        under this Indenture, then only the consent of the Holders of at least a majority in principal amount of the Notes of such series then outstanding (including, without limitation, consents obtained in connection with a purchase of, or tender offer
        or exchange offer for, such series of the Notes) shall be required and (y) if any such amendment, supplement or waiver by its terms will affect a series of Notes in a manner that is different from and materially adverse relative to the manner in
        which such amendment, supplement or waiver affects other series of Notes, then the consent of the Holders of at least a majority in principal amount of the Notes of such series then outstanding (including, without limitation, consents obtained in
        connection with a purchase of, or tender offer or exchange offer for, such series of the Notes) shall be required.

      

      

      (b)          Notwithstanding clause (a) of this Section 8.02, without the consent of each Holder of Notes issued under this Indenture affected thereby, an amendment or waiver may not (with respect to any Note held by a
        non-consenting Holder):

      

      

      (1)          reduce the principal amount of Notes issued under this Indenture whose Holders must consent to an amendment, supplement or waiver;

      

      

      (2)          reduce the principal amount of or change the Maturity Date of any Notes, or alter the provisions with respect to the redemption of any such Notes other than, except as set forth in
        clause (7) of this Section 8.02, the provisions of Section 4.07 of this Indenture and the provisions of Section 3.07 of this Indenture;

      

      

      (3)          reduce the rate of or change the time for payment of interest on any such Notes;

      

      

      (4)          waive a Default or Event of Default in the payment of principal of or premium, if any, or interest on any such Notes (except a rescission of acceleration of Notes by the Holders of at
        least a majority in aggregate principal amount of the then outstanding applicable series of Notes and a waiver of the payment default that resulted from such acceleration);

       

      

      
        
          

        -86-

      

      (5)          make any such Note payable in currency other than that stated in such Note;

      

      

      (6)          make any change to the provisions of this Indenture relating to waiver of past Defaults or the rights of Holders of the Notes issued hereunder to receive payments of principal of or
        interest on the Notes;

      

      

      (7)          after the Issuer’s obligation to make an offer to purchase Notes arises hereunder (because, for the avoidance of doubt, a Change of Control has occurred) amend, change or modify in any
        material respect the obligations of the Issuer to make and consummate a Change of Control Offer with respect to a Change of Control that has occurred, including, without limitation, in each case, by amending, changing or modifying any of the
        definitions relating thereto;

      

      

      (8)          release the Issuer or any Guarantor that is a Significant Subsidiary from any of its obligations under its Guarantee or this Indenture otherwise than in accordance with the terms of this
        Indenture; or

      

      

      (9)          modify or change any provision of this Indenture affecting the ranking of the Notes or Guarantees in a manner adverse to the Holders of Notes.

      

      

      (c)          It shall not be necessary for the consent of the Holders under this Section 8.02 to approve the particular form of any proposed amendment or waiver, but it shall be sufficient if such consent approves the
        substance thereof.

      

      

      	SECTION 8.03.	
              Revocation and Effect of Consents.

            

      

      

      (a)          After an amendment, supplement, waiver or other action becomes effective, a consent to it by a Holder of a Note is a continuing consent conclusive and binding upon such Holder and every subsequent Holder
        of the same Note or portion thereof, and of any Note issued upon the transfer thereof or in exchange therefor or in place thereof, even if notation of the consent is not made on any such Note.

      

      

      (b)          The Issuer may, but shall not be obligated to, fix a record date for the purpose of determining the Holders entitled to consent to any amendment, supplement or waiver.  If a record date is fixed, then,
        notwithstanding the preceding paragraph, those Persons who were Noteholders at such record date (or their duly designated proxies), and only such Persons, shall be entitled to consent to such amendment, supplement, or waiver or to revoke any
        consent previously given, whether or not such Persons continue to be Noteholders after such record date.  No such consent shall be valid or effective for more than 90 days after such record date unless the consent of the requisite number of
        Noteholders has been obtained.

       

      

      
        
          

        -87-

      

      (c)          After an amendment, supplement, waiver or other action under Section 8.01 or Section 8.02 becomes effective, it shall bind every Noteholder, unless it makes a change described in any of clauses (1) through
        (9) of Section 8.02(b).  In that case the amendment, supplement, waiver or other action shall bind each Noteholder who has consented to it and every subsequent Noteholder or portion of a Note that evidences the same debt as the consenting Holder’s
        Note.

      

      

      	SECTION 8.04.	
              Notation on or Exchange of Notes.

            

      

      

      If an amendment, supplement, or waiver changes the terms of a Note, the Trustee (in accordance with the specific written direction of the Issuer) shall request the Holder of the Note (in accordance with the specific
        written direction of the Issuer) to deliver it to the Trustee.  In such case, the Trustee shall place an appropriate notation on the Note about the changed terms and return it to the Noteholder.  Alternatively, if the Issuer or the Trustee so
        determines, the Issuer in exchange for the Note shall issue, the Guarantors shall endorse and, upon receipt of a written order of the Issuer in the form of an Officer’s Certificate in accordance with Section 2.01, the Trustee shall authenticate a
        new Note that reflects the changed terms.  Failure to make the appropriate notation or issue a new Note shall not affect the validity and effect of such amendment, supplement or waiver.

      

      

      	SECTION 8.05.	
              Trustee To Sign Amendments, etc.

            

      

      

      The Trustee shall sign any amendment or supplement authorized pursuant to this Article Eight if the amendment or supplement does not affect the rights, duties, liabilities or immunities of the Trustee.  If it does
        affect the rights, duties, liabilities or immunities of the Trustee, the Trustee may, but need not, sign such amendment or supplement.  Notwithstanding anything herein to the contrary, in signing or refusing to sign an amendment or supplement, the
        Trustee shall be entitled to receive and, subject to Section 7.01, shall be fully protected in relying upon an Officer’s Certificate and an Opinion of Counsel stating, in addition to the matters required by Section 11.03, that the execution of such
        amendment or supplement is authorized or permitted by this Indenture and an Opinion of Counsel stating that such amendment or supplement is a valid and binding obligation of the Issuer and the Guarantors, enforceable against the Issuer and the
        Guarantors in accordance with its terms (subject to customary exceptions).

      

      

      ARTICLE NINE

      

      

      SATISFACTION AND DISCHARGE OF INDENTURE; DEFEASANCE

      

      

      	SECTION 9.01.	
              Satisfaction and Discharge of Indenture.

            

      

      

      This Indenture will be discharged and will cease to be of further effect as to Notes of an applicable series and Guarantees, and the Trustee, at the expense of the Issuer, will execute proper instruments acknowledging
        satisfaction and discharge of this Indenture, the applicable series of Notes and the Guarantees, when all amounts due to the Trustee shall have been paid and either:

       

      

      
        
          

        -88-

      

      (1)          the Issuer delivers to the Trustee all outstanding Notes of an applicable series issued under this Indenture (other than (i) Notes which have been destroyed, lost or stolen and which
        have been replaced or paid as provided in Section 2.08 hereof and (ii) Notes for whose payment money has theretofore been deposited in trust or segre-gated and held in trust by the Issuer and thereafter repaid to the Issuer or discharged from such
        trust) for cancellation; or

      

      

      (2)          (a) all Notes outstanding of an applicable series under this Indenture (i) have become due and payable, whether at maturity or as a result of the mailing or sending of a notice of
        redemption, or (ii) will become due and payable within one year (including as result of the mailing or sending of a notice of redemption), or are to be called for redemption within one year, under arrangements for the giving of notice of redemption
        by the Trustee in the name, and at the expense, of the Issuer, and the Issuer or any Guarantor irrevocably deposits with the Trustee as funds in trust solely for the benefit of the Holders, cash in U.S. Dollars, U.S. Government Obligations or a
        combination thereof in such amounts as will be sufficient to pay the principal of, premium, if any, and interest on such Notes outstanding under this Indenture on the maturity date or on the applicable optional redemption date, as the case may be;
        (b) such deposit shall not result in a breach or violation of, or constitute a default under, any other material instrument to which the Issuer or any Guarantor is a party or by which the Issuer or any Guarantor is bound; (c) the Issuer or any
        Guarantor has paid or caused to be paid all sums payable by the Issuer or any Guarantor under this Indenture; and (d) the Issuer have delivered (i) irrevocable instructions to the Trustee under this Indenture to apply the deposited money toward the
        payment of such Notes at maturity or the redemption date, as the case may be, and (ii) an Officer’s Certificate and an Opinion of Counsel each stating that all conditions precedent herein provided for relating to the satisfaction and discharge of
        this Indenture have been complied with.

      

      

      The Trustee shall acknowledge satisfaction and discharge of this Indenture on demand of and at the expense of the Issuer.

      

      

      Notwithstanding the satisfaction and discharge of this Indenture, the obligations of the Issuer in Article Two and in Sections 4.02, 7.07, 9.05 and 9.06 shall survive such satisfaction and discharge.

       

      

      
        
          

        -89-

      

      	SECTION 9.02.	
              Legal Defeasance.

            

      

      

      The Issuer may, at its option and at any time, elect to have all of its obligations and the obligations of the Guarantors discharged with respect to the applicable series of outstanding Notes on a date the conditions
        set forth in Section 9.04 are satisfied (hereinafter, “Legal Defeasance”).  For this purpose, such Legal Defeasance means that the Issuer will be deemed to have paid and discharged the entire indebtedness represented by the applicable series
        of outstanding Notes and to have satisfied all their other obligations under such Notes and this Indenture insofar as such Notes are concerned (and the Trustee, at the expense of the Issuer, shall, subject to Section 9.06, execute instruments in
        form and substance reasonably satisfactory to the Trustee and the Issuer acknowledging the same), except for the following which shall survive until otherwise terminated or discharged hereunder:

      

      

      (1)          the rights of the Holders of the applicable series of outstanding Notes to receive solely from the trust described in Section 9.04 and as more fully set forth in Section 9.05, payments
        in respect of the principal amount of, premium, if any, and interest on such Notes when such payments are due,

      

      

      (2)          the Issuer’s obligations with respect to such series of Notes under Article Two and Section 4.02,

      

      

      (3)          the rights, powers, trusts, duties, and immunities of the Trustee hereunder (including claims of, or payments to, the Trustee under or pursuant to Section 7.07) and the Issuer’s
        obligations in connection therewith and

      

      

      (4)          this Article Nine.

      

      

      Concurrently with any Legal Defeasance, the Issuer may, at its further option, cause to be terminated, as of the date on which such Legal Defeasance occurs, all of the obligations under any or all of the Guarantees, if
        any, then existing and obtain the release of the Guarantees of any or all Guarantors.  In order to exercise such option regarding a Guarantee, the Issuer shall provide the Trustee with written notice of their desire to terminate such Guarantee
        prior to the delivery of the Opinions of Counsel referred to in Section 9.04.

      

      

      Subject to compliance with this Article Nine, the Issuer may exercise its option under this Section 9.02 with respect to the Notes notwithstanding the prior exercise of its option under Section 9.03 below with respect
        to the Notes.

       

      

      
        
          

        -90-

      

      	SECTION 9.03.	
              Covenant Defeasance.

            

      

      

      The Issuer may, at its option and at any time, elect to have its obligations and the obligations of the Guarantors under Section 4.05, 4.07, 4.08, 4.09, 4.10, 4.12, 4.13 and 4.14,clauses (2) and (3) of the first
        paragraph of Section 5.01 and clauses (2) and (3) of second first paragraph of Section 5.01 released with respect to an applicable series of outstanding Notes on a date the conditions set forth in Section 9.04 are satisfied (hereinafter, “Covenant

          Defeasance”).  For this purpose, Covenant Defeasance means that, with respect to the applicable series of outstanding Notes, the Issuer may fail to comply with and shall have no liability in respect of any term, condition or limitation set
        forth in any such covenant, whether directly or indirectly, by reason of any reference elsewhere herein to any such covenant or by reason of any reference in any such covenant to any other provision herein or in any other document and such omission
        to comply shall not constitute a Default or an Event of Default under Section 6.01, but, except as specified above, the remainder of this Indenture, each series of Notes and the Guarantees shall be unaffected thereby.  In addition, upon the
        Issuer’s exercise of the option in this Section 9.03, subject to the satisfaction of the conditions set forth in Section 9.04, Sections 6.01(3), (4), (5) and (6) shall not constitute Events of Default.

      

      

      Notwithstanding any discharge or release of any obligations under this Indenture pursuant to Section 9.02 or this Section 9.03, the Issuer’s obligations in Article Two and Sections 7.07, 9.05, 9.06, 9.07 and 9.08 shall
        survive until such time as the Notes have been paid in full.  Thereafter, the Issuer’s obligations in Sections 7.07, 9.05, 9.07 and 9.08 shall survive.

      

      

      	SECTION 9.04.	
              Conditions to Defeasance or Covenant Defeasance.

            

      

      

      The following shall be the conditions to application of Section 9.02 or Section 9.03 to each series of outstanding Notes:

      

      

      (1)          the Issuer must irrevocably deposit with the Trustee, in trust, for the benefit of the Holders of the applicable series of Notes issued under this Indenture, cash in U.S. Dollars, U.S.
        Government Obligations or a combination thereof, in such amounts as will be sufficient (with respect to non-callable U.S. government securities or a combination of cash in U.S. dollars and non-callable U.S. government securities in the opinion of a
        nationally recognized firm of independent public accountants (such opinion shall be delivered to the Trustee and upon which the Trustee shall have no liability in relying)), to pay the principal, premium, if any, and interest on the applicable
        series of Notes outstanding under this Indenture on the stated maturity or on the applicable optional redemption date, as the case may be, and the Issuer must specify whether such Notes are being defeased to maturity or to a particular redemption
        date;

      

      

      (2)          in the case of Legal Defeasance, the Issuer shall have delivered to the Trustee an Opinion of Counsel in the United States (upon which the Trustee shall have no liability in relying)
        confirming that (a) the Issuer has received from, or (b) there has been published by, the Internal Revenue Service a ruling or since the date of the Indenture, there has been a change in the applicable federal income tax law, in either case to the
        effect that, and based thereon such Opinion of Counsel shall confirm that, the Holders of the applicable series of Notes outstanding under this Indenture will not recognize income, gain or loss for federal income tax purposes as a result of such
        Legal Defeasance and will be subject to federal income tax on the same amounts, in the same manner and at the same times as would have been the case if such Legal Defeasance had not occurred;

       

      

      
        
          

        -91-

      

      (3)          in the case of Covenant Defeasance, the Issuer shall have delivered to the Trustee an Opinion of Counsel in the United States (upon which the Trustee shall have no liability in relying)
        confirming that the Holders of the applicable series of Notes outstanding under this Indenture will not recognize income, gain or loss for federal income tax purposes as a result of such Covenant Defeasance and will be subject to federal income tax
        on the same amounts, in the same manner and at the same times as would have been the case if such Covenant Defeasance had not occurred;

      

      

      (4)          no Default or Event of Default with respect to the Notes of the applicable series shall have occurred and be continuing on the date of such deposit (other than a Default or Event of
        Default resulting from the borrowing of funds to be applied to such deposit) or insofar as Events of Default from bankruptcy or insolvency events are concerned, at any time in the period ending on the 91st day after the date of deposit;

      

      

      (5)          such Legal Defeasance or Covenant Defeasance will not result in a breach or violation of, or constitute a default under any material agreement or instrument (other than this Indenture)
        to which the Parent Guarantor or any of its Subsidiaries is a party or by which the Parent Guarantor or any of its Subsidiaries is bound;

      

      

      (6)          the Issuer must deliver to the Trustee an Officer’s Certificate (upon which the Trustee shall have no liability in relying) stating that the deposit was not made by the Issuer with the
        intent of preferring the Holders of the applicable series of Notes issued under this Indenture over the other creditors of the Issuer with the intent of defeating, hindering, delaying or defrauding creditors of the Issuer or others; and

      

      

      (7)          the Issuer must deliver to the Trustee an Officer’s Certificate and an Opinion of Counsel upon which the Trustee shall have the right to rely, each stating that all conditions precedent
        provided for relating to the Legal Defeasance or the Covenant Defeasance have been complied with.

      

      

      	SECTION 9.05.	
              Deposited Money and U.S. Government Obligations To Be Held in Trust.

            

      

      

      Subject to Section 9.08, all money and U.S. Government Obligations (including the proceeds thereof) deposited with the Trustee pursuant to Section 9.04 in respect of each series of outstanding Notes shall be held in
        trust and applied by the Trustee, in accordance with the provisions of such Notes and this Indenture, to the payment, either directly or through any Paying Agents, to the Holders of such Notes, of all sums due and to become due thereon in respect
        of principal, premium, if any, and accrued interest, but such money need not be segregated from other funds except to the extent required by law.

       

      

      
        
          

        -92-

      

      The Issuer and the Guarantors shall (on a joint and several basis) pay and indemnify the Trustee against any tax, fee or other charge imposed on or assessed against the U.S. Government Obligations deposited pursuant to
        Section 9.04 or the principal, premium, if any, and interest received in respect thereof other than any such tax, fee or other charge which by law is for the account of the Holders of the applicable series of outstanding Notes.

      

      

      Anything in this Article Nine to the contrary notwithstanding, the Trustee shall deliver or pay to the Issuer from time to time upon a request of the Issuer any money or U.S. Government Obligations held by it as
        provided in Section 9.04 which, in the opinion of a nationally recognized firm of independent public accountants expressed in a written certification thereof delivered to the Trustee, are in excess of the amount thereof which would then be required
        to be deposited to effect an equivalent Legal Defeasance or Covenant Defeasance.

      

      

      	SECTION 9.06.	
              Reinstatement.

            

      

      

      If the Trustee or any Paying Agent is unable to apply any money or U.S. Government Obligations in accordance with Section 9.01, 9.02 or 9.03 by reason of any legal proceeding or by reason of any order or judgment of
        any court or governmental authority enjoining, restraining or otherwise prohibiting such application, the Issuer’s and each Guarantor’s obligations under this Indenture, the applicable series of Notes and the Guarantees shall be revived and
        reinstated as though no deposit had occurred pursuant to this Article Nine until such time as the Trustee or such Paying Agent is permitted to apply all such money or U.S. Government Obligations in accordance with Section 9.01; provided that if the Issuer or the Guarantors have made any payment of principal of, premium, if any, or accrued interest on any Notes of the applicable series because of the reinstatement of their obligations,
        the Issuer or the Guarantors, as the case may be, shall be subrogated to the rights of the Holders of such Notes to receive such payment from the money or U.S. Government Obligations held by the Trustee or any Paying Agent.

      

      

      	SECTION 9.07.	
              Moneys Held by Paying Agent.

            

      

      

      In connection with the satisfaction and discharge of this Indenture, all moneys and U.S. Government Obligations then held by any Paying Agent under the provisions of this Indenture shall, upon written demand of the
        Issuer, be paid or delivered to the Trustee, or if sufficient moneys and U.S. Government Obligations have been deposited pursuant to Section 9.04, to the Issuer upon a request of the Issuer (or, if such moneys and U.S. Government Obligations had
        been deposited by the Guarantors, to the Parent Guarantors), and thereupon such Paying Agent shall be released from all further liability with respect to such moneys.

        

      

      
        
          

        -93-

      

      	SECTION 9.08.	
              Moneys Held by Trustee.

            

      

      

      Any moneys and U.S. Government Obligations deposited with the Trustee or any Paying Agent or then held by the Issuer or the Guarantors in trust for the payment of the principal of, or premium, if any, or interest on
        any Note that are not applied but remain unclaimed by the Holder of such Note for two years after the date upon which the principal of, or premium, if any, or interest on such Note shall have respectively become due and payable shall be repaid or
        returned to the Issuer (or, if appropriate, the Guarantors) upon a request of the Issuer, or if such moneys and U.S. Government Obligations are then held by the Issuer or the Guarantors in trust, such moneys and U.S. Government Obligations shall be
        released from such trust; and the Holder of such Note entitled to receive such payment shall thereafter, as an unsecured general creditor, look only to the Issuer and the Guarantors for the payment thereof, and all liability of the Trustee or such
        Paying Agent with respect to such trust moneys and U.S. Government Obligations shall thereupon cease; provided that the Trustee or any such Paying Agent, before being required to make any such repayment,
        may, at the expense of the Issuer and the Guarantors, either mail to each Noteholder affected, at the address shown in the register of the Notes maintained by the Registrar pursuant to Section 2.06, or cause to be published once a week for two
        successive weeks, in one newspaper published in the English language, customarily published each Business Day and of general circulation in The City of New York, the State of New York, a notice that such moneys and U.S. Government Obligations
        remains unclaimed and that, after a date specified therein, which shall not be less than 30 days from the date of such mailing or publication, any unclaimed balance of such moneys and U.S. Government Obligations then remaining will be repaid or
        returned to the Issuer.  After payment or return to the Issuer or the Guarantors or the release of any moneys and U.S. Government Obligations held in trust by the Issuer or any Guarantors, as the case may be, Holders entitled thereto must look only
        to the Issuer and the Guarantors for payment as general creditors unless applicable abandoned property law designates another Person.

      

      

      ARTICLE TEN

      

      

      GUARANTEE OF SECURITIES

      

      

      	SECTION 10.01.	
              Guarantee.

            

      

      

      The Parent Guarantor, by execution of this Indenture, and any other Guarantor, by execution of a supplemental indenture substantially in the form of Exhibit H, jointly and severally, guarantee to each Holder
        and to the Trustee (i) the due and punctual payment of the principal of, premium, if any, and interest on each Note, when and as the same shall become due and payable, whether at maturity, by acceleration or otherwise, the due and punctual payment
        of interest on the overdue principal of and interest on the Notes, to the extent lawful, and the due and punctual payment of all other obligations and due and punctual performance of all obligations of the Issuer to the Holders or the Trustee all
        in accordance with the terms of such Note and this Indenture and (ii) in the case of any extension of time of payment or renewal of any Notes or any of such other obligations, that the same will be promptly paid in full when due or performed in
        accordance with the terms of the extension or renewal, at stated maturity, by acceleration or otherwise.  The Parent Guarantor, by execution of this Indenture, and any other Guarantor, by execution of a supplemental indenture substantially in the
        form of Exhibit H, agrees that, subject only to the applicable provisions, if any, of Section 10.06, its obligations hereunder shall be absolute and unconditional, irrespective of, and shall be unaffected by, any invalidity, irregularity or
        unenforceability of any such Note or this Indenture, any failure to enforce the provisions of any such Note or this Indenture, any waiver, modification or indulgence granted to the Issuer with respect thereto by the Holder of such Note, or any
        other circumstances which may otherwise constitute a legal or equitable discharge of a surety or such Guarantor.  Each Guarantor further agrees that its Guarantee herein constitutes a Guarantee of payment when due (and not a Guarantee of
        collection).

       

      

      
        
          

        -94-

      

      Each Guarantor hereby waives diligence, presentment, demand for payment, filing of claims with a court in the event of merger or bankruptcy of the Issuer, any right to require a proceeding first against the Issuer,
        protest or notice with respect to any such Note or the Indebtedness evidenced thereby and all demands whatsoever, and covenants that this Guarantee will not be discharged as to any such Note except by payment in full of the principal thereof and
        interest thereon.  Each Guarantor hereby agrees that, as between such Guarantor, on the one hand, and the Holders and the Trustee, on the other hand, (i) the maturity of the obligations guaranteed hereby may be accelerated as provided in Article
        Six for the purposes of this Guarantee, notwithstanding any stay, injunction or other prohibition preventing such acceleration in respect of the obligations guaranteed hereby, and (ii) in the event of any declaration of acceleration of such
        obligations as provided in Article Six, such obligations (whether or not due and payable) shall forthwith become due and payable by the Parent Guarantor for the purpose of this Guarantee.

      

      

      The Guarantors shall have the right to seek contribution from any non-paying Guarantor so long as the exercise of such right does not impair the rights of the Trustee or any Holder under the Guarantees.

      

      

      	SECTION 10.02.	
              Execution and Delivery of Guarantee.

            

      

      

      To further evidence the Guarantee set forth in Section 10.01, each Guarantor hereby agrees that a notation of such Guarantee, substantially in the form attached hereto as Exhibit G, shall be endorsed on each
        Note authenticated and delivered by the Trustee and such Guarantee shall be executed by either manual or facsimile. signature of an Officer of the each Guarantor.  The validity and enforceability of any Guarantee shall not be affected by the fact
        that it is not affixed to any particular Note.

      

      

      Each of the Guarantors hereby agrees that its Guarantee set forth in Section 10.01 shall be in full force and effect notwithstanding any failure to endorse on each Note a notation of such Guarantee.

      

      

      If an Officer of a Guarantor whose signature is on this Indenture or a Guarantee no longer holds that office at the time the Trustee authenticates the Note on which such Guarantee is endorsed or at any time thereafter,
        such Guarantor’s Guarantee of such Note shall be valid nevertheless.

       

      

      
        
          

        -95-

      

      The delivery of any Note by the Trustee, after the authentication thereof hereunder, shall constitute due delivery of any Guarantee set forth in this Indenture on behalf of the Guarantor.

      

      

      	SECTION 10.03.	
              Release of Guarantors.

            

      

      

      (a)          A Guarantee of a Guarantor will be unconditionally and automatically released and discharged upon any of the following (other than, with respect to a Guarantor that is a direct or indirect parent of the
        Issuer, clauses (1) and (2) below):

      

      

      (1)          any Transfer (including, without limitation, by way of consolidation or merger) by any Guarantor to any Person that is not a Guarantor of all or substantially all of the properties and
        assets of such Guarantor; provided that such Guarantor is also released from all of its obligations in respect of Indebtedness under each Credit Facility and any other Indebtedness that gave rise to the
        obligation to provide such Guarantee;

      

      

      (2)          any Transfer directly or indirectly (including, without limitation, by way of consolidation or merger) to any Person that is not a Guarantor of Equity Interests of a Guarantor or any
        issuance by a Guarantor of its Equity Interests, such that such Guarantor ceases to be a Subsidiary of the Parent Guarantor; provided that such Guarantor is also released from all of its obligations in
        respect of Indebtedness under each Credit Facility and any other Indebtedness that gave rise to the obligation to provide such Guarantee;

      

      

      (3)          the release of such Guarantor from all obligations of such Guarantor in respect of Indebtedness under each Credit Facility and any other Indebtedness that gave rise to the obligation to
        provide such Guarantee; or

      

      

      (4)          upon legal defeasance, covenant defeasance or satisfaction and discharge of this Indenture in accordance with Article Nine.

      

      

      (b)          No such release and discharge of a Guarantee of a Guarantor shall be effective against the Trustee or the Holders of the relevant series of Notes to which such Guarantee relates (i) if
        an Event of Default shall have occurred and be continuing under this Indenture as of the time of such proposed release until such time as such Event of Default is cured or waived (unless such release is in connection with the sale of the Equity
        Interests in such Guarantor constituting collateral for a Credit Facility in connection with the exercise of remedies against such Equity Interests or in connection with a Transfer permitted by this Indenture if, but for the existence of such Event
        of Default, such Guarantor would otherwise be entitled to be released from its Guarantee following the sale of such Equity Interests) and (ii) until the Issuer shall have delivered to the Trustee an Officer’s Certificate, upon which the Trustee
        shall have the right to rely, stating that all conditions precedent provided for in this Indenture relating to such release and discharge have been complied with and that such release and discharge is permitted under this Indenture.

       

      

      
        
          

        -96-

      

      (c)          If the Guarantee of any Guarantor is deemed to be released or is automatically released, the Issuer shall deliver to the Trustee an Officer’s Certificate stating the identity of the
        released Guarantor, the basis for release in reasonable detail, and that such release complies with this Indenture. At the request of the Issuer, and upon delivery to the Trustee of an Officer’s Certificate that a Guarantor has been released and
        that execution by the Trustee of an appropriate instrument evidencing the release of the Parent Guarantor from its Guarantee complies with this Indenture, the Trustee shall execute any documents reasonably requested by either the Issuer or a
        Guarantor in order to evidence the release of the Parent Guarantor from its obligations under its Guarantee endorsed on the Notes and under this Article Ten (it being understood that the failure to obtain any such instrument shall not impair any
        automatic release pursuant to this Section 10.03).

      

      

      	SECTION 10.04.	
              Waiver of Subrogation.

            

      

      

      Each Guarantor hereby irrevocably waives any claim or other rights which it may now or hereafter acquire against the Issuer that arise from the existence, payment, performance or enforcement of such Guarantor’s
        obligations under its Guarantee and this Indenture, including, without limitation, any right of subrogation, reimbursement, exoneration, indemnification, and any right to participate in any claim or remedy of any Holder of Notes against the Issuer,
        whether or not such claim, remedy or right arises in equity, or under contract, statute or common law, including, without limitation, the right to take or receive from the Issuer, directly or indirectly, in cash or other property or by set-off or
        in any other manner, payment or Note on account of such claim or other rights.  If any amount shall be paid to any Guarantor in violation of the preceding sentence and any series of Notes shall not have been paid in full, such amount shall have
        been deemed to have been paid to such Guarantor for the benefit of, and held in trust for the benefit of, the Holders of such Notes, and shall forthwith be paid to the Trustee for the benefit of such Holders to be credited and applied upon the
        Notes, whether matured or unmatured, in accordance with the terms of this Indenture.  Each acknowledges that it will receive direct and indirect benefits from the financing arrangements contemplated by this Indenture and that the waiver set forth
        in this Section 10.04 is knowingly made in contemplation of such benefits.

      

      

      	SECTION 10.05.	
              Notice to Trustee.

            

      

      

      The Issuer or any Guarantor shall give prompt written notice to the Trustee of any fact known to such Issuer or any such Guarantor which would prohibit the making of any payment to or by the Trustee at its Corporate
        Trust Office in respect of the Guarantees.  Notwithstanding the provisions of this Article Ten or any other provision of this Indenture, the Trustee shall not be charged with knowledge of the existence of any facts which would prohibit the making
        of any payment to or by the Trustee in respect of the Guarantees, unless and until a Responsible Officer of the Trustee shall have received written notice thereof from the Issuer no later than three Business Days prior to such payment; and, prior
        to the receipt of any such written notice, the Trustee, subject to the provisions of this Section 10.05, and subject to the provisions of Sections 7.01 and 7.02, shall be entitled in all respects to assume that no such facts exist; provided, however, that if the Trustee shall not have received the notice referred to in this Section 10.05 at least three Business Days prior to the date upon which by
        the terms hereof any such payment may become payable for any purpose under this Indenture (including, without limitation, the payment of the principal of, premium, if any, or interest on any Note), then, anything herein contained to the contrary
        notwithstanding, the Trustee shall have full power and authority to receive such money and to apply the same to the purpose for which such money was received and shall not be affected by any notice to the contrary which may be received by it less
        than three Business Days prior to such date.

       

      

      
        
          

        -97-

      

      	SECTION 10.06.	
              Limitation on Guarantor’s Liability.

            

      

      

      Each Guarantor, and by its acceptance hereof, each Holder and the Trustee, hereby confirm that it is the intention of all such parties that the Guarantee of a Guarantor does not constitute a fraudulent transfer or
        conveyance for purposes of Title 11 of the United States Code, as amended, the Uniform Fraudulent Conveyance Act, the Uniform Fraudulent Transfer Act or any similar U.S. Federal or state or other applicable law.  To effectuate the foregoing
        intention, each Holder and each Guarantor hereby irrevocably agree that the obligations of a Guarantor under its Guarantee shall be limited to the maximum amount as will, after giving effect to all other contingent and fixed liabilities of such
        Guarantor result in the obligations of such Guarantor not constituting such a fraudulent transfer or conveyance.

      

      

      ARTICLE ELEVEN

      

      

      MISCELLANEOUS

      

      

      	SECTION 11.01.	
              Notices.

            

      

      

      Except for notice or communications to Holders, any notice or communication shall be given in writing and delivered in person or mailed by first class mail (registered or certified, return receipt requested), telex,
        telecopier or overnight air courier guaranteeing next day delivery, addressed as follows:

       

      

      
        
          

        -98-

      

      If to the Issuer or any Guarantor:

      

      

      WESCO Distribution, Inc.

      225 West Station Square Drive, Suite 700

      Pittsburgh, Pennsylvania 15219-1122

      Facsimile: (412) 222-7566

      Attention: Chief Financial Officer

      

      

      with a copy to:

      

      

      225 West Station Square Drive, Suite 700

      Pittsburgh, Pennsylvania 15219-1122

      Facsimile: (412) 222-7304

      Attention: General Counsel

      

      

      If to the Trustee:

      

      

      U.S. Bank National Association

      225 W. Station Square Drive, Suite 380

      Pittsburgh, PA 15219

      Attention: Corporate Trust Services

      

      

      The Issuer, the Guarantors or the Trustee by written notice to the others may designate additional or different addresses for subsequent notices or communications.

      

      

      All notices and communications (other than those sent to Holders) shall be deemed to have been duly given at the time delivered by hand, if personally delivered; five (5) calendar days after mailing if sent by
        registered or certified mail, postage prepaid (except that a notice of change of address shall not be deemed to have been given until actually received by the addressee); when answered back, if telexed; when receipt acknowledged, if telecopied; and
        the next Business Day after timely delivery to the courier, if sent by overnight air courier guaranteeing next day delivery.

      

      

      The Trustee shall accept and act upon instructions, directions, reports, notices and other communications or information pursuant to this Indenture sent by unsecured electronic transmissions (including email and .pdf
        attachments); provided that (i) the Trustee shall not have any duty or obligation to verify or confirm that the Person sending instructions, directions, reports, notices or other communications or
        information by electronic transmission is, in fact, a Person authorized to give such instructions, directions, reports, notices or other communications or information on behalf of the party purporting to send such electronic transmission; and the
        Trustee shall not have any liability for any losses, liabilities, costs or expenses incurred or sustained by any party as a result of such reliance upon or compliance with such instructions, directions, reports, notices or other communications or
        information and (ii) each other party agrees to assume all risks arising out of the use of electronic methods to submit instructions, directions, reports, notices or other communications or information to the Trustee and the use of digital
        signatures, including the risk of the Trustee acting on unauthorized instructions, notices, reports or other communications or information, and the risk of interception and misuse by third parties. All notices, approvals, consents, requests and any
        communications hereunder must be in writing (provided that any communication sent to the Trustee hereunder must be in the form of a document that is signed manually or by way of a digital signature provided by DocuSign (or such other digital
        signature provider as specified in writing to the Trustee by an authorized representative), in English.

       

      

      
        
          

        -99-

      

      Any notice or communication to a Holder shall be mailed by first class mail, certified or registered, return receipt requested, or by overnight air courier guaranteeing next day delivery to its address shown on the
        register kept by the Registrar.  Failure to mail a notice or communication to a Holder or any defect in it shall not affect its sufficiency with respect to other Holders.  Where this Indenture or any Note provides for notice of any event (including
        any notice of redemption or repurchase) to a Holder of a Global Note (whether by mail or otherwise), such notice shall be sufficiently given if given to the Depositary (or its designee) pursuant to the standing instructions from the Depositary or
        its designee, including by electronic mail in accordance with applicable Depositary procedures.

      

      

      If a notice or communication to a Holder is mailed in the manner provided above, it shall be deemed duly given, whether or not the addressee receives it.

      

      

      In case by reason of the suspension of regular mail service, or by reason of any other cause, it shall be impossible to mail any notice as required by this Indenture, then such method of notification as shall be made
        with the approval of the Trustee shall constitute a sufficient mailing of such notice.

      

      

      Notwithstanding anything herein to the contrary, any notice to the Trustee shall be deemed given when actually received.

      

      

      	SECTION 11.02.	
              [reserved].

            

      

      

      	SECTION 11.03.	
              Certificate and Opinion as to Conditions Precedent.

            

      

      

      Upon any request or application by the Issuer or any Guarantor to the Trustee to take any action under this Indenture, such Issuer or such Guarantor shall furnish to the Trustee:

      

      

      (1)          an Officer’s Certificate (which shall include the statements set forth in Section 11.04 below) stating that, in the opinion of the signers, all conditions precedent and covenants, if
        any, provided for in this Indenture relating to the proposed action have been complied with; and

       

      

      
        
          

        -100-

      

      (2)          an Opinion of Counsel (which shall include the statements set forth in Section 11.04 below) stating that, in the opinion of such counsel, all such conditions precedent and covenants have
        been complied with.

      

      

      	SECTION 11.04.	
              Statements Required in Certificate and Opinion.

            

      

      

      Each certificate and opinion with respect to compliance by or on behalf of the Issuer or any Guarantor with a condition or covenant provided for in this Indenture shall include:

      

      

      (1)          a statement that the Person making such certificate or opinion has read such covenant or condition;

      

      

      (2)          a brief statement as to the nature and scope of the examination or investigation upon which the statements or opinions contained in such certificate or opinion are based;

      

      

      (3)          a statement that, in the opinion of such Person, it or he has made such examination or investigation as is necessary to enable it or him to express an informed opinion as to whether or
        not such covenant or condition has been complied with; and

      

      

      (4)          a statement as to whether or not, in the opinion of such Person, such covenant or condition has been complied with.

      

      

      	SECTION 11.05.	
              Rules by Trustee and Agents.

            

      

      

      The Trustee may make reasonable rules for action by or meetings of Noteholders.  The Registrar and Paying Agent may make reasonable rules for their functions.

      

      

      	SECTION 11.06.	
              Business Days; Legal Holidays.

            

      

      

      A “Business Day” is a day that is not a Legal Holiday.  A “Legal Holiday” is a Saturday, a Sunday or other day on which commercial banks in The City of New York, the State of New York are authorized or
        required by law to close.  If a payment date is a Legal Holiday at a place of payment, payment may be made at that place on the next succeeding day that is not a Legal Holiday, and no interest shall accrue for the intervening period.

      

      

      	SECTION 11.07.	
              Governing Law.

            

      

      

      This Indenture, each series of Notes and the Guarantees shall be governed by, and construed in accordance with the laws of the State of New York, but without giving effect to applicable principles of conflicts of law
        to the extent that the application of the law of another jurisdiction would be required thereby.

       

      

      
        
          

        -101-

      

      	SECTION 11.08.	
              No Adverse Interpretation of Other Agreements.

            

      

      

      This Indenture may not be used to interpret another indenture, loan, security or debt agreement of the Parent Guarantor or any Subsidiary thereof.  No such indenture, loan, security or debt agreement may be used to
        interpret this Indenture.

      

      

      	SECTION 11.09.	
              Successors.

            

      

      

      All agreements of the Issuer and the Guarantors in this Indenture and the Notes shall bind their respective successors.  All agreements of the Trustee, any additional trustee and any Agents in this Indenture shall bind
        its successor.

      

      

      	SECTION 11.10.	
              Multiple Counterparts.

            

      

      

      The parties may sign multiple counterparts of this Indenture.  Each signed counterpart shall be deemed an original, but all of them together represent one and the same agreement.  The exchange of copies of this
        Indenture and of signature pages by facsimile or PDF transmission shall constitute effective execution and delivery of this Indenture as to the parties hereto and may be used in lieu of the original Indenture for all purposes. Signatures of the
        parties hereto transmitted by facsimile or PDF shall be deemed to be their original signatures for all purposes.

      

      

      	SECTION 11.11.	
              Table of Contents, Headings, etc.

            

      

      

      The table of contents, cross-reference sheet and headings of the Articles and Sections of this Indenture have been inserted for convenience of reference only, are not to be considered a part hereof, and shall in no way
        modify or restrict any of the terms or provisions hereof.

      

      

      	SECTION 11.12.	
              Separability.

            

      

      

      Each provision of this Indenture shall be considered separable and if for any reason any provision which is not essential to the effectuation of the basic purpose of this Indenture or the Notes shall be invalid,
        illegal or unenforceable, the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby.

      

      

      	SECTION 11.13.	
              Waiver of Jury Trial.

            

      

      

      THE ISSUER, THE GUARANTORS AND THE TRUSTEE, AND EACH HOLDER OF A NOTE BY ITS ACCEPTANCE THEREOF, IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY AND ALL RIGHTS TO TRIAL BY JURY IN ANY LEGAL
        PROCEEDING ARISING OUT OF OR RELATING TO THIS INDENTURE, THE NOTES, THE GUARANTEES OR ANY TRANSACTION CONTEMPLATED HEREBY.

       

      

      
        
          

        -102-

      

      	SECTION 11.14.	
              Force Majeure.

            

      

      

      In no event shall the Trustee be responsible or liable for any failure or delay in the performance of its obligations hereunder arising out of or caused by, directly or indirectly, forces beyond its control, including,
        without limitation, strikes, work stoppages, accidents, acts of war or terrorism, civil or military disturbances, nuclear or natural catastrophes or acts of God, and interruptions, loss or malfunctions of utilities, communications or computer
        (software and hardware) services; it being understood that the Trustee shall use reasonable efforts which are consistent with accepted practices in the banking industry to resume performance as soon as practicable under the circumstances

      

      

      	SECTION 11.15.	
              U.S.A. Patriot Act.

            

      

      

      The Issuer and the Guarantors acknowledge that in accordance with Section 326 of the U.S.A. PATRIOT Act, the Trustee, like all financial institutions and in order to help fight the funding of terrorism and money
        laundering, is required to obtain, verify, and record information that identifies each person or legal entity that establishes a relationship or opens an account with the Trustee. The parties to this Indenture agree that they will provide the
        Trustee with such information as it may request in order for the Trustee to satisfy the requirements of the U.S.A. PATRIOT Act.

      

      

      [Signature Pages Follow]

      

      

      
        
          

      

      IN WITNESS WHEREOF, the parties have caused this Indenture to be duly executed all as of the date and year first written above.

      

      

      	 	
              WESCO DISTRIBUTION, INC.,

            
	 	
              as Issuer

            
	 	 	 	 
	 	
              By:

            	
              /s/ Brian M. Begg

            
	 	 	
              Name:

            	
              Brian M. Begg

            
	 	 	
              Title:

            	
              Vice President, Investor Relations& Treasurer

            

      

      

      
        
          

      

      	 	
              WESCO INTERNATIONAL, INC. as the Parent Guarantor

            
	 	 	 	 
	 	
              By:

            	
              /s/ Brian M. Begg

            
	 	 	
              Name:

            	
              Brian M. Begg

            
	 	 	
              Title:

            	
              Vice President, Investor Relations & Treasurer

            

      

      

      
        
          

      

      	 	
              U.S. BANK NATIONAL ASSOCIATION, as Trustee

            
	 	 	 	 
	 	
              By:

            	
              /s/ Robert P. Pavlovic

            
	 	 	
              Name:

            	
              Robert P. Pavlovic

            
	 	 	
              Title:

            	
              Vice President

            

      

      

      
        
          

      

      
      EXHIBIT A-1

      

      

      [FORM OF SENIOR NOTE DUE 2025]

      

      

      WESCO DISTRIBUTION, INC.

      

      

      7.125% SENIOR NOTE DUE 2025

      

      

      [Insert Global Note Legend, if applicable]

      

      

      [Insert Private Placement Legend, if applicable]

      

      

      	
              No.

            	 	
              CUSIP No.

            	 
	 	 	
              ISIN No.

            	 
	 	 	
              $

            	 

      

      

      WESCO DISTRIBUTION, INC., a Delaware corporation (the “Issuer”), for value received promises to pay to ___________ or registered assigns the principal sum of ______________ (or such other principal amount as
        shall be set forth in the Schedule of Exchanges of Interests in Global Note attached hereto), on June 15, 2025.

      

      

      	
              Interest Payment Dates:

            	
              June 15 and December 15, commencing on

            

      

      

      	
              Record Dates:

            	
              June 1 and December 1 (whether or not a Business Day).

            

       

      

      Reference is made to the further provisions of this Note contained herein, which will for all purposes have the same effect as if set forth at this place.

       

      

      
        A-1-1

        
          

      

      IN WITNESS WHEREOF, the Issuer has caused this Note to be signed manually or by facsimile by a duly authorized officer.

      

      

      	 	
              WESCO DISTRIBUTION, INC.

            
	 	 	 
	 	
              By:

            	 
	 	 	
              Name:

            
	 	 	
              Title:

            

      

      

      
        A-1-2

        
          

      

      Certificate of Authentication

      

      

      This is one of the 7.125% Senior Notes due 2025 referred to in the within-mentioned Indenture.

      

      

      	 	 	 	
              U.S. BANK NATIONAL ASSOCIATION,

            
	 	 	 	
              as Trustee

            

      

      

      	 	 	 	
              By:

            	 

      

      

      	
              Dated:

            	 	 	 	 

      

      

      
        A-1-3

        
          

      

      [FORM OF REVERSE OF SENIOR NOTE DUE 2025]

      

      

      WESCO DISTRIBUTION, INC.

      

      

      7.125% SENIOR NOTE DUE 2025

      

      

      Capitalized and certain other terms used herein and not otherwise defined have the meanings set forth in the Indenture referred to below unless otherwise indicated.

      

      

      1.            Interest.  WESCO DISTRIBUTION, INC., a Delaware corporation (the “Issuer”), promises to pay interest on the principal amount set forth on the face hereof at a rate of 7.125% per annum. 
        Interest hereon will accrue from and including the most recent date to which interest has been paid or, if no interest has been paid, from and including June 12, 2020 to but excluding the date on which interest is paid.  Interest shall be payable
        in arrears on each June 15 and December 15, commencing                 .  Interest will be computed on the basis of a 360-day year of twelve 30-day months and actual days elapsed.  The Issuer shall pay interest on overdue principal and on overdue
        interest (to the full extent permitted by law) at the rate borne by the 5-Year Notes.

      

      

      2.            Method of Payment.  The Issuer will pay interest hereon (except defaulted interest) to the Persons who are registered Holders at the close of business on June 1 or December 1 preceding the
        Interest Payment Date (whether or not a Business Day).  Holders must surrender 5-Year Notes to a Paying Agent to collect principal payments.  The Issuer will pay principal and interest in U.S. Dollars.  Interest may be paid by check mailed to the
        Holder entitled thereto at the address indicated on the register maintained by the Registrar for the 5-Year Notes.

      

      

      3.            Paying Agent and Registrar.  Initially, U.S. Bank National Association (the “Trustee”) will act as a Paying Agent and Registrar.  The Issuer may change any Paying Agent or Registrar without
        notice.  The Issuer or any Affiliate thereof may act as Paying Agent or Registrar.

      

      

      4.            Indenture.  The Issuer issued the 5-Year Notes under an Indenture dated as of June 12, 2020 (the “Indenture”) among the Issuer, the Parent Guarantor and the Trustee.  This is one of an
        issue of 5-Year Notes of the Issuer issued, or to be issued, under the Indenture.  The terms of the 5-Year Notes include those stated in the Indenture.  The 5-Year Notes are subject to all such terms, and Holders are referred to the Indenture for a
        statement of them.

       

      

      
        A-1-4

        
          

      

      5.            Optional Redemption.

      

      

      At any time prior to June 15, 2022, the Issuer may on any one or more occasions redeem up to (i) 35% of the original aggregate principal amount of 5-Year Notes issued under the Indenture and (ii) all or a portion of
        any applicable Additional Notes issued after the Issue Date, upon not less than 10 nor more than 60 days’ notice, at a redemption price equal to 107.125% of the principal amount of the 5-Year Notes redeemed, plus accrued and unpaid interest, if
        any, to but excluding the redemption date, with an amount of cash no greater than the cash proceeds (net of underwriting discounts and commissions) of all Equity Offerings since the Issue Date; provided
        that:

      

      

      (1)          at least 65% (calculated after giving effect to any issuance of applicable Additional Notes) of the aggregate principal amount of 5-Year Notes issued under the Indenture (excluding
        5-Year Notes held by the Issuer and its Subsidiaries) remains outstanding immediately after the occurrence of such redemption; and

      

      

      (2)          the redemption occurs within 180 days of the date of the closing of such Equity Offering.

      

      

      In addition, prior to June 15, 2022, the Issuer may redeem the 5-Year Notes, in whole or in part, at a redemption price equal to 100% of the principal amount thereof, plus accrued and unpaid interest, if any, to but
        excluding the applicable 5-Year Notes Make-Whole Redemption Date, plus the 5-Year Notes Make-Whole Premium. The Issuer will notify the Trustee of the 5-Year Notes Make-Whole Premium by delivering to the Trustee, on or before the applicable 5-Year
        Notes Make-Whole Redemption Date, an Officer’s Certificate showing the calculation thereof in reasonable detail, and the Trustee will not be responsible for verifying or otherwise for such calculation.

      

      

      On or after June 15, 2022, the Issuer may on any one or more occasions redeem all or a part of the 5-Year Notes, upon not less than 10 nor more than 60 days’ notice, at the redemption prices (expressed as percentages
        of principal amount) set forth below, plus accrued and unpaid interest, if any, on the 5-Year Notes redeemed, to but excluding the applicable Redemption Date, if redeemed during the twelve-month period beginning on June 15 of the years indicated
        below:

       

      

      	
              Year

            	
              Percentage 

              

            
	
              2022

            	
              103.563%

            
	
              2023

            	
              101.781%

            
	
              2024 and thereafter

            	
              100.000%

            

      

      

      Unless the Issuer defaults in the payment of the redemption price, interest will cease to accrue on the 5-Year Notes or portions thereof called for redemption on the applicable redemption date. Any notice of redemption
        of the 5-Year Notes may, at the Issuer’s discretion, be subject to one or more conditions precedent with respect to completion of a corporate transaction (including, but not limited to, any merger, acquisition, disposition, asset sale or corporate
        restructuring or reorganization) or financing (including, but not limited to, any incurrence of Indebtedness (or entering into a commitment with respect thereto), Sale and Leaseback Transaction, issuance of securities, equity offering or
        contribution, liability management transaction or other capital raise) and may be given prior to the completion thereof. If a redemption is subject to satisfaction of one or more conditions precedent, the notice shall describe each condition, and
        the notice may be rescinded in the event that any or all of the conditions shall not have been satisfied by the redemption date. The Issuer may provide in such notice that payment of the redemption price and performance of the Issuer’s obligations
        with respect to such redemption may be performed by another Person.

       

      

      
        A-1-5

        
          

      

      In addition, the Issuer may acquire 5-Year Notes by means other than a redemption, whether by tender offer, open market purchases, negotiated transactions or otherwise, in accordance with applicable securities laws, so
        long as such acquisition does not otherwise violate the terms of the Indenture.

      

      

      Notwithstanding the foregoing, the payment of accrued but unpaid interest in connection with the redemption of 5-Year Notes is subject to the rights of a Holder of 5-Year Notes on a record date for the payment of
        interest whose 5-Year Notes are to be redeemed on or after such record date but on or prior to the related interest payment date to receive interest on such interest payment date.

      

      

      6.            Notice of Optional Redemption.  Notices of redemption shall be mailed by first class mail or sent electronically at least 10 but not more than 60 days before the Redemption Date to each Holder of
        5-Year Notes to be redeemed at its registered address (or to the extent permitted or required by applicable Depositary procedures or regulations with respect to global Notes, sent electronically).  If any Note is to be redeemed in part only, the
        notice of redemption that relates to such Note shall state the portion of the principal amount thereof to be redeemed.  Any redemption and notice thereof may, in the Issuer’s discretion, be subject to the satisfaction of one or more conditions
        precedent described in the notice relating to such redemption.

      

      

      7.            Offers To Purchase.  The Indenture provides that upon the occurrence of a Change of Control or an Asset Sale and subject to further limitations contained therein, the Issuer shall make an offer to
        purchase outstanding 5-Year Notes in accordance with the procedures set forth in the Indenture.

      

      

      8.            Special Mandatory Redemption.

      

      

      The Indenture provides that upon a Special Mandatory Redemption Trigger Date and subject to further limitations contained therein, the Issuer shall redeem the outstanding 5-Year Notes in accordance with the procedures
        set forth in the Indenture.

      

      

      9.            Denominations, Transfer, Exchange.  The 5-Year Notes are in registered form without coupons in denominations of $2,000 and integral multiples of $1,000 in excess of $2,000.  A Holder may transfer
        or exchange 5-Year Notes in accordance with the Indenture.  The Registrar may require a Holder, among other things, to furnish appropriate endorsements and transfer documents and to pay to it any taxes and fees required by law or permitted by the
        Indenture.  The Registrar need not register the transfer of or exchange any 5-Year Notes or portion of a 5-Year Note selected for redemption, or register the transfer of or exchange any 5-Year Notes for a period of 15 days before a mailing of
        notice of redemption.

        

      

      
        A-1-6

        
          

      

      10.          Persons Deemed Owners.  The registered Holder of this 5-Year Note may be treated as the owner of this 5-Year Note for all purposes.

      

      

      11.          Unclaimed Money.  If money held by the Paying Agent or Trustee for the payment of principal or interest remains unclaimed for two years, the Paying Agent or Trustee, as applicable, will pay such
        money back to the Issuer at its written request.  After that, Holders entitled to the money must look to the Issuer and the Guarantors for payment as general creditors unless an “abandoned property” law designates another Person.

      

      

      12.          Amendment, Supplement, Waiver, Etc.  The Issuer and the Trustee may, without the consent of the Holders of any outstanding 5-Year Notes, amend, waive or supplement the Indenture or the 5-Year Notes
        for certain specified purposes, including, among other things, curing ambiguities, omissions, defects or inconsistencies, providing for the assumption by a successor to the Issuer of its obligations to the Holders and making any change that does
        not adversely affect the rights of any Holder in any material respect.  Other amendments and modifications of the Indenture or the 5-Year Notes may be made by the Issuer and the Trustee with the consent of Holders as further described in the
        Indenture.

      

      

      13.          Restrictive Covenants.  The Indenture imposes certain limitations on the ability of the Parent Guarantor and its Subsidiaries to, among other things, create liens, make Restricted Payments, enter
        into Sale and Leaseback Transactions or consolidate, merge or sell all or substantially all of the assets of the Parent Guarantor and its Subsidiaries and requires the Issuer to provide reports to Holders of the 5-Year Notes.  Such limitations are
        subject to a number of important qualifications and exceptions.  Pursuant to Section 4.05 of the Indenture, the Issuer must annually report to the Trustee on compliance with such limitations.

      

      

      14.          Successor Person.  When a successor Person assumes all the obligations of its predecessor under the 5-Year Notes and the Indenture and the transaction complies with the terms of Article Five of the
        Indenture, the predecessor Person will, except as provided in Article Five, be released from those obligations.

      

      

      15.          Defaults and Remedies.  Events of Default are set forth in the Indenture.  If an Event of Default occurs and is continuing under the Indenture, either the Trustee, by notice in writing to the
        Issuer, or the Holders of at least 25% in aggregate principal amount of the 5-Year Notes then outstanding, by notice in writing to the Issuer and the Trustee specifying the respective Event of Default and that it is a “notice of acceleration”, may
        declare the principal of and premium, if any, and accrued interest, if any, on the 5-Year Notes to be due and payable, and upon such declaration of acceleration, such principal of and premium, if any, and accrued interest, if any, shall be
        immediately due and payable; provided, however, that, notwithstanding the foregoing, if an Event of Default specified in Section 6.01(7) occurs with respect to the
        Issuer or the Parent Guarantor, the principal of and premium, if any, and accrued interest, if any, on the 5-Year Notes then outstanding shall become and be immediately due and payable without any declaration or other act on the part of the Trustee
        or any Holder.

       

      

      
        A-1-7

        
          

      

      Notwithstanding the foregoing, if after such acceleration but before a judgment or decree based on such acceleration is obtained by the Trustee, the Holders of a majority in aggregate principal amount of the 5-Year
        Notes then outstanding may rescind and annul such acceleration if:

      

      

      (1)          all Events of Default, other than nonpayment of principal, premium, if any, or interest that has become due solely because of the acceleration, have been cured or waived;

      

      

      (2)          to the extent the payment of such interest is lawful, interest on overdue installments of interest and overdue principal, which has become due otherwise than by such declaration of
        acceleration, has been paid;

      

      

      (3)          the Issuer has paid the Trustee its reasonable compensation and reimbursed the Trustee for its expenses, disbursements and advances; and

      

      

      (4)          in the event of the cure or waiver of an Event of Default of the type described in Section 6.01(7), the Trustee shall have received an Officer’s Certificate and an Opinion of Counsel
        that such Event of Default has been cured or waived.

      

      

      No such rescission shall affect any subsequent Default or impair any right consequent thereto.

      

      

      Holders may not enforce the Indenture or the 5-Year Notes except as provided in the Indenture.  The Trustee may require indemnity satisfactory to it before it enforces the Indenture or the 5-Year Notes.  Subject to
        certain limitations, Holders of a majority in principal amount of the then outstanding 5-Year Notes may direct the Trustee in its exercise of any trust or power.  The Trustee may withhold from Holders notice of any continuing Default or Event of
        Default (except a Default or Event of Default relating to the payment of principal of  or interest on the 5-Year Notes) if it determines that withholding notice is in their best interests.

      

      

      16.          Trustee Dealings with the Issuer.  The Trustee, in its individual or any other capacity, may make loans to, accept deposits from and perform services for the Issuer or its Affiliates, and may
        otherwise deal with the Issuer or its Affiliates, as if it were not Trustee.

      

      

      17.          No Recourse Against Others.  No director, officer, employee, incorporator, member of the Board of Directors or holder of Capital Stock of the Parent Guarantor or of any Subsidiary, as such, shall
        have any liability for any obligations of the Issuer or the Guarantors under the 5-Year Notes, the Indenture or the Guarantees or for any claim based on, in respect of, or by reason of, such obligations or their creation.  Each Holder of 5-Year
        Notes by accepting a Note waives and releases all such liability.

       

      

      
        A-1-8

        
          

      

      18.          Satisfaction and Discharge.  The Issuer’s and each Guarantors’ obligations pursuant to the Indenture will be discharged, except for obligations pursuant to certain sections thereof, subject
        to the terms of the Indenture, upon the payment of all the 5-Year Notes or upon the irrevocable deposit with the Trustee of cash in U.S. Dollars, U.S. Government Obligations or a combination thereof, in such amounts as will be sufficient to pay
        when due principal of and interest on the 5-Year Notes to maturity or redemption, as the case may be.

      

      

      19.          Guarantees.  From and after the Issue Date, the 5-Year Notes will be entitled to the benefits of certain Guarantees made for the benefit of the Holders.  Reference is hereby made to the Indenture
        for a statement of the respective rights, limitations of rights, duties and obligations thereunder of the Guarantors, the Trustee and the Holders.

      

      

      20.          Authentication.  This Note shall not be valid until the Trustee manually signs the certificate of authentication on the other side of this Note.

      

      

      21.          Governing Law.  THIS NOTE SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK, BUT WITHOUT GIVING EFFECT TO APPLICABLE PRINCIPLES OF CONFLICTS OF LAW TO THE
        EXTENT THAT THE APPLICATION OF THE LAW OF ANOTHER JURISDICTION WOULD BE REQUIRED THEREBY.

      

      

      22.          Abbreviations.  Customary abbreviations may be used in the name of a Holder or an assignee, such as:  TEN COM (= tenants in common), TENANT (= tenants by the entireties), JT TEN (= joint tenants with right
        of survivorship and not as tenants in common), CUST (= Custodian), and U/G/M/A (= Uniform Gifts to Minors Act).

      

      

      The Issuer will furnish to any Holder upon written request and without charge a copy of the Indenture.  Requests may be made to:

      

      

      WESCO Distribution, Inc.

      225 West Station Square Drive, Suite 700

      Pittsburgh, Pennsylvania 15219-1122

      Facsimile: (412) 222-7566

      Attention: Chief Financial Officer

      

      

      
        A-1-9

        
          

      

      ASSIGNMENT

      

      

      I or we assign and transfer this Note to:

       

      

      
        	 
	
                (Insert assignee’s social security or tax I.D. number)

              
	 
	
                 

              
	
                (Print or type name, address and zip code of assignee)

              

      

       

      

      	
              and irrevocably appoint

            	 

      

      

      Agent to transfer this Note on the books of the Issuer.  The Agent may substitute another to act for him.

      

      

      	
              Date:

            	 	 	
              Your Signature:

            	 
	 	 	 	 	
              (Sign exactly as your name appears on the other side of this Note)

            

      

      

      	
              Signature Guarantee:

            	 	 

      

      

      SIGNATURE GUARANTEE

      

      

      Signatures must be guaranteed by an “eligible guarantor institution” meeting the requirements of the Registrar, which requirements include membership or participation in the Security Transfer Agent Medallion Program
        (“STAMP”) or such other “signature guarantee program” as may be determined by the Registrar in addition to, or in substitution for, STAMP, all in accordance with the Securities Exchange Act of 1934, as amended.

      

      

      
        A-1-10

        
          

      

      OPTION OF HOLDER TO ELECT PURCHASE

      

      

      If you want to elect to have all or any part of this Note purchased by the Issuer pursuant to Section 4.07 or Section 4.08 of the Indenture check the appropriate box:

      

      

      	
              ☐

            	
              Section 4.07

            	
              ☐

            	
              Section 4.08

            

      

      

      If you want to have only part of the Note purchased by the Issuer pursuant to Section 4.07 or Section 4.08 of the Indenture, state the amount you elect to have purchased:

      

      

      	$	

            	 
	 	
              ($2,000 or integral multiples of $1,000 in excess

            
	 	
              of $2,000; provided that the part not

            
	 	
              purchased must be at least $2,000)

            

      

      

      	
              Date:

            	 	 

      

      

      	 	
              Your Signature:

            	 
	 	 	
              (Sign exactly as your name appears on the face of this Note)

            

      

      

      	 	 
	
              Signature Guaranteed

            	 

      

      

      SIGNATURE GUARANTEE

      

      

      Signatures must be guaranteed by an “eligible guarantor institution” meeting the requirements of the Registrar, which requirements include membership or participation in the Security Transfer Agent Medallion Program
        (“STAMP”) or such other “signature guarantee program” as may be determined by the Registrar in addition to, or in substitution for, STAMP, all in accordance with the Securities Exchange Act of 1934, as amended.

      

      

      
        A-1-11

        
          

      

      Schedule of Exchanges of Interests in Global Note*

      

      

      The following exchanges of a part of this Global Note for an interest in another Global Note or for a Physical Note, or exchanges of a part of another Global Note or Physical Note for an interest in this Global Note,
        have been made:

      

      

      	
              Date of Exchange

            	
              Amount of decrease in

              Principal Amount

              of

              this Global Note

            	
              Amount of increase in

              Principal Amount

              of

              this Global Note

            	
              Principal Amount

              of this Global Note

              following such

              decrease

              (or increase)

            	
              Signature of authorized

              signatory of Trustee

            
	 	 	 	 	 

      

      

      

      
        	
                *

              	
                Insert in Global Securities only.

              

         

        

      

      
        A-1-12

        
          

      

      
      EXHIBIT A-2

      

      

      [FORM OF SENIOR NOTE DUE 2028]

      

      

      WESCO DISTRIBUTION, INC.

      

      

      7.250% SENIOR NOTE DUE 2028

      

      

      [Insert Global Note Legend, if applicable]

      

      

      [Insert Private Placement Legend, if applicable]

      

      

      	
              No.

            	 	
              CUSIP No.

            	 
	 	 	
              ISIN No.

            	 
	 	 	
              $

            	 

      

      

      WESCO DISTRIBUTION, INC., a Delaware corporation (the “Issuer”), for value received promises to pay to ___________ or registered assigns the principal sum of ______________ (or such other principal amount as
        shall be set forth in the Schedule of Exchanges of Interests in Global Note attached hereto), on June 15, 2028.

      

      

      	
              Interest Payment Dates:

            	
              June 15 and December 15, commencing on

            

      

      

      	
              Record Dates:

            	
              June 1 and December 1 (whether or not a Business Day).

            

      

      

      Reference is made to the further provisions of this Note contained herein, which will for all purposes have the same effect as if set forth at this place.

      

      

      
        A-2-13

        
          

      

      IN WITNESS WHEREOF, the Issuer has caused this Note to be signed manually or by facsimile by a duly authorized officer.

      

      

      	 	
              WESCO DISTRIBUTION, INC.

            
	 	 	 
	 	
              By:

            	 
	 	 	
              Name:

            
	 	 	
              Title:

            

      

      

      
        A-2-14

        
          

      

      Certificate of Authentication

      

      

      This is one of the 7.250% Senior Notes due 2028 referred to in the within-mentioned Indenture.

      

      

      	 	 	 	
              U.S. BANK NATIONAL ASSOCIATION,

            
	 	 	 	
               as Trustee

            

      

      

      	 	 	 	
              By:

            	 

      

      

      	
              Dated:

            	 	 	 

      

      

      
        A-2-15

        
          

      

      [FORM OF REVERSE OF SENIOR NOTE DUE 2028]

      

      

      WESCO DISTRIBUTION, INC.

      

      

      7.250% SENIOR NOTE DUE 2028

      

      

      Capitalized and certain other terms used herein and not otherwise defined have the meanings set forth in the Indenture referred to below unless otherwise indicated.

      

      

      1.            Interest.  WESCO DISTRIBUTION, INC., a Delaware corporation (the “Issuer”), promises to pay interest on the principal amount set forth on the face hereof at a rate of 7.250% per annum. 
        Interest hereon will accrue from and including the most recent date to which interest has been paid or, if no interest has been paid, from and including June 12, 2020 to but excluding the date on which interest is paid.  Interest shall be payable
        in arrears on each June 15 and December 15, commencing                  .  Interest will be computed on the basis of a 360-day year of twelve 30-day months and actual days elapsed.  The Issuer shall pay interest on overdue principal and on overdue
        interest (to the full extent permitted by law) at the rate borne by the 8-Year Notes.

      

      

      2.            Method of Payment.  The Issuer will pay interest hereon (except defaulted interest) to the Persons who are registered Holders at the close of business on June 1 or December 1 preceding the
        Interest Payment Date (whether or not a Business Day).  Holders must surrender 8-Year Notes to a Paying Agent to collect principal payments.  The Issuer will pay principal and interest in U.S. Dollars.  Interest may be paid by check mailed to the
        Holder entitled thereto at the address indicated on the register maintained by the Registrar for the 8-Year Notes.

      

      

      3.            Paying Agent and Registrar.  Initially, U.S. Bank National Association (the “Trustee”) will act as a Paying Agent and Registrar.  The Issuer may change any Paying Agent or Registrar without
        notice.  The Issuer or any Affiliate thereof may act as Paying Agent or Registrar.

      

      

      4.            Indenture.  The Issuer issued the 8-Year Notes under an Indenture dated as of June 12, 2020 (the “Indenture”) among the Issuer, the Parent Guarantor and the Trustee.  This is one of an
        issue of 8-Year Notes of the Issuer issued, or to be issued, under the Indenture.  The terms of the 8-Year Notes include those stated in the Indenture.  The 8-Year Notes are subject to all such terms, and Holders are referred to the Indenture for a
        statement of them.

       

      

      
        A-2-16

        
          

      

      5.            Optional Redemption.

       

      

      At any time prior to June 15, 2023, the Issuer may on any one or more occasions redeem up to (i) 35% of the original aggregate principal amount of 8-Year Notes issued under the Indenture and (ii) all or a portion of
        any applicable Additional Notes issued after the Issue Date, upon not less than 10 nor more than 60 days’ notice, at a redemption price equal to 107.250% of the principal amount of the 8-Year Notes redeemed, plus accrued and unpaid interest, if
        any, to but excluding the redemption date, with an amount of cash no greater than the cash proceeds (net of underwriting discounts and commissions) of all Equity Offerings since the Issue Date; provided
        that:

      

      

      (1)          at least 65% (calculated after giving effect to any issuance of applicable Additional Notes) of the aggregate principal amount of 8-Year Notes issued under the Indenture (excluding
        8-Year Notes held by the Issuer and its Subsidiaries) remains outstanding immediately after the occurrence of such redemption; and

      

      

      (2)          the redemption occurs within 180 days of the date of the closing of such Equity Offering.

      

      

      In addition, prior to June 15, 2023, the Issuer may redeem the 8-Year Notes, in whole or in part, at a redemption price equal to 100% of the principal amount thereof, plus accrued and unpaid interest, if any, to but
        excluding the applicable 8-Year Notes Make-Whole Redemption Date, plus the 8-Year Notes Make-Whole Premium. The Issuer will notify the Trustee of the 8-Year Notes Make-Whole Premium by delivering to the Trustee, on or before the applicable 8-Year
        Notes Make-Whole Redemption Date, an Officer’s Certificate showing the calculation thereof in reasonable detail, and the Trustee will not be responsible for verifying or otherwise for such calculation.

      

      

      On or after June 15, 2023, the Issuer may on any one or more occasions redeem all or a part of the 8-Year Notes, upon not less than 10 nor more than 60 days’ notice, at the redemption prices (expressed as percentages
        of principal amount) set forth below, plus accrued and unpaid interest, if any, on the 8-Year Notes redeemed, to but excluding the applicable Redemption Date, if redeemed during the twelve-month period beginning on June 15 of the years indicated
        below:

       

      

      	
              Year

            	
              Percentage 

              

            
	
              2023

            	
              103.625%

            
	
              2024

            	
              102.417%

            
	
              2025

            	
              101.208%

            
	
              2026 and thereafter

            	
              100.000%

            

      

      

      Unless the Issuer defaults in the payment of the redemption price, interest will cease to accrue on the 8-Year Notes or portions thereof called for redemption on the applicable redemption date. Any notice of redemption
        of the 8-Year Notes may, at the Issuer’s discretion, be subject to one or more conditions precedent with respect to completion of a corporate transaction (including, but not limited to, any merger, acquisition, disposition, asset sale or corporate
        restructuring or reorganization) or financing (including, but not limited to, any incurrence of Indebtedness (or entering into a commitment with respect thereto), Sale and Leaseback Transaction, issuance of securities, equity offering or
        contribution, liability management transaction or other capital raise) and may be given prior to the completion thereof. If a redemption is subject to satisfaction of one or more conditions precedent, the notice shall describe each condition, and
        the notice may be rescinded in the event that any or all of the conditions shall not have been satisfied by the redemption date. The Issuer may provide in such notice that payment of the redemption price and performance of the Issuer’s obligations
        with respect to such redemption may be performed by another Person.

       

      

      
        A-2-17

        
          

      

      In addition, the Issuer may acquire 8-Year Notes by means other than a redemption, whether by tender offer, open market purchases, negotiated transactions or otherwise, in accordance with applicable securities laws, so
        long as such acquisition does not otherwise violate the terms of the Indenture.

      

      

      Notwithstanding the foregoing, the payment of accrued but unpaid interest in connection with the redemption of 8-Year Notes is subject to the rights of a Holder of 8-Year Notes on a record date for the payment of
        interest whose 8-Year Notes are to be redeemed on or after such record date but on or prior to the related interest payment date to receive interest on such interest payment date.

      

      

      6.            Notice of Optional Redemption.  Notices of redemption shall be mailed by first class mail or sent electronically at least 10 but not more than 60 days before the Redemption Date to each Holder of
        8-Year Notes to be redeemed at its registered address (or to the extent permitted or required by applicable Depositary procedures or regulations with respect to global Notes, sent electronically).  If any Note is to be redeemed in part only, the
        notice of redemption that relates to such Note shall state the portion of the principal amount thereof to be redeemed.  Any redemption and notice thereof may, in the Issuer’s discretion, be subject to the satisfaction of one or more conditions
        precedent described in the notice relating to such redemption.

      

      

      7.            Offers To Purchase.  The Indenture provides that upon the occurrence of a Change of Control or an Asset Sale and subject to further limitations contained therein, the Issuer shall make an offer to
        purchase outstanding 8-Year Notes in accordance with the procedures set forth in the Indenture.

      

      

      8.            Special Mandatory Redemption.

      

      

      The Indenture provides that upon a Special Mandatory Redemption Trigger Date and subject to further limitations contained therein, the Issuer shall redeem the outstanding 8-Year Notes in accordance with the procedures
        set forth in the Indenture.

      

      

      9.            Denominations, Transfer, Exchange.  The 8-Year Notes are in registered form without coupons in denominations of $2,000 and integral multiples of $1,000 in excess of $2,000.  A Holder may transfer
        or exchange 8-Year Notes in accordance with the Indenture.  The Registrar may require a Holder, among other things, to furnish appropriate endorsements and transfer documents and to pay to it any taxes and fees required by law or permitted by the
        Indenture.  The Registrar need not register the transfer of or exchange any 8-Year Notes or portion of a 8-Year Note selected for redemption, or register the transfer of or exchange any 8-Year Notes for a period of 15 days before a mailing of
        notice of redemption.

       

      

      
        A-2-18

        
          

      

      10.          Persons Deemed Owners.  The registered Holder of this 8-Year Note may be treated as the owner of this 8-Year Note for all purposes.

      

      

      11.          Unclaimed Money.  If money held by the Paying Agent or Trustee for the payment of principal or interest remains unclaimed for two years, the Paying Agent or Trustee, as applicable, will pay such
        money back to the Issuer at its written request.  After that, Holders entitled to the money must look to the Issuer and the Guarantors for payment as general creditors unless an “abandoned property” law designates another Person.

      

      

      12.          Amendment, Supplement, Waiver, Etc.  The Issuer and the Trustee may, without the consent of the Holders of any outstanding 8-Year Notes, amend, waive or supplement the Indenture or the 8-Year Notes
        for certain specified purposes, including, among other things, curing ambiguities, omissions, defects or inconsistencies, providing for the assumption by a successor to the Issuer of its obligations to the Holders and making any change that does
        not adversely affect the rights of any Holder in any material respect.  Other amendments and modifications of the Indenture or the 8-Year Notes may be made by the Issuer and the Trustee with the consent of Holders as further described in the
        Indenture.

      

      

      13.          Restrictive Covenants.  The Indenture imposes certain limitations on the ability of the Parent Guarantor and its Subsidiaries to, among other things, create liens, make Restricted Payments, enter
        into Sale and Leaseback Transactions or consolidate, merge or sell all or substantially all of the assets of the Parent Guarantor and its Subsidiaries and requires the Issuer to provide reports to Holders of the 8-Year Notes.  Such limitations are
        subject to a number of important qualifications and exceptions.  Pursuant to Section 4.05 of the Indenture, the Issuer must annually report to the Trustee on compliance with such limitations.

      

      

      14.          Successor Person.  When a successor Person assumes all the obligations of its predecessor under the 8-Year Notes and the Indenture and the transaction complies with the terms of Article Five of the
        Indenture, the predecessor corporation will, except as provided in Article Five, be released from those obligations.

      

      

      15.          Defaults and Remedies.  Events of Default are set forth in the Indenture.  If an Event of Default occurs and is continuing under the Indenture, either the Trustee, by notice in writing to the
        Issuer, or the Holders of at least 25% in aggregate principal amount of the 8-Year Notes then outstanding, by notice in writing to the Issuer and the Trustee specifying the respective Event of Default and that it is a “notice of acceleration”, may
        declare the principal of and premium, if any, and accrued interest, if any, on the 8-Year Notes to be due and payable, and upon such declaration of acceleration, such principal of and premium, if any, and accrued interest, if any, shall be
        immediately due and payable; provided, however, that, notwithstanding the foregoing, if an Event of Default specified in Section 6.01(7) occurs with respect to the
        Issuer or the Parent Guarantor, the principal of and premium, if any, and accrued interest, if any, on the 8-Year Notes then outstanding shall become and be immediately due and payable without any declaration or other act on the part of the Trustee
        or any Holder.

       

      

      
        A-2-19

        
          

      

      Notwithstanding the foregoing, if after such acceleration but before a judgment or decree based on such acceleration is obtained by the Trustee, the Holders of a majority in aggregate principal amount of the 8-Year
        Notes then outstanding may rescind and annul such acceleration if:

      

      

      (1)          all Events of Default, other than nonpayment of principal, premium, if any, or interest that has become due solely because of the acceleration, have been cured or waived;

      

      

      (2)          to the extent the payment of such interest is lawful, interest on overdue installments of interest and overdue principal, which has become due otherwise than by such declaration of
        acceleration, has been paid;

      

      

      (3)          the Issuer has paid the Trustee its reasonable compensation and reimbursed the Trustee for its expenses, disbursements and advances; and

      

      

      (4)          in the event of the cure or waiver of an Event of Default of the type described in Section 6.01(7), the Trustee shall have received an Officer’s Certificate and an Opinion of Counsel
        that such Event of Default has been cured or waived.

      

      

      No such rescission shall affect any subsequent Default or impair any right consequent thereto.

      

      

      Holders may not enforce the Indenture or the 8-Year Notes except as provided in the Indenture.  The Trustee may require indemnity satisfactory to it before it enforces the Indenture or the 8-Year Notes.  Subject to
        certain limitations, Holders of a majority in principal amount of the then outstanding 8-Year Notes may direct the Trustee in its exercise of any trust or power.  The Trustee may withhold from Holders notice of any continuing Default or Event of
        Default (except a Default or Event of Default relating to the payment of principal of  or interest on the 8-Year Notes) if it determines that withholding notice is in their best interests.

      

      

      16.          Trustee Dealings with the Issuer.  The Trustee, in its individual or any other capacity, may make loans to, accept deposits from and perform services for the Issuer or its Affiliates, and may
        otherwise deal with the Issuer or its Affiliates, as if it were not Trustee.

      

      

      17.          No Recourse Against Others.  No director, officer, employee, incorporator, member of the Board of Directors or holder of Capital Stock of the Parent Guarantor or of any Subsidiary, as such, shall
        have any liability for any obligations of the Issuer or the Guarantors under the 8-Year Notes, the Indenture or the Guarantees or for any claim based on, in respect of, or by reason of, such obligations or their creation.  Each Holder of 8-Year
        Notes by accepting a Note waives and releases all such liability.

       

      

      
        A-2-20

        
          

      

      18.          Satisfaction and Discharge.  The Issuer’s and each Guarantors’ obligations pursuant to the Indenture will be discharged, except for obligations pursuant to certain sections thereof, subject
        to the terms of the Indenture, upon the payment of all the 8-Year Notes or upon the irrevocable deposit with the Trustee of cash in U.S. Dollars, U.S. Government Obligations or a combination thereof, in such amounts as will be sufficient to pay
        when due principal of and interest on the 8-Year Notes to maturity or redemption, as the case may be.

      

      

      19.          Guarantees.  From and after the Issue Date, the 8-Year Notes will be entitled to the benefits of certain Guarantees made for the benefit of the Holders.  Reference is hereby made to the Indenture
        for a statement of the respective rights, limitations of rights, duties and obligations thereunder of the Guarantors, the Trustee and the Holders.

      

      

      20.          Authentication.  This Note shall not be valid until the Trustee manually signs the certificate of authentication on the other side of this Note.

      

      

      21.          Governing Law.  THIS NOTE SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK, BUT WITHOUT GIVING EFFECT TO APPLICABLE PRINCIPLES OF CONFLICTS OF LAW TO THE
        EXTENT THAT THE APPLICATION OF THE LAW OF ANOTHER JURISDICTION WOULD BE REQUIRED THEREBY.

      

      

      22.          Abbreviations.  Customary abbreviations may be used in the name of a Holder or an assignee, such as:  TEN COM (= tenants in common), TENANT (= tenants by the entireties), JT TEN (= joint tenants
        with right of survivorship and not as tenants in common), CUST (= Custodian), and U/G/M/A (= Uniform Gifts to Minors Act).

      

      

      The Issuer will furnish to any Holder upon written request and without charge a copy of the Indenture.  Requests may be made to:

      

      

      WESCO Distribution, Inc.

      225 West Station Square Drive, Suite 700

      Pittsburgh, Pennsylvania 15219-1122

      Facsimile: (412) 222-7566

      Attention: Chief Financial Officer

      

      

      
        A-2-21

        
          

      

      ASSIGNMENT

      

      

      I or we assign and transfer this Note to:

      

      

      
        	 
	
                (Insert assignee’s social security or tax I.D. number)

              
	
                 

              
	 
	
                (Print or type name, address and zip code of assignee)

              

      

      

      

      	
              and irrevocably appoint

            	 

      

      

      Agent to transfer this Note on the books of the Issuer.  The Agent may substitute another to act for him.

      

      

      	
              Date:

            	 	 	
              Your Signature:

            	 
	 	 	 	 	
              (Sign exactly as your name appears on the other side of this Note)

            

      

      

      	
              Signature Guarantee:

            	 	 

      

      

      SIGNATURE GUARANTEE

      

      

      Signatures must be guaranteed by an “eligible guarantor institution” meeting the requirements of the Registrar, which requirements include membership or participation in the Security Transfer Agent Medallion Program
        (“STAMP”) or such other “signature guarantee program” as may be determined by the Registrar in addition to, or in substitution for, STAMP, all in accordance with the Securities Exchange Act of 1934, as amended.

      

      

      
        A-2-22

        
          

      

      OPTION OF HOLDER TO ELECT PURCHASE

      

      

      If you want to elect to have all or any part of this Note purchased by the Issuer pursuant to Section 4.07 or Section 4.08 of the Indenture check the appropriate box:

      

      

      	
              ☐

            	
              Section 4.07

            	
              ☐

            	
              Section 4.08

            

      

      

      If you want to have only part of the Note purchased by the Issuer pursuant to Section 4.07 or Section 4.08 of the Indenture, state the amount you elect to have purchased:

      

      

      	$	

            	 
	 	
              ($2,000 or integral multiples of $1,000 in excess

            	 
	 	
              of $2,000; provided that the part not

            	 
	 	
              purchased must be at least $2,000)

            	 

      

      

      	
              Date:

            	 	 

      

      

      	 	
              Your Signature:

            	 
	 	 	
              (Sign exactly as your name appears on the face of this Note)

            

      

      

      	 	 
	
              Signature Guaranteed

            	 

      

      

      SIGNATURE GUARANTEE

      

      

      Signatures must be guaranteed by an “eligible guarantor institution” meeting the requirements of the Registrar, which requirements include membership or participation in the Security Transfer Agent Medallion Program
        (“STAMP”) or such other “signature guarantee program” as may be determined by the Registrar in addition to, or in substitution for, STAMP, all in accordance with the Securities Exchange Act of 1934, as amended.

      

      

      
        A-2-23

        
          

      

      Schedule of Exchanges of Interests in Global Note*

      

      

      The following exchanges of a part of this Global Note for an interest in another Global Note or for a Physical Note, or exchanges of a part of another Global Note or Physical Note for an interest in this Global Note,
        have been made:

      

      

      	
              Date of Exchange

            	
              Amount of decrease in

              Principal Amount

              of

              this Global Note

            	
              Amount of increase in

              Principal Amount

              of

              this Global Note

            	
              Principal Amount

              of this Global Note

              following such

              decrease

              (or increase)

            	
              Signature of authorized 

              signatory of Trustee

            
	 	 	 	 	 

      

      

      

      

      
        

      
        	
                *

              	
                Insert in Global Securities only.

              

      

       

      
        A-2-24

        
          

      

      
      EXHIBIT B

      

      

      [FORM OF LEGEND FOR RESTRICTED SECURITIES]

      

      

      Any Restricted Note authenticated and delivered hereunder shall bear a legend (which would be in addition to any other legends required in the case of a Global Note) in substantially the following form:

      

      

      THE SECURITY (OR ITS PREDECESSOR) EVIDENCED HEREBY WAS ORIGINALLY ISSUED IN A TRANSACTION EXEMPT FROM REGISTRATION UNDER SECTION 5 OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND THE
        SECURITY EVIDENCED HEREBY MAY NOT BE OFFERED, SOLD OR OTHERWISE TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR AN APPLICABLE EXEMPTION THEREFROM. EACH PURCHASER OF THE SECURITY EVIDENCED HEREBY IS HEREBY NOTIFIED THAT THE SELLER MAY BE RELYING
        ON THE EXEMPTION FROM THE PROVISIONS OF SECTION 5 OF THE SECURITIES ACT PROVIDED BY RULE 144A THEREUNDER. THE HOLDER OF THE SECURITY EVIDENCED HEREBY AGREES FOR THE BENEFIT OF THE ISSUER THAT (A) SUCH SECURITY MAY BE RESOLD, PLEDGED OR OTHERWISE
        TRANSFERRED, ONLY (1)(a) INSIDE THE UNITED STATES TO A PERSON WHO THE SELLER REASONABLY BELIEVES IS A QUALIFIED INSTITUTIONAL BUYER (AS DEFINED IN RULE 144A UNDER THE SECURITIES ACT) PURCHASING FOR ITS OWN ACCOUNT OR FOR THE ACCOUNT OF A QUALIFIED
        INSTITUTIONAL BUYER IN A TRANSACTION MEETING THE REQUIREMENTS OF RULE 144A UNDER THE SECURITIES ACT, (b) OUTSIDE THE UNITED STATES TO A FOREIGN PERSON IN A TRANSACTION MEETING THE REQUIREMENTS OF RULE 903 OR RULE 904 OF REGULATION S UNDER THE
        SECURITIES ACT, (c) PURSUANT TO AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT PROVIDED BY RULE 144 THEREUNDER (IF APPLICABLE) OR (d) IN ACCORDANCE WITH ANOTHER EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT (AND BASED
        UPON AN OPINION OF COUNSEL ACCEPTABLE TO THE ISSUER IF THE ISSUER SO REQUESTS), (2) TO THE ISSUER OR (3) PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT AND, IN EACH CASE, IN ACCORDANCE WITH ANY APPLICABLE SECURITIES LAWS OF ANY STATE OF THE UNITED
        STATES OR ANY OTHER APPLICABLE JURISDICTION AND (B) THE HOLDER WILL, AND EACH SUBSEQUENT HOLDER IS REQUIRED TO, NOTIFY ANY PURCHASER OF THE SECURITY EVIDENCED HEREBY OF THE RESALE RESTRICTIONS SET FORTH IN CLAUSE (A) ABOVE. NO REPRESENTATION CAN BE
        MADE AS TO THE AVAILABILITY OF THE EXEMPTION PROVIDED BY RULE 144 FOR RESALE OF THE SECURITY EVIDENCED HEREBY.

      

      

      
        B-1

        
          

      

      
      EXHIBIT C

      

      

      [FORM OF LEGEND FOR GLOBAL NOTE]

      

      

      Any Global Note authenticated and delivered hereunder shall bear a legend (which would be in addition to any other legends required in the case of a Restricted Note) in substantially the following form:

      

      

      THIS NOTE IS A GLOBAL NOTE WITHIN THE MEANING OF THE INDENTURE HEREINAFTER REFERRED TO AND IS REGISTERED IN THE NAME OF A DEPOSITARY OR A NOMINEE OF A DEPOSITARY.  THIS NOTE IS NOT EXCHANGEABLE FOR NOTES REGISTERED IN THE NAME OF A PERSON OTHER
        THAN THE DEPOSITARY OR ITS NOMINEE EXCEPT IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE, AND NO TRANSFER OF THIS NOTE (OTHER THAN A TRANSFER OF THIS NOTE AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE
        DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE OF THE DEPOSITARY) MAY BE REGISTERED EXCEPT IN THE LIMITED CIRCUMSTANCES DESCRIBED IN THE INDENTURE.

      

      

      UNLESS THIS CERTIFICATE IS PRESENTED BY AN AUTHORIZED REPRESENTATIVE OF THE DEPOSITORY TRUST COMPANY, A NEW YORK CORPORATION (“DTC”), TO THE ISSUER OR ITS AGENT FOR REGISTRATION OF TRANSFER, EXCHANGE, OR PAYMENT, AND ANY CERTIFICATE ISSUED IS
        REGISTERED IN THE NAME OF CEDE & CO. OR IN SUCH OTHER NAME AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC (AND ANY PAYMENT IS MADE TO CEDE & CO. OR SUCH OTHER ENTITY AS IS REQUESTED BY AN AUTHORIZED REPRESENTATIVE OF DTC), ANY
        TRANSFER, PLEDGE OR OTHER USE HEREOF FOR VALUE OR OTHERWISE BY OR TO ANY PERSON IS WRONGFUL INASMUCH AS THE REGISTERED OWNER HEREOF, CEDE & CO., HAS AN INTEREST HEREIN.

      

      

      
        C-1

        
          

      

      
      Exhibit D

      

      

      [FORM OF LEGEND FOR REGULATION S NOTE]

      

      

      Any Regulation S Note authenticated and delivered hereunder shall bear a legend (which would be in addition to any other legends required in the case of a Restricted Note) in substantially the following form:

      

      

      BY ITS ACQUISITION HEREOF, THE HOLDER HEREOF REPRESENTS THAT IT IS NOT A U.S. PERSON, NOR IS IT PURCHASING FOR THE ACCOUNT OF A U.S. PERSON, AND IS ACQUIRING THIS NOTE IN AN  OFFSHORE TRANSACTION IN ACCORDANCE WITH REGULATION S UNDER THE
        SECURITIES ACT.

      

      

      
        D-1

        
          

      

      
      Exhibit E

      

      

      FORM OF CERTIFICATE OF TRANSFER

      

      

      WESCO Distribution, Inc.

      225 West Station Square Drive, Suite 700

      Pittsburgh, Pennsylvania 15219-1122

      Facsimile: (412) 222-7566

      Attention: Chief Financial Officer

      

      

      U.S. Bank National Association

      225 W. Station Square Drive, Suite 380

      Pittsburgh, PA 15219

      Facsimile: (412)-552-2323

      Attention: Corporate Trust Services

      

      

      	 	Re:	
              WESCO Distribution, Inc.

            

      

      

      	 	Re:	
              [7.125][7.250]% Senior Notes due 20[25][28]

            

      

      

      (CUSIP _____________)

      (ISIN _______________)

      

      

      Reference is hereby made to the Indenture, dated as of June 12, 2020 (the “Indenture”), by and among WESCO Distribution, Inc. (the “Issuer”), the Parent Guarantor and U.S. Bank National Association, as trustee.  Capitalized terms
        used but not defined herein shall have the meanings given to them in the Indenture. ______________ (the “Transferor”) owns and proposes to transfer the Note[s] or interest in such Note[s] specified in Annex A hereto, in the principal amount
        of ___________ in such Note[s] or interests (the “Transfer”), to  __________ (the “Transferee”), as further specified in Annex A hereto.  In connection with the Transfer, the Transferor hereby certifies that:

      

      

      [CHECK ALL THAT APPLY]

      

      

      1.           ☐  Check if Transferee will take delivery of a beneficial interest in a Rule 144A Global Note or a Physical Note pursuant to Rule 144A.  The
        Transfer is being effected pursuant to and in accordance with Rule 144A under the United States Securities Act of 1933, as amended (the “Securities Act”), and, accordingly, the Transferor hereby further certifies that the beneficial interest
        or Physical Note is being transferred to a Person that the Transferor reasonably believed and believes is purchasing the beneficial interest or Physical Note for its own account, or for one or more accounts with respect to which such Person
        exercises sole investment discretion, and such Person and each such account is a “qualified institutional buyer” within the meaning of Rule 144A in a transaction meeting the requirements of Rule 144A and such Transfer is in compliance with any
        applicable blue sky securities laws of any state of the United States.  Upon consummation of the proposed Transfer in accordance with the terms of the Indenture, the transferred beneficial interest or Physical Note will be subject to the
        restrictions on transfer enumerated in the Private Placement Legend printed on the Rule 144A Global Note and/or the Physical Note and in the Indenture and the Securities Act.

       

      

      
        E-1

        
          

      

      2.           ☐  Check if Transferee will take delivery of a beneficial interest in a Regulation S Global Note or a Physical Note pursuant to Regulation S. 
        The Transfer is being effected pursuant to and in accordance with Rule 903 or Rule 904 under the Securities Act and, accordingly, the Transferor hereby further certifies that (i) the Transfer is not being made to a person in the United States and
        (x) at the time the buy order was originated, the Transferee was outside the United States or such Transferor and any Person acting on its behalf reasonably believed and believes that the Transferee was outside the United States or (y) the
        transaction was executed in, on or through the facilities of a designated offshore securities market and neither such Transferor nor any Person acting on its behalf knows that the transaction was prearranged with a buyer in the United States, (ii)
        no directed selling efforts have been made in contravention of the requirements of Rule 903(b) or Rule 904(b) of Regulation S under the Securities Act, (iii) the transaction is not part of a plan or scheme to evade the registration requirements of
        the Securities Act and (iv) if the proposed transfer is being made prior to the expiration of the Restricted Period, the transfer is not being made to a U.S. Person or for the account or benefit of a U.S. Person (other than an Initial Purchaser). 
        Upon consummation of the proposed transfer in accordance with the terms of the Indenture, the transferred beneficial interest or Physical Note will be subject to the restrictions on Transfer enumerated in the Private Placement Legend printed on the
        Regulation S Global Note and/or the Physical Note and in the Indenture and the Securities Act.

      

      

      3.           ☐  Check and complete if Transferee will take delivery of a beneficial interest in the Global Note or a Physical Note pursuant to any provision of the Securities Act other than Rule 144A or
            Regulation S.  The Transfer is being effected in compliance with the transfer restrictions applicable to beneficial interests in Restricted Global Notes and Restricted Physical Notes and
        pursuant to and in accordance with the Securities Act and any applicable blue sky securities laws of any state of the United States, and accordingly the Transferor hereby further certifies that (check one):

      

      

      (a)          ☐  such Transfer is being effected pursuant to and in accordance with Rule 144 under the Securities Act;

      

      

      or

      

      

      (b)          ☐  such Transfer is being effected to the Issuer or a Subsidiary thereof;

      

      

      or

       

      

      
        E-2

        
          

      

      (c)          ☐  such Transfer is being effected pursuant to an effective registration statement under the Securities Act and in compliance with the prospectus delivery requirements of the Securities
        Act;

      

      

      or

      

      

      (d)          ☐  such Transfer is being effected pursuant to an exemption from the registration requirements of the Securities Act other than Rule 144A, Rule 144 or Rule 904, and the Transferor hereby
        further certifies that it has not engaged in any general solicitation within the meaning of Regulation D under the Securities Act and the Transfer complies with the transfer restrictions applicable to beneficial interests in a Restricted Global
        Note or Restricted Physical Notes and the requirements of the exemption claimed, which certification is supported by, if such Transfer is in respect of a principal amount of Notes at the time of transfer of less than $250,000, an Opinion of Counsel
        provided by the Transferor or the Transferee (a copy of which the Transferor has attached to this certification), to the effect that such Transfer is in compliance with the Securities Act.  Upon consummation of the proposed transfer in accordance
        with the terms of the Indenture, the transferred beneficial interest or Physical Note will be subject to the restrictions on transfer enumerated in the Private Placement Legend printed on the Global Note and/or the Physical Notes and in the
        Indenture and the Securities Act.

      

      

      4.           ☐  Check if Transferee will take delivery of a beneficial interest in an Unrestricted Global Note or an Unrestricted Physical Note.

      

      

      (a)          ☐        Check if Transfer is pursuant to Rule 144.  (i)  The Transfer is being effected pursuant to and in accordance with Rule 144 under the Securities Act and
        in compliance with the transfer restrictions contained in the Indenture and any applicable blue sky securities laws of any state of the United States and (ii) the restrictions on transfer contained in the Indenture and the Private Placement Legend
        are not required in order to maintain compliance with the Securities Act.  Upon consummation of the proposed Transfer in accordance with the terms of the Indenture, the transferred beneficial interest or Physical Note will no longer be subject to
        the restrictions on transfer enumerated in the Private Placement Legend printed on the Restricted Global Notes, on Restricted Physical Notes and in the Indenture.

      

      

      (b)          ☐        Check if Transfer is pursuant to Regulation S.  (i)  The Transfer is being effected pursuant to and in accordance with Rule 903 or Rule 904 under the
        Securities Act and in compliance with the transfer restrictions contained in the Indenture and any applicable blue sky securities laws of any state of the United States and (ii) the restrictions on transfer contained in the Indenture and the
        Private Placement Legend are not required in order to maintain compliance with the Securities Act.  Upon consummation of the proposed Transfer in accordance with the terms of the Indenture, the transferred beneficial interest or Physical Note will
        no longer be subject to the restrictions on transfer enumerated in the Private Placement Legend printed on the Restricted Global Notes, on Restricted Physical Notes and in the Indenture.

       

      

      
        E-3

        
          

      

      (c)          ☐        Check if Transfer is pursuant to Other Exemption.  (i)  The Transfer is being effected pursuant to and in compliance with an exemption from the
        registration requirements of the Securities Act other than Rule 144, Rule 903 or Rule 904 and in compliance with the transfer restrictions contained in the Indenture and any applicable blue sky securities laws of any State of the United States and
        (ii) the restrictions on transfer contained in the Indenture and the Private Placement Legend are not required in order to maintain compliance with the Securities Act.  Upon consummation of the proposed Transfer in accordance with the terms of the
        Indenture, the transferred beneficial interest or Physical Note will not be subject to the restrictions on transfer enumerated in the Private Placement Legend printed on the Restricted Global Notes or Restricted Physical Notes and in the Indenture.

      

      

      (d)          ☐       Check if Transfer is pursuant to an Effective Registration Statement.  (i)  The Transfer is being effected pursuant to and in compliance with an effective
        registration statement under the Securities Act and any applicable blue sky securities laws of any State of the United States and in compliance with the prospectus delivery requirements of the Securities Act and (ii) the restrictions on transfer
        contained in the Indenture and the Private Placement Legend are not required in order to maintain compliance with the Securities Act.  Upon consummation of the proposed Transfer in accordance with the terms of the Indenture, the transferred
        beneficial interest or Physical Note will not be subject to the restrictions on transfer enumerated in the Private Placement Legend printed on the Restricted Global Notes or Restricted Physical Notes and in the Indenture.

      

      

      This certificate and the statements contained herein are made for your benefit and the benefit of the Issuer.

      

      

      	 	 	 	 
	 	 	 	
              [Insert Name of Transferor]

            
	 	 	 	 	 
	 	 	 	
              By:

            	 
	 	 	 	 	
              Name:

            
	 	 	 	 	
              Title:

            
	
              Dated:

            	 	 	 	 
	 	 	 	 	 

      

      

      
        E-4

        
          

      

      ANNEX A TO CERTIFICATE OF TRANSFER

      

      

      	1.	
              The Transferor owns and proposes to transfer the following:

            

      

      

      [CHECK ONE]

      

      

      	

            	(a)	
              ☐  a beneficial interest in a:

            

      

      

      	

            	(i)	
              ☐  Rule 144A Global Note (CUSIP ______) (ISIN ______), or

            

      

      

      	

            	(ii)	
              ☐  Regulation S Global Note (CUSIP ______) (ISIN ______), or

            

      

      

      	

            	(b)	
              ☐  a Restricted Physical Note.

            

      

      

      	2.	
              After the Transfer the Transferee will hold:

            

      

      

      [CHECK ONE]

      

      

      	

            	(a)	
              ☐  a beneficial interest in the:

            

      

      

      	

            	(i)	
              ☐  Rule 144A Global Note (CUSIP _______) (ISIN ______), or

            

      

      

      	

            	(ii)	
              ☐  Regulation S Global Note (CUSIP ______)(ISIN ______), or

            

      

      

      	

            	(iii)	
              ☐  Unrestricted Global Note (CUSIP ______) (ISIN ______), or

            

      

      

      	

            	(b)	
              ☐  a Restricted Physical Note; or

            

      

      

      	

            	(c)	
              ☐  an Unrestricted Physical Note,

            

      

      

      in accordance with the terms of the Indenture.

      

      

      
        E-5

        
          

      

      
      EXHIBIT F

      

      

      FORM OF CERTIFICATE OF EXCHANGE

      

      

      WESCO Distribution, Inc.

      225 West Station Square Drive, Suite 700

      Pittsburgh, Pennsylvania 15219-1122

      Facsimile: (412) 222-7566

      Attention: Chief Financial Officer

      

      

      U.S. Bank National Association

      225 W. Station Square Drive, Suite 380

      Pittsburgh, PA 15219

      Facsimile: (412)-552-2323

      Attention: Corporate Trust Services

      

      

      	

            	re:	
              WESCO Distribution, Inc.

            

      

      

      	

            	Re:	
              [7.125][7.250]% Senior Notes due 20[25][28]

            

      

      

      (CUSIP______________)

      (ISIN _______________)

      

      

      Reference is hereby made to the Indenture, dated as of June 12, 2020 (the “Indenture”), by and among WESCO Distribution, Inc. (the “Issuer”), the Parent Guarantor and U.S. Bank National Association, as trustee.  Capitalized terms
        used but not defined herein shall have the meanings given to them in the Indenture.

      

      

      ____________ (the “Owner”) owns and proposes to exchange the Note[s] or interest in such Note[s] specified herein, in the principal amount of ____________ in such Note[s] or interests (the “Exchange”). 
        In connection with the Exchange, the Owner hereby certifies that:

      

      

      1.           Exchange of Restricted Physical Notes or Beneficial Interests in a Restricted Global Note for Unrestricted Physical Notes or Beneficial Interests in an Unrestricted Global Note

       

        

      
        F-1

        
          

      

      (a)          ☐        Check if Exchange is from beneficial interest in a Restricted Global Note to beneficial interest in an Unrestricted Global Note.  In connection with the Exchange of the Owner’s beneficial interest in a Restricted Global Note for a beneficial interest in an Unrestricted Global Note in an equal principal amount, the Owner hereby certifies
        (i) the beneficial interest is being acquired for the Owner’s own account without transfer, (ii) such Exchange has been effected in compliance with the transfer restrictions applicable to the Global Notes and pursuant to and in accordance with the
        United States Securities Act of 1933, as amended (the “Securities Act”), (iii) the restrictions on transfer contained in the Indenture and the Private Placement Legend are not required in order to maintain compliance with the Securities Act
        and (iv) the beneficial interest in an Unrestricted Global Note is being acquired in compliance with any applicable blue sky securities laws of any state of the United States.

      

      

      (b)          ☐        Check if Exchange is from Restricted Physical Note to beneficial interest in an Unrestricted Global Note. 
        In connection with the Owner’s Exchange of a Restricted Physical Note for a beneficial interest in an Unrestricted Global Note, the Owner hereby certifies (i) the beneficial interest is being acquired for the Owner’s own account without transfer,
        (ii) such Exchange has been effected in compliance with the transfer restrictions applicable to Restricted Physical Notes and pursuant to and in accordance with the Securities Act, (iii) the restrictions on transfer contained in the Indenture and
        the Private Placement Legend are not required in order to maintain compliance with the Securities Act and (iv) the beneficial interest is being acquired in compliance with any applicable blue sky securities laws of any state of the United States.

      

      

      (c)          ☐        Check if Exchange is from Restricted Physical Note to Unrestricted Physical Note.  In connection with the
        Owner’s Exchange of a Restricted Physical Note for an Unrestricted Physical Note, the Owner hereby certifies (i) the Unrestricted Physical Note is being acquired for the Owner’s own account without transfer, (ii) such Exchange has been effected in
        compliance with the transfer restrictions applicable to Restricted Physical Notes and pursuant to and in accordance with the Securities Act, (iii) the restrictions on transfer contained in the Indenture and the Private Placement Legend are not
        required in order to maintain compliance with the Securities Act and (iv) the Unrestricted Physical Note is being acquired in compliance with any applicable blue sky securities laws of any state of the United States.

      

      

      2.           Exchange of Restricted Physical Notes for Restricted Physical Notes or Beneficial Interests in Restricted Global Notes.

      

      

      (a)          ☐        Check if Exchange is from Restricted Physical Note to beneficial interest in a Restricted Global Note.  In connection with the Exchange of the
        Owner’s Restricted Physical Note for a beneficial interest in the [CHECK ONE] __ Rule 144A Global Note, __Regulation S Global Note with an equal principal amount, the Owner hereby certifies (i) the beneficial interest is being acquired for the
        Owner’s own account without transfer and (ii) such Exchange has been effected in compliance with the transfer restrictions applicable to the Restricted Global Notes and pursuant to and in accordance with the Securities Act, and in compliance with
        any applicable blue sky securities laws of any state of the United States.  Upon consummation of the proposed Exchange in accordance with the terms of the Indenture, the beneficial interest issued will be subject to the restrictions on transfer
        enumerated in the Private Placement Legend printed on the relevant Restricted Global Note and in the Indenture and the Securities Act.

      

      

      
        F-2

        
          

      

      This certificate and the statements contained herein are made for your benefit and the benefit of the Issuer.

      

      

      	 	 	 	 
	 	 	 	
              [Insert Name of Owner]

            
	 	 	 	 	 
	 	 	 	
              By:

            	 
	 	 	 	 	
              Name:

            
	 	 	 	 	
              Title:

            
	 	 	 	 	 
	
              Dated:

            	 	 	 	 

      

      

      
        F-3

        
          

      

      
      EXHIBIT G

      

      

      GUARANTEE

      

      

      The undersigned (the “Guarantor”) hereby jointly and severally unconditionally guarantees, to the extent set forth in the Indenture, dated as of June 12, 2020, by and among WESCO Distribution, Inc. (the “Issuer”), the Parent
        Guarantor and U.S. Bank National Association, as trustee (as amended, restated or supplemented from time to time, the “Indenture”), and subject to the Indenture, (a) the due and punctual payment of the principal of, and premium, if any, and
        interest on the Notes, when and as the same shall become due and payable, whether at maturity, by acceleration or otherwise, the due and punctual payment of interest on overdue principal of, and premium and, to the extent permitted by law,
        interest, and the due and punctual performance of all other obligations of the Issuer to the Noteholders or the Trustee, all in accordance with the terms set forth in Article Ten of the Indenture, (b) in case of any extension of time of payment or
        renewal of any Notes or any of such other obligations, that the same will be promptly paid in full when due or performed in accordance with the terms of the extension or renewal, whether at stated maturity, by acceleration or otherwise and (c) all
        amounts due to the Trustee pursuant to the Indenture.

      

      

      The obligations of the Guarantor to the Noteholders and to the Trustee pursuant to this Guarantee and the Indenture are expressly set forth in Article Ten of the Indenture, and reference is hereby made to the Indenture for the precise terms and
        limitations of this Guarantee.  Each Holder of the Note to which this Guarantee is endorsed, by accepting such Note, agrees to and shall be bound by such provisions.

      

      

      [Signatures on Following Pages]

      

      

      
        G-1

        
          

      

      IN WITNESS WHEREOF, the Guarantor has caused this Guarantee to be signed by a duly authorized officer.

      

      

      	 	 	 	
              as the Guarantor

            
	 	 	 	 
	 	
              By:

            	 
	 	 	
              Name:

            	 
	 	 	
              Title:

            	 

      

      

      
        G-2

        
          

      

      
      EXHIBIT H

      

      

      FORM OF SUPPLEMENTAL INDENTURE

      

      

      TO BE DELIVERED BY SUBSEQUENT GUARANTORS

      

      

      SUPPLEMENTAL INDENTURE (this “Supplemental Indenture”), dated as of                     , among                      (the “Guaranteeing Subsidiary”), a subsidiary of WESCO Distribution,
        Inc. (or its permitted successor), a Delaware corporation (the “Issuer”), and U.S. Bank National Association, as trustee under the Indenture referred to below (the “Trustee”).

      

      

      W I T N E S S E T H

      

      

      WHEREAS, the Issuer has heretofore executed and delivered to the Trustee an indenture, dated as of June 12, 2020 (the “Indenture”), providing for the issuance of the Issuer’s 7.125% Senior Notes due 2025 (the “5-Year

          Notes”) and 7.250% Senior Notes due 2028 (the “8-Year Notes” and, together with the 5-Year Notes, the “Notes”);

      

      

      WHEREAS, the Indenture provides that, under certain circumstances, the Guaranteeing Subsidiary shall execute and deliver to the Trustee a supplemental indenture pursuant to which the Guaranteeing Subsidiary shall
        unconditionally guarantee all of the Issuer’s Obligations under the Notes and the Indenture on the terms and conditions set forth herein (the “Guarantee”); and

      

      

      WHEREAS, pursuant to Section 8.01 of the Indenture, the Trustee is authorized to execute and deliver this Supplemental Indenture.

      

      

      NOW, THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt of which is hereby acknowledged, the Guaranteeing Subsidiary and the Trustee mutually covenant and agree for
        the equal and ratable benefit of the Holders of the Notes as follows:

      

      

      1.            CAPITALIZED TERMS.  Capitalized terms used herein without definition shall have the meanings assigned to them in the Indenture.

      

      

      2.            AGREEMENT TO GUARANTEE.  The Guaranteeing Subsidiary hereby agrees to provide an unconditional Guarantee on the terms and subject to the conditions set forth in the Guarantee and in the Indenture
        including but not limited to Article 10 thereof.

      

      

      4.            NO RECOURSE AGAINST OTHERS.  No director, officer, employee, incorporator member of the Board of Directors or holder of Capital Stock of the Issuer or of any Guarantor, as such, shall have any liability
        for any obligations of the Issuer or the Guarantors under the Notes, this Supplemental Indenture or the Guarantees or for any claim based on, in respect of, or by reason of, such obligations or their creation.  Each Holder of Notes by accepting a
        Note waives and releases all such liability.

       

      

      
        H-1

        
          

      

      5.            THIS SUPPLEMENTAL INDENTURE SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK, BUT WITHOUT GIVING EFFECT TO APPLICABLE PRINCIPLES OF CONFLICTS OF LAW TO THE EXTENT
        THAT THE APPLICATION OF THE LAW OF ANOTHER JURISDICTION WOULD BE REQUIRED THEREBY.

      

      

      6.            COUNTERPARTS.  The parties may sign any number of copies of this Supplemental Indenture.  Each signed copy shall be an original, but all of them together represent the same agreement.

      

      

      7.            EFFECT OF HEADINGS.  The Section headings herein are for convenience only and shall not affect the construction hereof.

      

      

      8.            THE TRUSTEE.  The Trustee shall not be responsible in any manner whatsoever for or in respect of the validity or sufficiency of this Supplemental Indenture or for or in respect of the recitals contained
        herein, all of which recitals are made solely by the Guaranteeing Subsidiary and the Issuer.

      

      

      IN WITNESS WHEREOF, the parties hereto have caused this Supplemental Indenture to be duly executed and attested, all as of the date first above written.

      

      

      	
              Dated:

            	 	 	 	 
	 	 	 	 	 
	 	 	 	
              [GUARANTEEING SUBSIDIARY]

            
	 	 	 	 	 
	 	 	 	
              By:

            	 
	 	 	 	 	
              Name:

            
	 	 	 	 	
              Title:

            
	 	 	 	 	 
	 	 	 	
              WESCO DISTRIBUTION, INC.

            
	 	 	 	 	 
	 	 	 	
              By:

            	 
	 	 	 	 	
              Name:

            
	 	 	 	 	
              Title:

            

      

      

      
        H-2

        
          

      

      	 	
              U.S. BANK NATIONAL ASSOCIATION,

            
	 	
              as Trustee

            
	 	 	 
	 	
              By:

            	 
	 	 	
              Name:

            
	 	 	
              Title:

            

      

      

      

      

      
        H-3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00310-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00310-of-00352.parquet"}]]